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Abbreviations 
AMA1 Apical merozoite antigen 1 
Amp Ampicillin 
AP Alkaline phosphatase 
ATP Adenosine triphosphate 
BLAST Basic Local Alignment Search Tool 
BMGY Buffered glycerol-complex medium 
BMMY Buffered methanol-complex medium 
BSA Bovine serum albumin 
CAT Chloramphenicol acetyl-transferase 
cDNA Complementary DNA 
CHO cells Chinese hamster ovary cells 
CIDR Cysteine-rich interdomain region 
CSA Chondroitin sulphate A 
CSP Circumsporozoite protein 
DBL domain Duffy binding-like domain 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxy nucleotide triphosphate 
dsDNA Double stranded DNA 
DTT Dithiothreitol 
ELISA Enzyme-linked Immunosorbent Assay 
FCS Fetal calf serum 
GAG(s) Glycosarninoglycan(s) 
Ik'A 
gDNA Genomic deoxyribonucleic acid 
WA Indirect immunofluorescence assay 
]PTG Isopropyl-1 thio-3-D-gaiactopyranoside 
iRBC(s) Infected red blood cell(s) 
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KDa kilodalton 
LB Luria Bertani medium 
mAb Monoclonal antibody 
MCS Multiple cloning site 
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MSP 1 Merozoite surface protein-1 
PBS Phosphate buffered saline 
PCR Poiymèrase chain reaction 
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PfEMP-1 Plasmodiumfalciparum erythrocyte membrane protein-1 
RNA Ribonucleic acid 
RPMI-1640 Roswell Park Memorial Institute Medium 1640 
SDS Sodium dodecyl sulphate 
Tris Tris [hydroxymethyl]aminomethane 
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Plasmodium faiciparum is the major cause of human malaria morbidity and 
mortality. Despite considerable research efforts, no effective vaccine against 
P.falciparum malaria is yet available. There is thus urgent need for basic pre-clinical 
and clinical research on vaccine development. To obtain antigens in suitable state for 
initiating vaccine prototype development it will be necessary to scale up production, 
in optimal expression systems, of recombinant proteins that are correctly folded and 
which induce appropriate antibody responses. 
In the intra-erythrocytic parasite, only mature forms can adhere to the host 
endothelial surfaces and thus sequester in different organs. This sequestration 
appears to be mediated by parasite-encoded molecules exported to the erythrocyte 
surface. The best understood, and probably the most important of these molecules is 
the P. falciparum erythrocyte membrane protein-i PfEMP-l. Although PfEMP-1 is 
highly polymorphic it nevertheless has structurally conserved features and these are 
considered possible vaccine targets. Antibodies directed to these molecules could 
protect patients from the clinical symptoms by blocking cytoadhesion. Humans make 
antibody responses to these molecules and particularly agglutinating antibody 
responses to PfEMP1 have been shown to correlate with the development of acquired 
immunity in endemic areas. 
The main aim of this study was to develop a fast and efficient way of expressing 
P. faiciparum antigenic epitopes as conformationally conserved antigenic structures 
whose expression can be readily 'scaled-up' for clinical testing. The E. coil and P. 
pastoris systems were used, both singly and as linked production systems using 
'shuttle vectors' that can be dually expressed in both microorganisms. Initially a 
proof-of-principle experiment to express the CIDR1 domain of PfEMP1 has been 
conducted. It was expressed and purified in good quantity and used to immunize 
rabbits. Polyclonal antibodies from rabbit were then assessed with immunoblotting, 
ELISA studies and immuno-fluorescence. The sequenced 3D7 P. falciparum genome 
was then exploited to construct degenerate primers for several domains of PfEMP1 
(namely DBLa, P and ny). These primers were used to amplify targets from 
FCR3CSA parasites. PCR products were then ligated into the dual expression vector 
KI 
pPICHOLI1 plasmid. Several erythrocyte surface antigen expression libraries were 
constructed and shown to be a representative and reliable. 
Development and optimisation of microarray and high-throughput screening 
assays in malaria vaccine development was carried out to accelerate the process of 
identifying malaria vaccine candidates. Growth of colonies of P. pastoris on filters 
on agar plates for high-throughput screening, a novel procedure, was optimized. 
These libraries were screened using pooled sera patients from endemic areas in 
Sudan, as well as sera from male and pregnant women suffering from the pregnancy 
malaria syndrome from a holoendemic malaria transmission zone, Ghana. Different 
domains from a gene of particular interest, the NF54 var2CSA gene were also 
amplified for study. The domains of DBL3X and DBL4a have been produced and 
purified from mid-scale induction experiments. These recombinant proteins then 
were then assessed by immunoblotting and ELISA methods. 
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Chapter 1. Introduction. 
1.1 The Malaria Problem. 
Malaria is caused by protozoan parasites of the genus Plasmodium (Kingdom: 
Protista, Subkingdom: Protozoa, Phylum: Apicomplexa, Class: Aconoidasida, 
Subclass: Coccidiasina, Order: Haemosporida, Suborder: Haemosporidina) (Smith, 
T., 2002). About 40% of the world's population lives in areas potentially at risk of 
malaria, mainly in tropical and subtropical regions (Figure 1.1). This results in 300-
500 million clinical cases and 1.5- 2.7 million deaths annually, although the majority 
of serious cases occur in children under the age of five years (Snow et a!, 2005, 
Nahien eta!, 2005). 
Malaria is a disease that can be cured if the symptoms are recognized and adequate 
treatment is initiated promptly (WHO, 2005). Unfortunately, in many parts of the 
world this is not being done and the malaria situation is barely under control. 
Resurgent malaria is due to the combined effects of global spread of parasite drug 
resistance, insecticide resistance, civil disturbance, climatic changes, increase in 
population, increase in mobility, lack of healthcare infrastructure and difficulties in 
implementing and maintaining vector control programs (Greenwood & Mutabingwa, 
2002). There is also a strong relationship between malaria and poverty and there has 
been essentially no economic growth or improvement of living standards for most 
people in sub-Saharan Africa in the last three decades (Sachs & Maloney, 2002, 
Chima et at, 2003). The increase in drug resistance of the malaria parasites requires 
the continuous discovery of new and more potent drugs. Escaping from this burden is 
highly desirable and underlies much of the current interest in finding a malaria 
vaccine to aid in the fight against the disease. 
The overall aim of the work in this thesis, a small part of the malaria vaccine 
development effort, is to investigate the problem of identifying malaria-protective 
antigens and developing such antigens more efficiently into vaccine prototypes that 
could be used in 'proof-of-principal' clinical trials. 
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Figure 1.1: Global distribution of malaria (WHO, 2002). 
1.2 Life cycle and parasite-host interactions linked to each stages of 
P. falciparum. 
Human beings are infected with malaria through the bite of the female mosquitoes 
of the genus Anopheles which have previously been infected with Plasmodium 
(Phillips, 1984, Good et at, 2001). Sporozoites (between 10 and 100 sporozoites) are 
injected into the dermis and blood capillaries (Rosenberg et at, 1990, Frevert et at, 
2005). Sporozoites are initially arrested by binding to stellate cell-derived 
extracellular matrix proteoglycans. The arrested sporozoites glide along the 
sinusoidal cell layer until they recognize heparan sulfate and chondroitin sulfate 
proteoglycans on the surface of Kupffer cells. The sporozoites then actively invade 
and safely traverse these cells of the liver and eventually invade and develop in 
hepatocytes (Frevert et at, 2005). They make their way to liver and enter the 
hepatocytes to initiate the DNA replication and growth phase referred to as pre-
erythrocytic schizogony (Shin et at, 1982). No clinical signs of disease are observed 
during this stage. The circumsporozoite protein (CSP) and thrombospondin-related 
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adhesive proteins (TRAP) are both associated with the surface of sporozoites and 
have been identified as major parasite ligands. Both the heparan sulphate (HS) 
receptor and the low-density lipoprotein receptor related protein (LRP) have been 
identified as hepatocyte surface receptors for sprorozoite invasion (Cerami et al, 
1994, Chitnis, 2001). 
After 5 to 6 days, P. falciparum exo-erythrocytic schizonts mature and burst, 
releasing thousands of merozoites into the blood stream where they invade the red 
blood cells (RBCs) to begin the asexual blood cycle of erythrocytic schizogony. The 
parasite feeds on the hemoglobin leaving behind a free haem, which is sequestered as 
a de-toxified crystalline substance called haemozoin (Egan, 2002). During a 48 
period the parasite grows from small 'ring stages' to the rapidly metabolizing 
trophozoite and finally to the schizont stage at which the multiplication of the single 
invading nucleus to 8-40 daughter merozoites is complete. The parasite bursts the 
erythrocyte, releasing merozoites into the circulation where they invade fresh 
erythrocytes and continue to multiply via this asexual cycle (Kirk, 2001). 
The erythrocytic cycle is responsible for the development of most of the pathology 
of the disease (Nagao et al, 2003). It is also the period of maximum exposure of the 
parasite to the human immune system and most of the drugs currently used for 
malaria treatment target the rapidly metabolising erythrocytic stages. Several 
proteins such as merozoite surface protein-1 (MSP- 1), erythrocyte-binding protein 
(EBA-175) and apical merozoite antigen-1 (AMA-1) have been characterized and 
identified as the parasite ligands during this stage (Duraisingh et al, 2003a and b). 
Sialic acid and glycophonn B and C have been identified as P. falciparum merozoite 
receptors on the erythrocyte surface (Dolan, 1994). 
Through mechanisms which are still largely unknown, some merozoites in the 
blood are triggered to develop into sexual forms known as male or female 
gametocytes. In P. falciparum these mature over 12-17 days into elongated or 
crescent shaped parasitized cells respectively (Carter et al, 1984). When a female 
Anopheles mosquito ingests parasitized erythrocytes in a blood meal, these 
gametocytes are released to become free gametes in the mosquito stomach and after 
sexual fusion and migration of the resulting ookinete into the gut wall, undergo 
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further development into mature sporozoites within the oocyst. Sporozoites migrate 
to the salivary glands and penetrate the acinar cells ready to be injected into skin 
capillaries when the mosquito again takes a human blood meal (Sinden, 2002) 
(Figure 1.2). 
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Figure 1.2: Life cycle of P. falciparum. 
1.3 Clinical manifestation of malaria. 
Three Plasmodium species cause malaria morbidity, Plasmodium vivax (Grassi and 
Felletti, 1890, Labbac, 1899), Plasmodium malariae (Laveran, 1881, Grassi and 
Felletti, 1890) and Plasmodium ovale (Stephens, 1922) but only Plasmodium 
falciparum (Welch, 1897, Schaudinn, 1902) results in both high morbidity and 
mortality. The most characteristic features of malaria are fever paroxysms occurring 
at regular intervals. This coincides with the discharge of metabolic waste along with 
the merozoites after erythrocyte lysis (Beeson et al, 2002b). Anaemia is also 
common, mainly due to parasite destruction of infected red blood cells (iRBC), 
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decreased erythropoiesis and enhanced clearance of both infected and non-infected 
RBC, by the spleen and macrophages (Ekvall, 2003). Malaria complications can also 
include splenomegaly, pulmonary oedma, respiratory distress, hypoglycemia and 
renal failure (Greenwood et al, 2005). 
However cerebral malaria is the most serious complication and the most frequent 
cause of death. Severe headache is the usual presenting symptom, followed by 
drowsiness, confusion, and coma. This may be due to the occlusion of the blood flow 
in the brain by infected cells sequestering inside the microvasculature. Host receptors 
such as the intercellular adhesion molecule-i (ICAM-1), and vascular cell adhesion 
molecule-i (VCAM-l) are up-regulated in cerebral malaria. This sequestration of 
mature stage parasites in the microvasculature is caused by parasite ligands such as 
PfEMP-1 binding to these host receptors (Miller et al, 2002). 
In children and adults without exposure to malaria, an increase in parasitaemia 
correlates with increase in severity of clinical symptoms. However, after a number of 
malaria episodes, some degree of immunity will develop among people living in 
areas endemic for the disease. This acquired immunity appears to be lost in the 
syndrome of pregnancy associated malaria (PAM) (it will be described in detail in 
section 1.8 of this chapter). Because of the interesting, important and clearly-defined 
nature of the syndrome, PAM-derived sera from Ghanaian females have been used in 
this thesis to help distinguish between specific and more generalized antibody-
mediated immune responses to malaria. 
1.4 	The molecular pathology and malaria parasite-host 
interactions. 
1.4.1 Modifications to parasitized erythrocytes (PE). 
During the asexual intra-erythrocytic stages, the composition and function of the 
PE cytosol and plasma membrane are extensively altered, in a programmed pattern 
that is synchronized with the parasite's cell cycle (Arnot & Gull, 1998). About 12 - 
16 hours after invasion of the erythrocytes, as the ring stage begins to transform to 
trophozoite stage, a tubolvesicular membrane network (TVM) extending from the 
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parasite vacuole membrane (PVM), that surrounds the parasite, is established. The 
parasite appears to establish a system within the iRBC cytosol to allow the 
trafficking of parasite proteins in and out of the infected cell. Several parasite-
derived proteins are translocated and sorted to compartments in the EE cytosol and to 
different locations near or at the plasma membrane where they can be associated with 
the cytoskeleton as well as anchored in the lipid bi-layer and displayed at the surface. 
Membranous structures such as the Maurer' s clefts are formed beyond the PVM. 
Vesicles have also been observed budding off from the parasite and moving through 
the RBC cytoplasm, perhaps independently of the TVM (Hibbs & Saul, 1994, Hibbs 
et al, 1997). The parasite also modifies the erythrocyte membrane itself so that it 
changes its permeability and places the parasite-derived proteins in knob like 
structures at the cell surface. These knobs act as attachment points for the 
sequestering parasites in the vascular beds (Beeson et al, 2002b). 
1.4.2 Parasite cytoadherence and sequestration. 
Probably to avoid immune clearance by the spleen, erythrocytes infected with the 
more mature stages of parasites (trophozoites), adhere to endothelial cells and 
sequester in post-capillary venules of various organs (Baruch et al, 2002b). The most 
important parasite-derived molecule expressed on the surface of infected RBCs 
involved in mediating these adhesion reactions is PfEMP- 1 (P. falciparum-infected 
erythrocyte membrane protein). Around 60 loci encoding different members of this 
gene family have to date been found in the near complete genome sequence of the 
3D7 clone. Specific forms of these variants have been shown to correlate with 
adhesion to different ligands on the human endothelium (Smith, J. et al, 1995, Su et 
al, 1995, Baruch et al, 1997). 
Host ligands of PfEMP1 include Chondroitin Sulfate A (CSA), intercellular 
adhesion molecule 1(ICAM-1), CD36, CD31, P- and E-selectin and vascular cell 
adhesion molecule-1 (VCAM-l). Adhesion to these ligands has in several cases been 
localized to specific parts of the PfEMP- 1 molecule. The contact residues for CD36 
binding, for example, have been proposed to be in the CIDR1a domain (Baruch et al, 
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1995, Baruch et al, 1999), binding to CSA has been reported to be localized to 
DBLy3 (Reeder et al, 1999, Buffet et al, 1999) and binding of ICAM1 to DBL32 
(Smith et a!, 2000a, b) (see Figure: 1.3). CD3 1 and P-selectin binding parasites are 
found in patients with malaria, although at lower frequency than CD36 and ICAM-1. 
Both P-selectin and ICAM-1 are able to mediate rolling adhesion of the (PE) and this 
may play a role in capturing TEs from the blood flow, working in synergy with other 
receptors (e.g. CD36) to produce efficient tethering (McCormick et a!, 1997). 
VCAM-1 and E-selectin have also been shown to act as receptors in vitro, but do not 
seem to play a major role in - vivo (Ockenhouse et al, 1992). 
1.4.3 Rosetting. 
Infected RBCs of some parasites can adhere to uninfected RBCs to form 'rosettes' 
(Udomsangpetch et al, 1989). Parasites with the rosetting phenotype are more likely 
to occur in patients with cerebral disease (Carlson et a!, 1990), although definitive 
proof that rosetting causes severe malaria is lacking. It is postulated that rosetting 
could facilitate invasion of new erythrocytes after schizogony or the iRBCs use the 
uninfected erythrocytes as 'shields' that help them avoid recognition by the immune 
system. Rosetting may also play a direct role in malaria pathogenesis by obstructing 
microvascular blood-flow (Kaul et al, 1991). 
The only consistent difference between rosetting and non-rosetting clones is the 
expressed PfEMP1 molecule, although it seems that rosetting is mediated by multiple 
receptor-ligand interactions (Heddini et a!, 2001). It therefore seems likely that 
PfEMP1 is the rosetting ligand in all parasites and the DBL1a domain may be the 
responsible ligand (Rowe et at, 1997, 2002b). A central part of the domain between 
the fifth and the twelfth cysteine residues has been found to be the functionally 
important section (Mayor et a!, 2005). Chen et al. raised antibodies against DBL1a 
that disrupted rosette formation in vitro and prevented sequestration in vivo (Chen et 
at, 2004). Heparin sulfate (HS) proteoglycans (Chen et a!, 1998), and complement 
receptor 1 (CR1) (Rowe et a!, 1997), ABO blood group sugars (Carlson & Wahlgren, 
1992) and CD36 (Handunnetti et at, 1992) on the surface of uninfected RBCs are 
Chapter 1 	 7 
thought to act as receptors for the adhesion of infected RBCs in the formation of 
rosettes. 
1.5 P. falciparum antigens implicated in disease severity. 
1.5.1 PIEMP1 and the var gene family. 
The PfEMP-1 molecule was first characterized in the early 1980s. It was identified 
as a large parasitized erythrocyte surface molecule varying considerably in size (200 
—400kDa) (Leech et al, 1984). More than a decade later, the genes encoding 
PfEMP1, known now as the var gene family, were discovered. Most var genes are 
located in the subtelomeric regions on both ends of the parasite's 14 chromosomes, 
although chromosomes 4,7,12 and 8 contain var genes that are centrally located 
(Gardener et-al, 2002). Further analysis of var gene sequences indicate that most of 
the family can be divided into three broadly defined classes based on chromosomal 
location (either telomeric, subtelomeric or in the central part of the chromosome), 
direction of transcription (either towards or away from the telomere), and type of 
upstream flanking region, referred to as Ups A, B, C, D and E (Lavstsen et al, 2003). 
Var genes have a two-exon structure separated by a 0.17-1.2 kb intron. The first exon 
is highly polymorphic, encodes the extra-cellular binding region and transmembrane 
domain and varies in size between 3.5 and 9.0 kb. The second exon is more 
conserved, encodes an acidic cytoplasmic tail and is between 1.0 and 1.5 kb in size. 
(Gardner et al, 2002) (Figure 1.3.A). Each parasite genotype encodes approximately 
60 different var loci (Thompson et a!, 1997, Gardner et a!, 2002, Bahl et al, 2002, 
www.plasmodb.com), gene repertoires differing extensively between parasite strains 
(Peterson et a!, 1995, Kyes et a!, 1997a, Ward et a!, 1999, Fowler et al, 2002). 
However, there are var genes that appear quite conserved between parasite genotypes 
and which may play important roles in malaria pathogenesis (Fried and Duffy, 2002, 
Rowe et al, 2002a, Lavstsen eta!; 2003, Salanti et a!, 2003, 2004, Winter et a!, 2003, 
Gupta et a!, 1994, Bull et al, 1999, Nielsen et a!, 2002, Deitsch & Hviid, 2004). 
The PfEMP1 extracellular framework is predominantly composed of the following 
basic building blocks: an N- (NTS) region, DBL domains (from a to a domains), 
Chapter 1 	 8 
C]DR domains (a and 13) and C2 (Fig 1.3-13). DBL domains have as a unifying 
feature a conserved structure composed of invariant cysteine residues. The cysteines 
are unevenly distributed among ten semi-conserved homology blocks (AA) in which 
DBL conservation is significantly concentrated. Within the DBL fold is a vast 
diversity of sequences, with a large proportion of differences occurring in the 
hypervariable blocks (I—X) that flank the homology blocks. Conserved CIDR 
characteristics include 13 or more invariant cysteine residues. However, unlike other 
variant gene families that apparently function only as clonally valiant targets of 
immunity, such as the Trypanosome variant surface antigens, var genes also encode 
cytoadherent properties. Thus, the var gene repertoire is shaped by selective forces 
acting to both maintain binding capability and escape immunity (Roberts et al, 1993, 
Smith, J et al, 2001). 
 
EXON 1 	 _J 	EXON2 
 
The PE-',%4P-1 protein and binding domains 
- CR1 CD 36 ICAM-1 	CSA 	 CD31 
Host 	- Heparih 
receptors - Blood group A 
Figure 1.3: Schematic representation of a var gene (A) and PfEMP1 protein 
architecture and binding domains (B). Individual domains involved in binding to 
several host receptors are indicated. CR1=complement receptor 1, HS=heparan 
sulfate, CSA=chondroitin sulfate A, ICAM-1=intracellular adhesion molecule 1 and 
CD36 (after Smith, J. et al, 2001). 
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1.5.1 The rf, stevor and clag gene families. 
Other antigenically variable multi-gene families genes have been discovered in 
Plasmodium such as the rif (repetitive interspersed family) genes encoding proteins 
known as rifins (Kyes et a!, 1999). These 27-39 kDa antigens comprise a 200 
member family, the largest gene family in P. falciparum. Rif genes are transcribed in 
the asexual stages of the parasite and rifins are transported to the surface of the 
infected red blood cell where they are detectable 14 to 16 hours after parasite 
invasion (Kyes et a!, 1999). They can switch transcription and undergo antigenic 
variation. Rif genes have 2 exons, the first of which encodes a putative signal peptide 
and the second of which encodes an extracellular domain made up of a conserved 
and a variable region, followed by a transmembrane segment and a short intracellular 
portion (Cheng et al, 1998, Abdel-Latif et a!, 2002). Unlike var genes, several rif 
genes are believed to be concomitantly expressed on the surface of the infected 
erythrocyte. They are immunogenic and their high copy number, sequence variability 
and red blood cell surface location indicate a potentially important role for rifin in 
malaria host-parasite interaction (Gardener et al, 2002) although a specific role in 
parasite adhesion has not yet been determined. 
Another multi-gene family called the stevor genes (subtelomeric variable open 
reading frame) which comprise 30-40 genes/haploid genome. These genes encoding 
30KDa proteins are called stevors. They may be variant antigens and have sequence 
similarity to rifins, but are less polymorphic and their function is unknown. It is not 
clear if they are actually surface exposed antigens. Some of these genes are 
expressed in gametocytes and the structure of these genes differs from those 
expressed in asexual parasites (Cheng et a!, 1998, Gardener et at, 2002). The clag 
family (cytoadherence linked asexual gene), another gene family potentially involved 
in adhesion, although probably not surface expressed, may affect cytoadherence 
indirectly through PfEMP1 transport rather than interacting directly with a host 
receptor (Craig, 2000, Craig & Scherf, 2001). 
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1.6 Immunity to malaria: the general situation. 
Infection with malaria parasites can induce a specific immunity, which may bring 
about clinical cure, but does not usually lead to complete elimination of parasites 
from the body (Bull & Marsh, 2002, Moorthy & Hill, 2002). Whereas immunity to 
many pathogens, particularly viruses, is long lived after a single infection/clinical 
episode, immunity to P. falciparum is incomplete, even in adults who have lived in 
high transmission areas all their lives. The main burden of disease falls on young 
children (Baird, 1995, 1998, Bull & Marsh, 2002). Anti-malaria immunity develops 
slowly and its precise mechanisms are unclear. Nor have unambiguously 'protective' 
antigens of the parasite been identified. Both the extreme antigenic diversity of the 
parasite and the existence of mechanisms of immune evasion may explain the 
difficulty in clearly identifying such protective antigens and acquired immunity is 
clearly not an absolute defence against re-infection (Warrell & Gilles, 2002). This 
state of disease resistance in an infected host associated with continuous parasitic 
infection is sometimes called premonition (Smith, T. et al, 1998). The host is 
resistant to new clinical episodes, as long as the pre-existing infection continues but 
once the infection is eradicated, immunity does not persist for long and cannot 
prevent re-infection (Smith, T. et a!, 1999a, b and c). 
Where malaria transmission is stable and holo-endemic, transmission occurs for at 
least 6 months in a year and is intense. Children suffer repeated attacks from the age 
of around 6 months. Those who do not die, have a substantial degree of immunity by 
the age of five or six years (Gupta et a!, 1999). When immunity is established, 
patients may still suffer attacks of malaria, but these are comparatively mild and last 
for only a few days. Older people are little affected (Moore et a!, 2002). In areas 
where malaria transmission is unstable, there are changes in transmission from one 
season to another, and from one year to the next. The transmission season is short, 
and infection of any one individual is comparatively infrequent, so that immunity 
does not reach a high level (Giha et a!, 2000). When an outbreak of malaria occurs, 
usually following explosive breeding of mosquitoes, it does so in the form of an 
epidemic with people of all ages being susceptible, although there are indications of 
age-dependent diminution of incidence (Creasey et a!, 2004). 
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Individuals living in endemic areas exposed to repeated infection, ultimately 
develop partial resistance or tolerance to the disease (Good, 2001). In such cases, 
even if the individual develops relatively high parasitemia, they show mild 
symptoms. Persons with this type of immunity can however be reservoirs for 
infection, because, though they show little or no symptoms, they carry the parasites. 
There is good evidence of trans-placental transfer of antibodies to a child born of an 
immune mother. This gives passive immunity to the child, but only during the first 6 
- 9 months of life (Miller & Smith, 1998). 
1.7 Immune mechanisms against red blood stages. 
A Innate immunity. 
Non-specific innate immune mechanisms are clearly important in the acquisition of 
protection against malaria. Theoretically, following infection with a single P. 
falciparum sporozoite infection in humans, one would expect all erythrocytes to be 
infected within about 16-18 days after the rupture of the initial liver schizont. 
However, in practice, parasitemia peaks much lower than this, at only 0.1% on 
average, suggesting that non—specific defense mechanisms may effectively control 
parasite growth even before strain antigen-specific immunity develops. Neutrophil, 
macrophage, and natural killer (NK) cells have been shown to be involved in this 
type of immunity. NK cells have been thought primarily to secret cytokines rather 
than have direct cytotoxicity (Sherman, 1998). Nevertheless, because of their ability 
to lyse target cells in non-MHC restricted fashion, NK cells participate in innate 
immunity mechanisms against malaria. Neutrophils also produce IFNy that activates 
macrophages thus linking innate and acquired responses. 
Neutrophil-mediated phagocytosis of P. falciparum has been observed in infected 
individuals, as has killing of intra-erythrocytic, asexual forms of P. falciparum. 
Cytokines, such as IFN-y and TNFa and TNFf3 appear to augment the anti-parasitic 
effect of neutrophils (Kumaratilake , 1990, Kumaratilake et al, 1991). Macrophages 
can also detect, 'screen out' and destroy abnormal and deformed iRBCs in the spleen 
during malaria infection (Weiss, 1990). 
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B Humoral Immunity. 
That this arm of immunity operates has been confirmed experimentally using the 
IgG fraction of sera from immune adults to transfer protective immunity. Transfer of 
purified, pooled hyper-immune IgG from African adults to Thai patients acted to 
reduce the parasite load, although this treatment did not induce sterile immunity 
(Bouharoun-Tayoun et a!, 1990). In terms of the mechanisms involved in antibody-
mediated protection, cytophilic antibodies (IgG 1, IgG3) have been proposed to exert 
an anti—parasitic effect by their participation in the so-called ADCI reaction 
(Antibody-Dependent Cellular Inhibition) (Brown et al, 1986, Bouharoun-Tayoun et 
al, 1995). Opsonizing antibodies promoting merozoite phagocytosis have been also 
observed (Warrell & Gilles, 2002). Antibodies have been found to be important in 
monocyte/macrophage and neutrophil mediated inhibition of P. falciparum 
replication in vitro (Kumaratilake et al, 1991). Antibodies capable of binding to the 
parasitized erythrocyte surface may also prevent binding and sequestration of these 
cells to the capillary endothelium and enhance removal of these cells by the spleen 
and other tissues of the reticulo-endothelial system (Urban et al, 1999). 
In the newborn child of an immune mother, the transfer of IgG across the placenta 
and possibly other factors protects the child during the early months of life (Riley et 
a!, 2001). Antibody-mediated protective responses could be directed against surface 
proteins of the merozoite leading them to agglutinate, thereby prevent the invasion of 
RBCs, in which case they act either by blocking key steps in the invasion process 
(Green, 1981), or by rendering the merozoite susceptible to secondary effects, such 
as phagocytosis or complement-mediated damage (Taylor et al, 2001). There is 
experimental evidence for all these reactions, and it is difficult to determine which 
are important. There are likely to be several distinct mechanisms whereby the host 
inhibits parasite replication. Where the destruction of parasites occurs is not known, 
but it does not seem to be in the circulating blood. The major site is probably the 
spleen, and evidence for this comes from experimental models and of course the 
classical observations on splenic enlargement in disease endemic populations. 
The flow of blood is slowed down in the spleen and infected RBCs come in close 
contact with the macrophages lining the blood vessels, causing the release of radical 
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oxygen intermediates (ROl), Nitric oxide (NO), and TNFa that damage the intra-
enythrocytic parasites, while infected cells and free merozoites are phagocytosed 
(Jacobs et at,. 1995). Auto-antibodies against normal RBC produced during human 
malaria may play a role in the pathogenesis of hemolysis and anemia of malaria 
(Daniel-Ribeiro, 2000). 
C Cellular immunity. 
CD8 T cells operate via the major histocombatibility complex (MHC) restricted 
mechanisms to destroy hepatocytes infected by pre-erythrocyte stage parasites. 
However direct, contact-mediated cytotoxicity is not effective against infected 
erythrocytes, probably because of lack of expression of Class 1 MHC on the 
erythrocyte surface (Hoffman, 1989 a and b). However as the parasite matures, it 
induces a series of morphological and antigenic changes in the host erythrocyte 
membrane. Some changes are because of alteration of the host constituents, perhaps 
by partial disruption or digestion of integral membrane proteins, but others result 
from the parasite inserting its own molecules into the host cell membrane. These 
antigens are potentially targets for immunity (Chen et at, 2000 a and b, Malaguarnera, 
& Musumeci, 2002). 
The major involvement of T cells in immunity to the erythrocyte stage of the 
parasite seems to be in providing help for the production of antibodies and in 
activation of macrophages and NK cells through CD4 Th2 cells. The malaria 
antigens are captured by antigen presenting cells (APC) and presented to Th2 T cells 
that are activated by interleukin-4 (IL-4), Th2 in turn secretes IL-4, 5, 6, and 13 that 
activates B cells to proliferate and differentiate into antibody secreting cells. 
Antibody binding to the surface of the merozoite and to the proteins that are 
externalized from the apical complex of organelles involved in erythrocyte 
recognition and invasion, may have an important role in immunity to asexual blood 
stages. Such antibody could neutralize the parasite, e.g. by blocking invasion of 
RBC, or lead to immunoglobulin constant region (FC) dependent mechanisms of 
parasite killing by macrophages, agglutinate the merozoites and/or possibly 
contribute to antibody-dependent cellular inhibition (ADC) (Taylor-Robinson, 1995 
a and b, Garraud et al, 2003). 
Chapter 1 	 14 
The intracellular parasite and its antigens activate CD4 T cells through 
interleukin- 12 that in turn induces secretion of IFNy that promotes activation of 
macrophages and NK cells. These cells secrete low levels of TNFa that work 
together with IFN1 to induce production of NO and reactive oxygen intermediates 
(Taylor-Robinson, 1995 a and b). The intracellular parasites are thought to be 
susceptible to cytokines produced by these immune cells. One possibility is that there 
would be initial parasite clearance by phagocytic cells in the reticule-endothelial 
system, leading to the recruitment of antigen—specific lymphocytes and the 
production of cytokines. Parasites would then be damaged whenever they passed 
through organs such as the spleen that are acting as parasite-killing 'cytokine 
factories'. High levels of circulating of INF'y and TNFa are more often found in 
patients with severe malaria than uncomplicated cases (Kwiatkowski, 1990) Animal 
models and indirect evidence from clinical observations suggest phagocytosis of 
infected red blood cells by splenic macrophage are important potential components 
of host defence mechanisms against blood-stage parasites (Wyler et al, 1981). 
Red blood cells lack nuclei and nucleic acid synthesis and thus cannot support viral 
replication, and express little or no MHC molecules, particularly in humans (mouse 
RBCS have higher levels of residual MHC). The absence of MHC classe I and II 
molecules makes the interior of erythrocytes a privileged site where infections can 
escape T cell surveillance. Different individuals in a population differ in the MHC 
molecules they express and will present different sets of peptides from pathogens. 
All individuals in a population will not be equally susceptible to any given pathogen, 
thereby limiting its spread. That pathogens can exert selective pressure on 
frequencies of particular MHC alleles is suggested by the finding that HLA-B53 
alleles are significantly associated with survival from lethal malaria. This allele is 
common in individuals living in West Africa, where malaria is endemic (Hill, T. et 
al, 1991, 1992 a and b). 
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1.8 An immunological and parasitological puzzle: the syndrome of 
pregnancy- associated malaria (PAM). 
Tens of thousands of pregnant women are infected annually with P. falciparum 
resulting in an estimated 75,000 — 200,000 infant deaths directly attributable to PAM 
(Steketee et a!, 1996b and c, Steketee et a!, 2001). P. falciparum infection in adults 
living in holo-endemic areas rarely causes severe malaria. Pregnant women are an 
exception. Both immature and mature stage parasites appear to be associated with the 
syncytio-trophoblast surface (Figure: 1.4). It has been suggested that parasites 
responsible for PAM express a distinct set of molecules mediating adhesion to 
receptors located only in placental tissue (Staalsoe et a!, 2004, Cox et a!, 2005). 
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Figure 1.4: Placenta containing P. falciparum -infected erythrocytes. Infected 
erythrocytes recovered from placenta bind CSA and adhere to syncytiotrophoblasts. 
Immunity to PAM has been shown to be parity-dependent; therefore multiparous 
women have fewer placental parasites when compared to primiparous women. 
Women who have antibodies that block infected erythrocyte adherence to CSA have 
fewer parasites in the placenta at delivery when compared to women without these 
blocking antibodies. (Staalsoe et a!, 2004). 
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1.8.1 Epidemiology of pregnancy associated malaria. 
In all malarious areas, the frequency and severity of this infection are greater in 
pregnant women than in the same women before pregnancy and in non-pregnant 
adult women (Gilles, 1986). The risk of infection is also higher for women in their 
first pregnancies (primigravidis) (Rasti et a!, 2004). 
In areas where malaria transmission is low, the degree of the acquired immunity 
present in women prior to pregnancy is likely to be low, rendering both the mother 
and her foetus susceptible to the most severe form of malaria. In contrast, in areas of 
high malaria endemicity, women have acquired a significant protective immunity and 
the effects on the mother and her foetus are less severe (Steketee et al, 1996a). 
Primigravidae are always the most at risk in all areas (Okoko et a!, 2002). However, 
in meso-endemic area where exposure to malaria is low, secundigravidae have been 
documented to suffer similar effects of infection to those of primigravidae (Nosten et 
a!, 1991). The increased risk of malaria is highest in the first half of the pregnancy 
and decreases progressively until delivery (Menendez, 1994). 
Adhesion of P. falciparum to placental receptors causes sequestration of mature 
infected erythrocytes in the placental blood spaces, allowing these parasites to grow 
and multiply. This leads to inflammatory responses and deposition of fibrinoid 
material in the placental wall (Brabin et a!, 2004). Foetal and postnatal consequences 
include spontaneous abortion, stillbirth and intrauterine growth retardation (Kasumba 
et a!, 2000), low birth weight and premature delivery (Menendez et al, 2000). it is 
uncertain how placental infection contributes to foetal morbidity, but it could impair 
exchange of nutrients and gases, and allow the foetus to be exposed to maternal 
immune cells of pro-inflammatory cytokines such as TNFa and IFN1 (Warrell & 
Gilles, 2002). 
1.8.2 Host-parasite interactions in placenta. 
The var genes called varlCSA, CS2var and var2CSA have all, at various times 
been implicated as the key genes encoding the parasite receptor that is both capable 
of binding placental receptors such as CSA and the target of protective, parity 
dependent antibodies (Ricke et a!, 2000). 
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The recombinant derived fragments of the varlCSA gene DBL3y domain were the 
first molecules to be shown to have some capacity to bind CSA and their 
transcription seemed to be concomitantly selected with CSA binding (Buffet et al, 
1999). However it has since been found that this gene is relatively rarely transcribed 
in parasites from placental infections (Rowe et a!, 2002 a) and transcribed equally in 
parasites from placental infections and infections of children (Fried & Duffy, 1996, 
2002) as well as being transcribed by non-CSA binding parasites (Kyes et al, 2003, 
Salanti et a!, 2003). An alternative candidate for the role of encoding the key 
protective immunogen is CS2var (Reeder et al, 1999). It has been identified that both 
the CIDR1ct and DBL1 domains of this gene bind CSA (Reeder et al, 2000). 
Antibodies raised to DBLy showed specific inhibition of CS2 parasite to CSA 
(Reeder et al, 1999). However Rowe and colleagues showed that this gene is not well 
conserved among different isolates (Rowe et al, 2002 a and b) and it appears that 
gene has no direct involvement in placental adhesion, thus seeming to eliminate its 
candidacy as the key protective immunogen for PAM (Rowe & Kyes, 2004). 
Salanti and colleagues have identified a third candidate CSA-binding ligand , the 
var2CSA gene (Salanti et a!, 2003, 2004). It is well conserved among different 
parasite isolates and its transcription is up regulated following CSA-selection. Unlike 
the first two genes, the transcription of this gene is consistent with the pattern that 
would be expected for a placental parasite CSA-binding ligand (Rowe & Kyes, 
2004). A number of recent publications have shown that placental P. falciparum 
isolates transcribed var2csa but not van csa (Salanti et a!, 2004, Jensen et a!, 2004, 
Tuikue Ndam et a!, 2005). The PfEMP1 proteins expressed on the surface of these 
parasite contains CIDR regions but do not bind to CD36 (Buffet et a!, 1999, Reeder 
et a!, 1999). This suggests that the DBL3 and CIDR1 region may combine to form 
the CSA binding site (Craig & Scherf, 2001). It has been proposed that the CIDR1 
from CSA binding parasites may be able to mediate adhesion to CSA (Degen et a!, 
2000). It is possible that this domain represents a cryptic binding domain, in vivo 
(Craig & Scherf, 2001). 
Different host receptors have been identified as possible targets for placental 
parasite sequestration (Bessin et a!, 2002b). The most studied is CSA, a 
glycosaminoglycan (Fried and Duffy, 1996). The minimal binding motif was 
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identified as a dodecasaccharide with two to three sulphate groups (Wahigren & 
Spillman, 2000). While low sulphated CSA appears to be the main receptor for 
parasite cytoadhesion in the placenta, other adhesive host/parasite receptor 
interactions probably contribute to placental sequestration. CD36 and ICAM-1 have 
been suggested to contribute the cytoadhesion to placenta (Andrews & Lanzer, 
2002). Another member of the GAG family, hyaluronic acid (HA), has been 
identified as a potential receptor for PE adhesion in the placenta (Besson et al, 2000, 
2002b). It has also been shown that natural 1gM antibodies bind to CSA-selected 
parasite clones, potentially enhancing placental sequestration (Creasey et al, 2003) 
and the nonimmune IgG (Flick et al, 2001). Shading and colleagues also showed that 
the placental parasites that are differentially recognized by males and females from 
malaria endemic regions recognize a trypsin-resistant entity (Sharling et al, 2004). 
1.8.3 Antibody-mediated Protection from PAM. 
Antibodies that develop after multiple pregnancies are associated with lower levels 
of PE's in the placenta and these have the capacity to block the CSA binding of P. 
falciparum isolated from various different parts of the world. When a woman is 
infected with P. falciparum in her first or second pregnancy, antibodies develop 
against the parasite variants that adhere in the placenta. These antibodies then 
contribute to protection from malaria in subsequent pregnancies (Rowe et al, 2002a). 
The broad specificity of this protection implies that a vaccine which can reproduce 
this effect is feasible. 
One of this study aims is develop effective techniques of identifying iRBC surface 
molecules that may play a role in eliciting a strong immune response. This would be 
useful for vaccine prototypes by applying these techniques to the specific 
phenomenon of PAM. The principles of this strategy however could be applied to 
other specific types of malaria. 
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1.9 Vaccine development in the post—genomic era. 
About 5300 P. falciparum antigens have been identified after whole-genome 
sequencing (Gardner et al, 2002). The genome database can be used for identifying 
hundreds of candidates for vaccination. Researchers have now sequenced the 
genomes of 140 bacteria, 1,600 viruses and 9 parasites (Rappuoli & Covacci, 2003). 
Genome sequences and supercompqters are thus directing vaccine science 
researchers through the genome sequences of microbes to develop potential vaccines 
for a variety of infectious diseases. Looking at homology in surface proteins across 
species may help scientists make better predictions of which genes might code for 
proteins that would make promising vaccine candidates. However to move from 
databases of microbe genomes then to vaccines, it is necessary to insert pathogen 
genes into recombinant expression systems to produce experimental antigens. 
Cloning of the gene coding for the antigen is usually necessary in order to produce 
the antigen (Capecchi et al, 2004). However, while straightforward in theory, this 
approach has difficulties where disease agents do not have obvious immuno-
dominant protective antigens to form the basis for the experimental vaccine. 
1.10 Is a malaria vaccine feasible? 
There are several thousand proteins, carbohydrates and lipids made by malaria 
parasites during human infection. Antibody and/or cellular immune responses are 
made to most of these molecules or antigens. An additional and serious obstacle to 
vaccine development is the fact that many antigenic proteins vary between different 
individuals of the malaria parasite population. Malaria parasite populations are not 
composed of identical organisms but are mixtures of genetically different and 
antigenically polymorphic individual clones. 
Malaria parasites can switch production of infected red blood cell surface protein 
antigens probably to evade the host's antibody-mediated immune response against 
surface-exposed molecules. Thus each member of the diverse and polymorphic 
population has an additional capacity for immune system evasion by clonal antigenic 
variation. In many areas of Africa where conditions sustain huge populations of 
mosquitoes, humans receive one or more infected bites each night and every bite 
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may introduce 10-100 sporozoites belonging to half a dozen, or more, different 
clonal lines. Malaria clearly poses a formidable challenge to the human immune 
system. Where it not for the fact that humans living with malaria transmission 
become partially immune to malaria, albeit after heavy childhood morbidity and 
mortality, it would be difficult to imagine a successful malaria vaccine being 
invented. 
The biological evidence that suggests that a malaria vaccine is possible includes, 
The observation that people living in endemic areas who have been repeatedly 
exposed to malaria eventually develop immunity against severe disease (Baird, 
1995). 
The demonstration that protection against malaria can be induced by immunising 
volunteers with irradiated malaria sporozoites (Clyde et al, 1973, Hoffman et al, 
2002). 
The demonstration that antibodies purified from life-long residents of endemic 
areas can be transferred into other individuals and confer some protection against the 
effects of malaria infection (Cohen et al, 1961). 
The demonstration that experimental vaccines already in hand can provide 
significant protection against malaria infection in humans. Anti-sporozoite vaccines 
such RTS, S have provided consistent, if relatively low-level, short duration 
protection in humans (Kester et al, 2001, Alonso et al, 2004). 
1.11 Vaccine bio-technology: Protein expression. 
Heterologous expression systems are based on the insertion of a gene of interest 
into a host cell for translation and expression into protein. There are several protein 
expression systems in prokaryotes and eukaryotes. They include: bacteria - e.g. E. 
colt, yeast (e.g. P. pastoris and S. cerevisiae), cultured insect cells and cultured 
mammalian cells. The advent of recombinant DNA technology makes it technically 
feasible to produce any protein of interest in a number of different organisms. 
However technical feasibility does not guarantee production success. Factors 
affecting expression include initiation of transcription, RNA elongation, RNA 
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stability, initiation of translation, translational elongation, polypeptide folding and 
post-translational processing including amino-terminal modification of polypeptide, 
disulphide bond formation, proteolytic cleavage of precursor forms, glycosylation 
and modification of amino acids within proteins. Production is also affected by the 
rate of degradation (Rai & Padh, 2001) 
The prokaryotic E. coli expression system is the most frequently used. Although it 
has many advantages, recombinant production often leads to inactive and insoluble 
proteins in inclusion bodies. Although methods have been developed to obtain 
correctly folded proteins from these inclusion bodies, the process of refolding cannot 
be successfully applied to all proteins (Pandey et a!, 2002). In addition, E. coli does 
not readily produce proteins with disulfide bonds and it produces all its proteins 
without glycosylation due to its lacking enzymes that carry out eukaryotic-type post-
translational modifications. Yeasts are simple eukaryotes and the most frequently 
used alternative to bacteria. The main species used are P. pastoris and S. cerevisiae. 
The main advantages of yeast cells are that they perform many eukaryotic and thus 
more human type post-translational modifications. The main disadvantage of yeast 
cells is the presence of highly active proteases that degrade foreign proteins. Insect 
cell expression systems using baculovims and mammalian cells can produce 
correctly folded proteins (Pizarro et al, 2003). However, so far only a few proteins 
have been successfully produced on an industrial scale using these systems mainly 
because these systems achieve very limited yields, thus making large-scale 
production uneconomical. 
1.12 Malaria gene expression. 
High A/T content and consequences of frequent asparagine and lysine-rich repeats 
in the P. falciparum genome are thought to be the main reason for the frequent 
problem of early termination in the mRNA translation process. The genetic code is 
degenerate and not all of the 61 codons that encode amino acids are used equally. 
Which of these 61 codons are the most commonly used depends strongly on the 
organism and, in fact, its genomic base composition. Usually, the frequency of the 
codon usage reflects the abundance of their cognate tRNAs. Thus, in a situation 
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where the codon usage of the pathogen protein of interest differs significantly from 
the common codon of the, expression host, this can and does cause problems during 
expression. The majority of P. falciparum derived recombinant proteins are 
expressed only as truncated forms or as insoluble inclusion bodies within the 
bacterial cells and the expression of P. falciparum derived proteins, especially 
membrane-bound proteins, is still a considerable challenge (Flick et al, 2004). 
Three main methods are available to increase the expression levels of gene 
sequences whose codon usage is different from that of the host cell; site-directed 
mutagenesis, co-expression of the sequence with genes which encode rare tRNAs 
and re-synthesis of the whole gene to be expressed to make it more consistent with 
the codon usage of the host expression system. Such methods have been used to 
express the entire EBA 175 protein (Yadava & Ockenhouse, 2003). X-ray 
crystallography has since been used to determine the atomic structure of a key 
portion of the EBA-175 (Duraisingh et al, 2003 a and b). For expression in P. 
pastoris, the codons of P. falciparum antigens also need to be optimized and 
potential glycosylation sites have to be removed. So far, this system is perhaps the 
most promising one for GMP (industrial scale and guaranteed quality) productions. 
P. pastoris has been used to express several malaria proteins such as CSP, MSP-119 
and MSP-1-AMA-1 hybrids for malaria vaccine studies (Kocken et al, 2002, Thang 
and Pan 2005). The more conventional yeast expression system S. cerevisiae has 
been used to express the Pvs25 (Miles et al, 2002). 
1.13 Current P. falciparum vaccine development projects. 
A genetically engineered, recombinant-produced malaria vaccine appears to 
offer the greatest hope of adding to the armoury of weapons for malaria control and 
significantly improving global child and public health. There are four general targets 
of possible vaccine candidate antigens derived from the different life-cycle stages of 
the parasite (Figure 1.5). 
rA 
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Figure 1.5: Malaria life cycle and long established vaccine targets. CS = 
circumsporozoite, TRAP = thrombospondin-related adhesive protein, EXP- 1 = 
exported antigen 1, LSA1 = liver stage antigen 1, MSP-1 = merozoite stage protein 
1, GLURP = glutamate-rich protein, AMA-i = apical membrane antigen 1. 
1.13.1 The pre-erythrocytic stage malaria vaccines. 
An ideal malaria vaccine would induce high titres of functional antibodies against 
sporozoites to prevent parasites entering the liver stage and induce potent cytotoxic T 
-lymphocyte imrnunogenicity to kill infected hepatocytes. The circumsporozoite 
protein (CSP) is the predominant antigen on the surface of sporozoites, and many 
vaccine constructs including CSP are in various stages of studies and trials in Africa, 
the USA, and Europe (Milich, 2001, Moorthy & Hill, 2002, Nardin et al, 2004, 
Oliveira et al, 2005). However the CSP-based malaria vaccine for which clinical 
development is most advanced is the well-known candidate RTSS/AS02A. 
RTSS/AS02A is a hybrid recombinant polypeptide produced by S. cerevisiae and 
consists of two compoñeñts: RTS is a polypeptide chain consisting of part (2/3) of 
the circumsporozoite protein fused to HBsAg and S is the hepatitis B surface antigen 
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polypeptide alone. RTS,S with adjuvant SBAS02 confers sterile immunity in 
approximately 50% of volunteers when administered on a two- or three-dose 
schedule. (Kester et al, 2001, Alonso et al, 2004). The adjuvant, SBAS2, is an oil-in-
water emulsion of Salmonella enterica cell wall-derived monophoryl lipid A and a 
saponin-type detergent adjuvant (QS-21). This adjuvant is essential for the protective 
effect seen with this vaccine (Lalvani et al, 1999). A variation on this type of 
CS/virus like particle vaccine is the ICC-1 132 CS/hepatitis B core particle. It 
contains B cell epitopes and a universal T cell epitope in combination with the highly 
immunogenic hepatitis B core antigen (HBcAg) as a delivery vector. It has been 
shown that antibodies neutralize these epitopes and appears to be safe and well 
tolerated (Milich, 2001). 
Other synthetic peptide CS-based vaccines include the Pf CS 282-383 long 
synthetic peptide vaccine, shown to elicit CD8 and CD4 T lymphocyte responses in 
humans. This vaccine was well tolerated and strong sporozoite-specific antibodies 
were elicited in a Phase 1 clinical trial (Lopez et at, 2001). Among other pre-
erythrocytic stage candidates are the thrombospondin-related. adhesive protein 
(TRAP, also known as SSP2) and several liver stage antigens expressed on the 
hepatocytes containing exo-erythrocytic schizonts, including LSA-1, LSA-3, and 
exported antigen 1 (EXP-l). LSA-3 is a conserved 200-kilodalton protein. In two 
chimpanzees (Pan troglodytes) immunization with LSA-3 induced protection against 
successive heterologous challenges with large numbers of P. falciparum sporozoites. 
(Daubersies et at, 2000). 
1.13.2 Asexual or blood stage vaccines. 
Parasites antigens are expressed on the surface of infected erythrocytes and also on 
free merozoites. These antigens are being studied in many of the current attempts to 
manufacture malaria vaccines. The goal of anti-erythrocytic vaccines is to 
dramatically improve upon naturally acquired immunity. Such vaccines would be 
designed for the community to reduce the total burden of the disease without 
necessarily eliminating the infection. 
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A Merozoite vaccine candidates. 
The majority of candidate blood stage vaccines in advanced development and early 
stage clinical trials are proteins identified as being on, or closely associated with, the 
surface of the merozoites. The most advanced production prototypes are merozoite 
surface protein 1 (MSP-i) (C-terminal domains MSP-1 1 9 or MSP-142) (Angov et at, 
2003) and apical membrane antigen 1 (AMA-1). MSP-1 has been produced as C-
terminal lyophilized recombinant antigen expressed in E. coli, consisting of the 42-
kD C-terminal end combined with the adjuvant AS02A. It has been found to be safe 
and immunogenic in mice, rabbits, and rhesus macaques and induced antibodies as 
measured by ELISA and against native parasite MSP-i on infected red blood cells by 
IFA assay and invasion inhibition assay (Angov et at, 2003, Polley et at, 2005). 
Vaccine candidates based on the smaller 19-kDa C-terminal fragment of MSP-i are 
also being developed independently as candidate vaccines (Garraud et at, 1999). 
The apical membrane protein 1 molecule of P. falciparum (PfAMA-1) is 
synthesized as an 83-kDa precursor, from which an N-terminal pro-domain is 
cleaved. The mature 66-kDa form of PfAMA- 1 is found in merozoite micronemes. 
Further processing results in the shedding of fragments of 44 or 48 kDa and occurs in 
association with the relocation of the molecule to the merozoite surface (Narum et al, 
1994). Recombinant AMA-1 has been shown to protect animal models (rodents and 
primates) against parasite challenge and this protection appears to be antibody-
dependent (Anders et at, 1998). Both rabbit and human anti-AMA1 antibodies were 
found to be strongly inhibitory to the invasion of erythrocytes by merozoites (Saul et 
at, 2005). P. falciparuin AMA-1, produced in P. pastoris, has also been tested in 
challenge experiments by vaccinating Aotus vocferans monkeys and then 
challenging them with P. falciparum parasites. Significant protection from an 
otherwise lethal challenge with P. falciparum was observed and the protection 
induced by AMA1 was superior to that obtained with a form, of MSP1 used in the 
same trial. However the protection induced by a combination vaccine of AMA1 and 
MSP1 was not superior to the protection obtained with AMA1 alone, although the 
immunity (i.e. antibody responses) generated appeared to operate against both 
vaccine components (Stowers et at, 2002). While AMA-i is an attractive candidate 
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antigen, there is considerable antigenic polymorphism in this molecule. This could 
affect the degree of protection afforded by a monomorphic variant. 
Other merozoite proteins (e.g. MSPs 2-7) are at an earlier stage of development 
although MSP-2 has been used in two Phase I trials in test of the immunogenicity 
and safety of a vaccine containing three recombinant malaria antigens (fragments 
from MSP-1, MSP-2 and RESA) from the asexual stage of P. falciparum. Human 
antibody responses observed with MSP2 in Montanide 1SA720 were similar those 
obtained in an earlier trial which used MSP2 with alum as the adjuvant (Saul et al, 
1999). Merozoite surface protein 3 (MSP-3) is a vaccine candidate antigen of 
molecular mass of 48 KDa. Purified anti-MSP-3 IgG from naturally immune adults 
subjects have been shown to be capable of inducing antibody-dependent cellular 
inhibition reaction (ADCI) in an assay that mimics cooperation between monocytes 
and cytophilic parasite-specific antibodies (Oeuvray et al, 1994). Glutamate-rich 
protein (GLURP) derived long synthetic peptides have also been identified as targets 
of human antibodies that are potentialy effective in ADCI. It has been proposed that 
GLURP may also play a role in the induction of protective immunity against P. 
falciparum malaria. (Oeuvray et al, 2000). 
The rhoptry-associated protein 1 and 2 (RAP1IRAP2) are located in the rhoptry 
internal organelles of merozoites. It has been reported that the anti-RAP1 mAb are 
able to inhibit merozoite invasion in vitro. Additionally, successful immunization 
with parasite-derived or recombinant RAN and RAP2 of P. falciparum in monkeys 
has been demonstrated (Collins .et al, 2000). Another vaccine candidate antigen, the 
ring-infected erythrocyte surface antigen (RESA) is present in the apical region of 
merozoites. This antigen is released into the parasitophorous vacuole during 
merozoite invasion and translocated to the inner surface of the RBC membrane. 
Ring-infected erythrocyte surface antigen elicits both humoral and cellular immune 
responses in P. falciparum-primed donors (Wipasa et al, 2002). 
Most vaccine clinical trials during the 1990s were carried out with the chemically 
synthesized multi-epitope peptide vaccine SPf66, by the Pattaroyo group in 
Colombia (Moreno & Pattarroyo, 1989). This vaccine is a multi-antigen multi-stage 
vaccine comprising chiefly of peptides 35.1, 55.1 and 83.1. Peptide 83.1 corresponds 
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to the N-terminal sequences of MSA-1 while peptides 35.1 and 55.1 are partial 
sequences from unidentified blood stage proteins (Facer & Tanner, 1997). The 
construct also includes two linking NANP sequences from the circumsporozoite 
protein. Although there have been numerous controversies about this vaccine (e.g. 
see Herrera et al, 1990, Acosta et al, 1999, Schellenberg et at, 1999) using very large 
numbers of Amazonian monkeys, the Pattaroyo group claimed to have been able to 
identify a multi-epitope synthetic vaccine that initially showed great promise in 
Aotus monkey challenge experiments and in early human clinical trials in South 
America (Perlaza et at, 1998). However further field trials in Africa and S.E Asia 
failed to repeat this early success and this candidate has now been largely dropped 
from the global vaccine development effort. 
B Malaria vaccines based on infected erythrocyte surface proteins. 
In addition to antigens on the surface of merozoites, parasite proteins exposed on 
the surface of infected RBC are regarded as potential vaccine candidates. Antibodies 
can be directed against such exposed antigens to enhance opsonization, complement 
mediated killing and to block the infected erythrocytes from adhering to the lining of 
blood vessels. A potentially serious obstacle to malaria vaccine development is the 
fact that many antigenic proteins, and particularly those present on the surface of the 
parasitized red blood cell, vary between different individuals of the Plasmodium 
population. As mentioned above, malaria parasite populations are not identical 
clones but are genetically diverse and antigenically polymorphic. 
Furthermore, individual malaria parasites can switch their production of infected 
red blood cell surface protein antigens in order to evade the host's antibody-mediated 
immune response against these vulnerable blood-stage surface-exposed molecules. 
Thus each member of the genetically diverse and antigenically polymorphic 
population has the additional capacity for individual immune system evasion by 
clonal antigenic variation. Plasmodium falciparum erythrocyte membrane protein-i 
(PfEMP-1) is the major family of variant surface proteins expressed on the surface of 
infected RBC. PIEMP1 proteins contain a conserved head structure composed of 
300-400 amino acid long Duffy binding like domains (DBL domains), named after 
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their homology to the Plasmodium vivax merozoite protein that binds to the Duffy 
antigen on red blood cells). 
DBL domains are often separated by the so-called cysteine residue rich inter-
domain regions (CIDR domains). The C]DR domains are also known to be 
responsible for binding to several host receptors and have been used as the 
immunization antigen in Aotus monkey challenge experiments with P. falciparum. 
After immunization with a particular CIDR1 domain (Malayan camp isolate), the 
monkeys controlled the primary infection (Baruch et al, 2002a). It has also been 
found that immunization with PfEMP1-DBL1 domains can generate antibodies that 
will disrupt the 'rosettes' formed by the binding of uninfected red blood cells to 
infected erythrocytes. Antibodies against PfEMP-1 have been generated in a variety 
of ways including immunization with hybrid PfEMP-1 Semliki Forest Virus like 
particles RNA particles and boosting with recombinant PfEMP-1 protein (Chen et al, 
2004) and using recombinant DBL-fusion proteins expressed in E. coli to generate 
antibodies in rats. Five out of ten recombinant DBLa fusion proteins were 
immunogenic and induced antibodies that reacted with conserved peptides derived 
from PIEMP1 (Oguariri et al, 2003). 
1.13.3 Anti-toxin vaccines. 
A number of the parasite antigens expressed on the surface of the infected red 
blood cell are linked to the surface through a glycophosphatidyl inositol (GPI) 
anchor. The concept of an antitoxic vaccine is based on the observation that 
individuals who are frequently exposed to malaria suffer few symptoms, although 
they remain susceptible to infection. An effective GPI vaccine may prevent or reduce 
the severity of disease. Proof of principle experiments carried out in rodent models 
indicate that the observed levels of morbidity and mortality are greatly reduced in 
mice immunised with GPI preparations (Schofield et a!, 2002). The role of GPIs in 
the establishment of malaria in the human host remains to be unraveled. People 
living in malaria endemic areas express naturally elicited anti-GPI Ab. Sera from 
adults who are resistant to clinical malaria contain high levels of persistent anti-GPI 
Ab, whereas susceptible children lack or have low levels of short-lived Ab. Anti-GPI 
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Ab responses are correlated with protection against malaria-related febrile illness and 
haemoglobin loss (Naik et a!, 2000). 
1.13.4 Transmission Blocking Vaccines. 
Transmission-blocking vaccines aim to stimulate the production of human 
antibodies to molecules present on the surface of the sexual stage gametes. When the 
gametocytes are ingested by the mosquito, antibodies in the blood meal will have 
access to the released gametes in the mosquito mid-gut and inhibit the development 
of the parasite through the mosquito phase of the life cycle thus halting transmission. 
Transmission blocking vaccines on their own, if developed, will not confer 
protection against the development of the disease in at risk populations and will need 
wide-spread and long periods of sustained vaccination in order to significantly cut 
down on transmission levels (Ballou et a!, 2004). Pfs25, a 25-kDa surface antigen of 
zygotes and ookinetes and Pfs28, a 28-kDa surface antigen of late ookinetës, are two 
of the lead vaccine candidates. Both comprise four tandem epidermal growth factors 
(EGF)-like domains that anchored to the parasite surface by 
glycosylphosphatidylinositol. Produced as recombinant proteins in yeast, both of 
these antigens have been shown to induce transmission-blocking antibodies in 
experimental laboratory animals (Barr et a!, 1991). 
Two vaccine candidates, Pfs25 and Pfs28, were produced as single recombinant 
fusion proteins. The 39-kDa chimeric proteins, having a C-terminal His6 tag, were 
secreted by S. cerevisiae, using the prepro-factor leader sequence. Pfs25-28 fusion 
proteins were more potent than either Pfs25 or Pfs28 alone in eliciting antibodies in 
mice that blocked oocyst development in Anopheles mosquitoes. Complete inhibition 
of oocyst development in the mosquito midgut was achieved with fewer 
vaccinations, at a lower dose, and for a longer duration than with either Pfs25 or 
Pfs28 alone (Gozar et al, 1998). 
Pfs25 is a dominant protein on the surface of P. falciparum zygotes and a 
transmission blocking vaccine based on this is currently in clinical trials. Pfs25 was 
discovered by a monoclonal antibody which when fed along with a parasitized blood 
meal to a mosquito resulted in a blockage in the infectivity of that mosquito. A 
number of Pfs25 - like compounds have also been discovered in other species of 
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Plasmodium. Their structure all shares four tandem EGF-like domains (Duffy & 
Kaslow, 1997). Duffy and his co-workers discovered Pfs28, a similar but 
immunologically distinct antigen to Pfs25. Pfs230 another sexual-stage P. falciparum 
surface antigen can also elicit antibodies which block the infectivity of gametes to 
mosquitoes (Duffy & Kaslow, 1997). 
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1.14 Thesis aims and methodology. 
To obtain antigens in a suitable state for initiating vaccine prototype development 
it is necessary to scale up production in optimal expression systems. The 
recombinant proteins needtobe correctly folded and which induce appropriate 
antibody responses. The overall aim of this study is to find faster and more effective 
ways of identifying and developing vaccine candidate antigens that can be used to 
elicit immunity to the erythrocytic stage in the human host and produce biologically 
active proteins in quantities that can be easily scaled up for vaccine test batch 
production. Methods chosen for analysis were based upon the yeast expression 
system P. pastoris and E. coli. A specific aim of this study was to develop a fast and 
efficient way of expressing P. faiciparum antigenic epitopes as conformationally 
conserved antigenic structures whose expression can be readily 'scaled-up' for 
clinical testing. The E. coil and Pichia pastoris systems were used both singly and as 
linked production systems using 'shuttle vectors' that can be dually expressed in both 
microorganisms. 
Initially a proof-of-principle type experiment to express and purify in good quantity 
the recodoned CIDR1 domain of PfEMP1 of 3D7 parasite in P. pastoris (strain X33) 
was conducted. The plasmid pPICZtA was used as the expression vector. The 
recombinant protein was used to immunize rabbits. The Polyclonal rabbit serum was 
assessed using immuno-blotting and irumuno-fluorescence assays. 
The sequenced 3D7 P. falciparum genome was exploited to construct degenerate 
primers for several domains of PfEMP1 (namely DBLa, DBLI3 and DBLy). These 
primers were used to amplify targets from FCR3CSA parasites. PCR products were 
ligated into the dual expression pPICHOLI1 vector. Six different P. falciparum 
gDNA DBL expression libraries were successfully produced in E.coli and in P. 
pastoris. Experiments were conducted to optimise the growth, lysis and 
immunoscreening of colonies on filters on agar plates for high-throughput screening. 
Different domains from a gene of particular interest, the var2CSA gene were 
also amplified for expression and screening studies. These recombinant proteins were 
screened to investigate differential recognition by pools of serum from selected 
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groups living in malaria endemic zones, notably adult males and females who had 
experienced malaria during pregnancy. 
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Chapter 2. Heterologous expression of PfEMP-1 
fragments in Pichia pastoris. 
2.1. Aims. 
The aim of this study was to investigate the utility of a heterologous expression 
system, the yeast P. pastoris, for expression of one of the major structural domains of 
the modular and variant protein PfEMP1. A Cysteine-Rich Interdomain Region 
(CIDR) domain of PfEMP1 was chosen as the first domain-type structure to be 
expressed. The reasons underlying this were that the CIDR region has been reported 
to encode a particular binding property, particularly that of binding to CD36 (Baruch 
et a!, 1995, Newbold et al, 1997). Immunization of Aotus monkeys with the 'M2 
region', a conserved motif of CIDR1 has elicited high titre anti-sera that were found 
to be primarily variant-specific. (Baruch et a!, 2003, Miller et al, 2002). There are 
also reports that some variants of this region can mediate binding to CSA on the 
surface CHO cells (Degen et a!, 2000). The sequences of the CIDR1 domain have 
thus been considered to be potential vaccine candidates - a part of the so-called 
'conserved head structure' of PfEMP-1 molecules (Gamain et al, 2001). 
The CIDRI domain used in this study was derived from the 3D7 strain of P. 
falciparum. The PfEMP1 var gene containing this particular CIDR1 was classified as 
a type 5 var gene organised into DBLa, CIDRa, DBLI3, C2, DBL7 and CIDR-nona 
domains (Gardener et al, 2002) (Figure 2.1). A similar but somewhat differently 
organised classification scheme has been proposed by other workers (Lavstsen et a!, 
2003). Previously, the CIDR was re-codoned in the laboratory (T. Fagin and P. 
Bruce) to match the codon usage of P. pastoris and cloned into the pPICZaA 
expression vector (Figure 2.2). The objective was to explore whether the Pichia 
system can be used to produce large quantities of correctly folded recombinant 
CIDR1. Such conformationally correct antigens are needed in order to raise specific 
antibodies to this antigen and to develop assays to assess its immunogenicity. The 
choice of this domain was basically due to its ability fro binding to CD36 receptors, 
and if we managed of express this domain, we will be able to carry out host /parasite 
adhesion inhibition assays. Later on, it was found that the gene contains this domain 
was categorised in the group A (comprises telomeric genes transcribed towards the 
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telomere encoding PfEMP1 s with complex domain structures) that consists of ten 
genes consistently identified as a distinct group by sequence analysis of Sequence of 
var 5' regions (Lavstsen et al, 2003). Interestingly, recombinant CIDR domains 
based on the group A sequences do not bind CD36, by contrast to CIDR domains 
produced on the basis of groups B and C. Group A var genes mainly encode large 
PfEMP1s with complex multi-domain structure (Lavstsen et al, 2003). 
DBLa X CIDRct ( DBL3 )C2 DBLc )(CDR-nona 
Figure 2.1. PfEMP1 protein architecture of type 5 var genes that includes the 
CI1DR1a investigated in this study (Gardner et a!, 2002). 
2.2. A+T.richness, codon usage bias and re-codonisation. 
Different organisms often show strong preference for one of the several codons 
that encode the same amino acid in the 'degenerate' genetic code. Why such 
preferences arise is debated but in practical biotechnological terms, if the tRNA pool 
sizes do not correspond to the preferred codon usage, translation will not be optimal. 
Expression in heterologous systems is usually up-regulated and driven by a strong 
promoter and this increases the likelihood of 'draining the tRNA pool' for 
uncommon tRNAs. This could lead to premature chain termination and affect protein 
folding as the polypeptide chain is progressively synthesized by the ribosome 
moving along the mRNA. In S. cerevisiae and P. pastoris, it is known that adenosine 
rich stretches of sequence, prevalent in P.falciparum genes, can act as 
polyadenylation and/or transcription termination signals, resulting in low-level gene 
expression or truncated mRNA (Sreekrishna et al, 1997, Sorensen et al, 1989, Pizzi 
& Frontali 2001). The P. falciparum genome is one of the most AlT rich of any 
genome known (typically 80% A/T rich genes and up to 85% A+T in its intragenic 
regions). In general, taxonomically close organisms- use similar codons for their 
protein synthesis whereas taxonomically distant organisms tend to utilize different 
codons (Ikemura, 1982). All heterologous expression systems thus experimented 
with, apart from Dictyostelium (HOward et a!, 1988) and Tetrahymena (Peterson et 
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al, 2002), have more G+C rich codon-usage than P. falciparum. Notably,. the entire 
CS protein of P. falciparum has been expressed and localized to the cell surface in 
the free-living ciliate Tetrahymena thennophila. (Peterson et a!, 2002). The codon 
bias problem, as it affects E. coli expression, has been addressed by Stratagene who 
have engineered novel bacterial expression lines (BL21C odonPlus® RPIL line). This 
E.coli strain contains a plasmid encoding extra copies of tRNA that recognize rare E. 
coli codons. This has had success in allowing over-expression of A+T codon rich 
Plasmodium genes (Makoff et al, 1989, 1994). However this has not removed the 
need to synthesise a codon-optimized version of the sequence of interest (Yadava & 
Ockenhouse, 2003). 
2.3. Pichia pastoris expression system. 
P. pastoris (Guillermand) Phaff 1956; is a methylotrophic budding yeast 
(Phylum: Ascomycota, Class: Hemiacomycetes, Order: Saccharomycetules, Family: 
Saccharomycetaceae). It is considered as non-conventional yeast, compared with the 
conventional baker's yeast S. cerevisiae (Cereghino & Cregg, 1999). This system has 
a number of advantages for protein expression. Pichia can be grown to higher 
densities than S. cerevisiae and it has the capability of performing many eukaryotic 
post-translational modifications, such as glycosylation, disulfide bond formation, and 
proteolytic processing. The post-translational modifications made by P. pastoris may 
be more suitable for protein production for use in humans. It is specialised for growth 
on methanol as a sole carbon and energy source, and has an extremely powerful 
regulated promoter for alcohol oxidase. Alcohol oxidase expression is induced by 
methanol and when fully induced this enzyme can comprise 30% of total cell protein. 
The system is relatively easy to scale up for bulk production, particularly if the 
product can be secreted by the yeast cell (Cregg et al, 1993, 2000, Sreekrishna, 1997, 
Bretthauer & Castellino, 1999, Cereghino & Cregg, 1999, 2000). However, whether 
P.pastoris is the system of choice for P. falciparum gene expression remains to be 
established. The Pichia expression vector pPICZaA has been designed for 
heterologous expression and secretion of recombinant proteins. This expression 
vector carries a C-terminal tag sequence to allow purification and detection of fusion 
proteins. The 'tag' consists of six histidine residues to allow purification on nickel 
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affinity resins and the c-myc epitope sequence for rapid detection by antibodies. 
Other features of this plasmid include; an inducible AOX1 promoter, (X-factor 
secretion signal for transport/secretion of proteins and the zeocin resistance gene for 
selection in E. coli and yeast. After initial ligation of an insert into the plasmid 
vector, the construct is amplified in and then extracted from E.coli cells of the XL-10 
Gold type (Stratagene). PCR-screening was used to confirm the presence of inserts, 
using primers hybridising to sequences in the yeast alcohol oxidase gene (AOX3' and 
AOX5'). The structure of this vector is shown in Figure 2.2. 
EE* 
Sacli I Recodoned CIDR1 	oti 
0 - E 	-. 
Figure 2.2. The pPICZaA construct used for expression of the secreted version 
of the synthetic CIDR1. pPICZctA makes use of the AOX1 promoter and it has a-
factor signal sequence for secretion of the expressed protein. It carries Zeocin 
resistance for selection of both yeast and E.coli in antibiotic media. 
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2.4. A Codon-Optimised Version of CIDR1. 
A synthetic CIDR1 gene was designed based on (P. falciparum 3D7 var gene 
located on chromosome no.6, acc.No. 103738432) to decrease the AlT richness of 
the sequence and replace rare codons with more commonly used codons in 
methylotrophic yeast systems. Potential N-glycosylation sites were also mutated as 
P. falciparum lacks the N-glycosylation(Diechmann-Schuppert et al, 1992) . Re-
synthesis also involved removal of restriction sites that may interfere with 
downstream cloning techniques. Predicted N-glycoslyation sites (N- X- SIT- N) in 
the amino acid sequence were identified using the web-based program 'NetNGlyc' at 
http:/Iwww.cbs.dtu.dkIservicesINetNGlcI. To modify these sites, the serine (S) or 
threonine (T) in the motif was replaced with an alanine (A), as it is the smallest 
amino acid, predicted to have the minimum effect on secondary structure. It was 
considered appropriate to remove the N-glycosylation sites as P. pastoris is known to 
glycosylate (and sometimes hyper-glycosylate) at asparagine residues and this can 
interfere with correct folding and tertiary structure of the protein (Bretthauer & 
Castellino 1999). 
Zeocin resistant clones were sequenced to confirm they were in-frame with the 5' 
a-factor signal sequence and 3' tag sequences. Resulting recombinant plasmids were 
linearised by sal 1 before transfection by electroporation. The resulting recombinant 
insert was sequenced. The native and recodoned sequences are compared in Figure 
2.3(See Appendix 1 for the amino acids alignment). 
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CIDR1-native --------------- GAAAAACAAAAAATTATGCCCTTTGATGr-ATTTTTTTCCTTTGG 
CIDR1-Racodoned CCGCTCGAGAAAAGAGAGAAGCAGAAGATCATGCCATTCGACGCCTTCTTTTCCTGTGG 
** ** ** ** ** ***** ** ** ** ** ******* *** 
CIDR1-native CTAACACAAATGTAATGACTATAGAATGGPGAAAAAAACTTAAAACCTGTATT 
CIDR1-Recodoned CTGACTCAATGCTGGACGACTCCATCGAGTGGCGTAAAACAACCTGCATCAAC 
** ** ** *** * ** ** ** ** ** *** * ** ** ***** ***** ** ** 
CIDR1 -nat iva AATGAAAAACCAACTAATTFTATACGGGGTTGTAAAAAGCCCTGCGAATG1AAAA 
CIDR1-Racodoned AACGAGAAXCCAACCAACTGTATCCGTGGTTGTAAGAAGCCTTGCGAGTGTTTCAA 
** ** ** ***** ** * *** ** ******** ***** ***** ***** ** *** 
CIDR1 -nat ive TGGGTTGAACAAAAAAAGAAGAATGGATTTCAATTGAAAAACATTTTGACAAACAAAA 
CIDR1-Racodoned TGGGrrGAACAGAAGGAGCAGGAGTGGATCTCCATTGAGACACTTGACAACAA 
*********** ** ** 	* ** ***** ** ***** ** ** ******** ** *** 
CIDR1-native GATATATCAGAAAAAACGTTATATAACACGAATATATTTTGAATGAATrI'ILATG 
CIDR1-Recodoned GACATCTCCGAGGAAGAGCGTTACATCACCCTGGAGTACATCCTGAACGAGTTCTTCATC 
** ** ** ** ***** ***** ** ** ** ** ** ** 	**** ** ** ** ** 
CIDR1-native GATAAAATTGAAAA7GCTTATGGAATAGAAAAATCAAAAAATTAAAGAGAAATTAAAA 
CIDR1-Recodofled GACAAGATCGAGAAGGCTTACGGAATTGAGAAGTCCAAGGAGTTGAAGGAGAAGCTGAAG 
** ** ** ** ** ***** ***** ** ** ** ** ** ** ******** 	* ** 
CIDR1 -native TCAAATAAAGGTCACGGAATTATAAGATACAGAACATTCACAGGATGCAATAAATA 
CIDR1-Racodonad TCCAACAAGGGTCACGGAATCATCCGTGACACTGAACACTCCCAAGACGCCATCATC 
** ** ** *********** ** 	* ** ** ***** ** ** ** ** ** ** ** 
CIDR1-native TTGCTAGAACATGAATTAGAATGC1AAAAAATGCACAGAAACCCATAATGATAAAAA 
CIDR1-Recodoned TTGCTGGACACGAATTGGAGGACGCTAAGAAGTGCACCGAAACCCACAACGACGAGAAG 
**** * ** ** ***** ** ** ** ** ** ***** ******** ** ** ** ** 
CIDR1-native TGTAAAGAACAAGAAGAGAGCGGAGGTCGCTCTTTAAACCCGGATCCAGAATCCGACGA 
CIDR1-Recodoned TGTAAGGAGCAGGAGGAGTCCGGTGGTAGATCCCTGAACCCTGATCCAGAATCCGACGA 
***** ** ** ** **** 	*** *** * ** 	* ***** ***************** 
CIDR1-native 	 CGAAGAAGAAACGGATAATGTAAAAGAGAACCCGTGTGCTGTAGGGAAAAAACTCACTAA  
CIDR1-Racodonad 	CGAAGAGGAGACTGACAACGTCAAGGAAAACCCATGTGCTGTCGGAAAGAAGCTGACCAA  
****** ** ** ** ** ** ** ** ***** ******** ** ** ** ** ** ** 
CIDR1-native 	 AACTGTGAAACAAATCGCTAGACAGATGCATCAAGCGGCAAAGAAACAATTGGGTTAG 
CIDR1-Recodoned 	GACCGTCAAGCAAATCGCTAGACAAATGCACCAAGCTGCCAAAAGCAX3TTGGGTTCCTC 
** ** ** ************** ***** ***** ** ***** ** ****** 
CIDR1-native 	 TAGTAGTACGGCATTGAAGGCTCAT 
CIDR1-Racodonad 	TTCCTCTAGACCTTGAAGGCTCACCACCATCACCATCATTAACGGCCGCCGC 
* 	*** ** *********** 
Figure 2.3. Nucleotide Sequence alignment of native and codon-optimised 
C11DR1. * indicates unchanged nucleotides while gaps indicate where substitutions 
have been made. The A+T content was reduced from 67.6% to 48.6%. 
2.5. Induction and immunodetection experiments. 
Small-scale and mid-scale expression of CIDR1 in P. pastoris resulted in secretion 
of protein of the expected size showing little degradation (Figure 2.4). To investigate 
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whether the construct CIDR1 -pPICZctA is secreting the altered CIDR1 protein in 
large quantities, small-scale induction experiments were used to screen selected drug 
resistant clones for secretion! production. These cultures were grown for 2 days at 
30°C in 10 ml of BMGY in 50-ml Falcon tubes with vigorous shaking. Cells were 
harvested by low-speed centrifugation, resuspended in 100 ml of BMMY, and 
cultured for an additional 3 days. Cells were harvested and culture supernatants 
analyzed for the presence of secreted CIDR1 on a 15% SDS gel. Gels were stained 
with Coomassie Brilliant Blue to visualise the protein bands (Figure 2.4). 
The hexa-histidine tagged protein was detected using an antibody specific for the 
histidine tag sequence in the expression vector. The positive control used in Western 
blot analysis of the Pichia derived recombinant protein was a His-tagged protein, 
serpin, a -55KD Brugia malayi serine protease inhibitor expressed in E. coli. When 
the induction was scaled up, a secreted CIDR1 band of the expected molecular 
weight, 28 KDa was detected by Western blotting. For mid-scale production of 
CIDR1, recombinant P. pastoris was initially cultured in 2-liter baffled flasks (1000 
ml of BMGY per flask) for 48 h at 30°C with vigorous shaking (300rpm). Cells were 
harvested and the pellet from this one litre culture was re-suspended in 120mls of 
BMMY in a one litre baffled flask then incubated for 72 hours at 30°C with vigorous 
shaking (300rpm). Methanol was added to a final concentration of 0.5% every 24 
hours (although continuous infusion of methanol is preferable to facilitate constant 
induction by the alcohol oxidase promoter). Culture supernatant samples 
(1 5microlitres) were incubated in an equal volume of loading buffer, heated for 10 
minutes at 95°C and run on two SDS gels. Following electrophoresis, one gel was 
stained and the other was transferred to a PVDF membrane using semi wet method 
for immuno-detection. After overnight blocking in 5% non-fat milk/PBS, membranes 
were probed with His-tag-HRP antibody (Qiagen). The blot was visualised using an 
ECL plus detection kit (Amersham Biosciences) (Figure 2.4). 
Unfortunately attempts to obtain large quantities (-10 mg/L) of the protein in basic 
laboratory cultures and shakers failed, probably because of the lack of control of 
optimal levels of key metabolites such as methanol. Therefore attempts were made to 
scale up production using the more controlled conditions available with more 
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sophisticated fermentation technology, available to us at the Edinburgh University in 
ICMB. 
A. 
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Figure 2.4. Analysis of Pichia supernatants from small-scale cultures. A. 
Coomassie blue stained polyacrylamide gel. M. Molecular weight marker. 1. P. 
pastoris culture supernatant, 24 hours after methanol induction. 2. Culture 
supernatant after 48 hours of induction. 3. Culture supernatant prior to induction. B. 
Duplicate gel analysed by Western blot using the anti- His tag antibody. 
2.6. Pichia expression using a fermentor. 
The fermentation run consisted of the following stages: 
• 	Glycerol Batch Phase - 20 hours. 
• 	Glycerol Feed Batch phase - 2 hours. 
• 	Starvation phase - 1 hour. 
• 	Methanol Feed Batch - 70 hours. 
• 	Harvest. 
Expression was optimized for production using a New Brunswick BioFlo5000 
fermentor. One millilitre of frozen glycerol culture (50 mIs of the culture obtained 
after 24 hours of growth of a single colony in YPD plus zeocin, made 80% with 
glycerol and then stored in aliquots) was used to inoculate 600 ml of BMGY medium 
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and grown until the culture reached an optical density of 10 at 600 nm. The 
fermentor, containing 9 litres of bulk fermentation medium was then inoculated with 
this seed preparation and grown until the glycerol carbon source in the medium is 
completely consumed (20 hours). The culture is then supplemented with 50% 
glycerol in the 'glycerol feed phase'. The culture consumes this glycerol in about 
after 2 hours and a further 1 hour of carbon source starvation is carried out before the 
production phase of the culture starts. The production phase is started by the addition 
of 12mlllitre of PTM (a trace salt medium) dissolved in methanol, the alcohol 
oxidase inducer and carbon source, for three hours. Then after the initial addition a 
constant feed inoculation was set at 7.3 mis/litre/hour for 2 hours. The methanol feed 
rate was changed to 11 mlIlIh for 34 hours (giving a total run length of 65 hours). 
The pH was controlled with 14% ammonium hydroxide. Other fermentation 
parameters were as follows: the dissolved-oxygen level was maintained by airflow of 
90 litres per minute, the air supplemented with oxygen. The pH was maintained at 
5.0 and the temperature at 30°C. The culture was subjected to an agitation cascade 
from 360 to 550 rpm over the 65 hours of the run. Controlled fermentation is the 
most effective way for the recombinant protein to be expressed in the Pichia system 
because the parameters for maximally effective expression can be met. These include 
control of the temperature, dissolved oxygen, constant pH, agitation and aeration and 
methanol concentration. A time dependent product (CIDR1 recombinant) of the 
expected MW (-28kDa) was consistently increasing in quantity after 24 hours 
(Figure 2.5). 
30 KDa 
Figure 2.5. Analysis of supernatants from a CIDR1a-pPICZaA-transformed 
Pichia after fermentor expression. Supernatants were concentrated by 
centrifugation using a Vivaspin 6 (5,000 MW cut-off), reduced and separated by 
SDS-PAGE on 4-12% polyacrylamide gels. Proteins were stained using Coomassie 
blue. Time-dependent expression of a protein of 28kDa is observed; most clearly at 
72 hours post induction. MW markers are indicated in kDa. 
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2.7. Purification of His-Tagged Protein. 
After bulk fermentation runs the supernatant was precipitated with ammonium 
sulfate, and the proteinaceous pellet re-suspended in PBS and dialysied. A 1 ml Ni-
NTA 1-li Trap chelating column and then a gel filtration column were used for the 
purification of the recombinant CIDR1. The column was pre-washed with 1120, 
loaded with 100mM NiSO4 and then washed again with H20. Prior to loading onto 
the column, the protein sample was dialysed against the column binding buffer (20 
mM sodium phosphate, 0.5M NaCl, p11 7.4). The column was then equilibrated and 
washed with binding buffer. The dialysed protein intended for column purification 
was spun at 1000g for 30 minutes at room temperature to remove debris. 
The cleared supernatant was loaded on the column at a flow rate of 1.2-1.5 ml/min 
nickel resin-bound; His tagged protein was eluted with 20 MM sodium phosphate, 
0.5M NaCl, 0.5M imidazole pH 7.4. Samples were then analysed by SDS-PAGE and 
quantified by reading the absorbance at 280nm of the fractions after the BioRad DC 
protein assay had been carried out. Those samples with the greatest concentration of 
protein were pooled and the elution buffer exchanged by dialysis against PBS. Using 
SDS-PAGE to analyse the purified product, a dense band of the expected size was 
detected in addition to a very faint band (z I3KDa). The smaller band, of unknown 
origin, can be eliminated by passage over a gel filtration column (Sephadex 0-50). 
For the gel filtration, the matrix was pre-swollen in I  Tris, 20 mM NaCl. The PBS 
dissolved sample was loaded onto the colum and then washed through in the 
TrisINaCl buffer. The leading fractions collected contain the larger molecular weight 
proteins. Figure 2.6 shows the quality of this product. 
The results show that the majority of the gel filtered sample is monomeric (80%) 
with about the expected size (30 KDa). Estimated protein yields were 50 mg/litre. 
These results confirm our expectation that the controlled fermentation is a much 
more effective method for the expression of the recombinant protein than induction 
in flasks. 
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Figure 2.6: Coomassie stained polyacrylamide gel showing the results obtained 
after two-step purification of the recombinant Cll)R1. Lane M is MW marker 
(Bio-Rad). Lanes 1 and 2 are fractions after washing with the washing buffer and 
lane 3 is the pooled eluted protein after elution. 
2.8. Glycosylation Testing. 
In designing the synthetic CIDR1 DNA coding sequence, mutations have been 
introduced to the sequence to remove sites that are generally N-glycosylated by 
eukaryotic expression systems. The rationale for this is that glycosylation, rare or 
absent from native P.falciparwn antigens, may interfere with the correct folding and 
sero-recognition of the epitopes. Protein over-glycosylation frequently results in 
highly heterogeneous products which may be difficult to reproducibly purify to 
acceptable standards under cGMP. Hyper-glycosylation can also cause antigen 
hyper-immunogenicity, which can be lethal in experimental animals. 
To test for glycosylation, the Pro-Q Fuchsia Glycoprotein Gel Stain Kit 
(Molecular Probes) was used. This depends on the Periodic acid-Schiff (PAS) 
reaction. After fixing the gel with 500 mIs of 50% methanol, it was washed with 
ddH20 and incubated in oxidizing solution ( 20% Periodic acid). In the dark, the gel 
was washed in Pro-Q Fuchsia reagent, before being incubated in the metabisuiphite 
reducing agent. After staining with the glycoprotein staining kit, the recombinant 
CIDR1 expressed in Pichia is shown in Figure 2.7. No glycosylation of the 28-kD 
Chapter 2 	 44 
1 
r 
5 KDa. A. NI 






wasdetected although some glycosylated high molecular weight material appears to 
be present in the supernatant. 
Figure 2.7. A 15 % SDS-PAGE Coomassie stained gel of recombinant CIDRI 
(A) and its duplicate gel (B) alter glycoprotein staining. 
Lane M. Molecular weight marker. Lane 1. Purified proteins stained by 
Coomassie stain (A) and its duplicate stained with glycoprotein staining kit (B) to 
detect both N-linked and 0-linked oligosaccharides. The positive controls in the 
marker in gel (B) stained with the Pro-Q Fuschia reagent. 
2.9. Reactivity of malaria infection serum with the Pichia produced 
CIDR1. 
To investigate whether humans mount an immune response following malaria 
infection to CIDR1, an ELISA assay was set up using plasma samples collected in 
Sudan. Serum antibodies to the recombinant CIDRI were measured using enzyme-
linked immunosorbent assay (ELISA). Plate wells were coated with 0.5, 1 and 5 
tg/rnl of the recombinant CIDRI in 100iJ of coaling buffer (15mM Na 2CO3, 35 mM 
NaCO3 pH 9.3). The wells were then washed three times in washing buffer (0.05% 
Tween 20 in PBS). The adherent antigens were blocked to prevent non specific 
proteinaceous binding with blocking buffer (1% skimmed milk powder in washing 
buffer). Human plasma diluted 1:500 in blocking buffer was added and incubated 
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overnight at 4°C. After 3 more washes with the blocking buffer, the wells were 
incubated for 3 hours at room temperature with horseradish peroxidase-conjugated 
rabbit anti-human IgG (Dako, diluted 1:5000 in washing buffer). The wells were then 
washed again 3 times with the washing buffer and incubated for 15 min at room 
temperature with the substrate (Sigma)(0.1 mg mF' 0-Phenylendiamine +0.012% 
H202) in developing buffer (24.5mM citric acid monohydrate and 52 mM Na2HPO4, 
PH 5). The reaction was stopped by addition of 250 2M H2SO4  and OD measured at 
492nm. 
The human plasma samples were collected by Dr. Nasreddin Abdulahi from 
adolescents and adults of both sexes as they presented with malaria symptoms at 
clinics in and around Gedaref, a large town in Eastern Sudan, during 1989. These 
samples were part of a batch that Dr. Abdulahi brought to Dr. Arnot's laboratory for 
analysis during a research visit in 1990. In 1999 Dr. Arnot provided this collection 
to Dr. Cavanagh for use as a 'bulk source' of anti-malaria antibodies and Dr. 
Cavanagh identified a subset of this collection (around 20% of the samples) that had 
moderate-to-high levels of antibodies that recognised C-terminal recombinant 
fragments of MSP-1. Their known reactivity to merozoite surface antigens made 
them a useful and available (but not particularly 'valuable') sample set for initial 
investigation of possible antibody responses to erythrocyte surface antigens. 
MSP 119  was used as positive control and measure of that individual serum's 
reactivity to a defined P.falciparum merozoite antigen (the GST-fusion protein 
containing MSP-1 1 9 was a gift from Dr David Cavanagh). Because a pooled malaria 
naïve serum was used a negative control, and no positive control serum or 
monoclonal antibody was applicable to this assay, it is not possible to create a 
standard curve for either positive or negative control sera. Nonetheless with these 
sera and controls it is certainly possible to detect a fairly strong level of reactivity to 
at least one recombinant antigens with the majority of Sudanese infection serum. No 
such malaria antigen reactive antibodies are present in the Scottish malaria naïve 
serum pools (Figure 2.8). 
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Figure 2.8. Detection of recombinant CIDR1 and MSP-119 by individual 
Sudanese acute infection sera. Columns 1-24 show individual Sudanese sera 
reacted with the two malaria antigens coated to microtitre plate wells. Column 25 is 
the Scottish malaria naïve serum pool reaction with these antigens. 
These results show there were different levels of reactive antibodies in different 
individuals. As MSP119 is both less polymorphic and more abundant than CIDR1, 
this probably explains why its reactivity was generally higher than that observed to 
the CIDR. In fact these 'Gedaref clinic' sera were pre-selected. because they were 
known to be 'mid-high-responder' anti-MSP-1 samples, with antibody levels similar 
to those found in many Sudanese infection and post-infection samples from the 
nearby village of Daraweesh (Cavanagh et al, 1998). Few or none of the donors of 
these original blood samples were pregnant; many were certainly males and children. 
Low, but usually above negative control responses were made by most of these 
Sudanese individuals to the recombinant CIDR1. In one or two cases (9 and 17) 
moderately high antibody responses to the CIDR1 antigen are made. There is no 
absolute correlation between responses to MSP119 and the PfEMP1 derived CIDR 
domain but where there is a clear response to the CIDR there tends to be a medium to 
strong response to the MSP 119  antigen. 7/25 samples gave very low or negative 
responses to the two recombinant antigens (serum 4, 11, 12, 13, 20, 21 and 22). In 6 
positive samples (out of 25 tested samples), responses to CIDRiwere stronger than 
those to the MSP 119  antigen. To further test the antigenicity of the purified yeast 
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recombinant protein, the CIDR1 protein was tested against pools of antisera from a 
more highly endemic malaria transmission zone. The serum consisted of a 'male 
serum pool' of 20 serum samples from men living in a malaria endemic region of 
Ghana. The 'pregnant female serum pool' consists of pooled serum from blood 
stream of 15 Ghanaian women, collected from the peripheral blood. This pool 
included 5 primigravidae, nine secundigravidae and one multigravid woman. Six 
Scottish malaria naive individuals donated sera to create the 'malaria negative pool' 
serum. The bacterially produced MSP 119 GST fusion recombinant protein was again 
included as a positive control. The Ghanaian sera were a gift from Dr. Mike Ofori 
and Dr Trine Staalsoe, University of Copenhagen. 
When the PfEMP- 1 CIDR 1 derived antigens were probed with both the male and 
the pregnant female serum pools sera, there was strong reaction with both sera, again 
stronger to MSP-1, but no gender specific reactivity was observed. This was not in 
any case expected, as neither protein has been implicated in placental adhesion 
(Figure 2.9). This finding is not exclusive as if we are to conclude a clear gender 
specific recognition, reasonable number of individual male and pregnant sera should 
be tested , then a statically conclusion could be reveal whither an antigen is 
recognised in gender specific manner. 
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Figure 2.9. ELISA readings from male, pregnancy and Scottish serum pools 
with the purified CIDR1 and MSP-1 proteins. All sera were used in a dilution of 
(1:1000). 
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2.10. Rabbit iimnunization to produce anti-CIDR1 antibodies. 
Immunisations experiments using the CIDR recombinant product were carried 
out by the Harlan Bio-Sera lab Company according to their rabbit immunisation 
protocols (see Material and Methods). The antigen concentrations required for each 
immunization was 50 - 200p.g administered with complete Freund's adjuvant to 
ensure a high quality/quantity response. This was followed by three booster 
injections of 100 .tg at days 14, 28, and 56 with Freund's incomplete adjuvant. Both 
ELISA and IFA assays tested antisera obtained 4 weeks after the last injection of 
adjuvanted protein for reactivity. Antibodies were purified on protein A columns. In 
ELISA, affinity purified rabbit anti-CIDR1 immunoglobulin reacted strongly with 
the Pichia product, as they did in Western blot (the pre-immune rabbit was the 
negative control). 
2.11. IFA assays using anti-CIDR1 antibody. 
Rabbit sera from the immunization study were tested for reactivity to P. 
falciparum 3D7 parasite(from which the var gene that contains the CIDR1 domain 
were isolated) infected RBCs. IFA was carried out on acetone-fixed iRBCs, infected 
with the 3D7 parasite. The corresponding rabbit pre-immune sera as used as a 
negative control. Panels of well-characterised monoclonal antibodies to the late 
trophozoites and MSP1 on the surface of the merozoites (Dr. Jana McBride, 
Edinburgh University) were used as positive controls. Whilst the monoclonal 
antibody controls strongly recognized acetone-fixed RBCs infected with late stage 
parasites, the immunised rabbit sera showed either very faint or no recognition at all. 
Thus the immunization regime failed to produce antibodies that recognize any 
antigen on the surface of continuously cultured 3137 parasite. As the var gene 
containing the CIDR1 domain has Ups A sequence, it most likely that gene will not 
be detected in the transcriptional level and then will not be translated. 
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2.12. Conclusions. 
These results indicate that the Pichia expression system expresses recombinant 
CIDR1 protein, although controlled fermentation is necessary to obtain good 
quantities of material for functional and structural analysis. Using this system, a time 
dependent product of the expected MW (-28kDa) was consistently produced. This 
product was confirmed as CIDR1 in Western Blot using antibodies to the 
polyhistidine tag. Detection of CIDRI during fermentation peaked and then 
decreased with time, suggesting that some degradation was taking place. Measures 
were taken to protect and maintain the integrity of the Pichia expressed protein; 
protease inhibitors were added to supernatants to prevent degradation and 
concentrated supernatants were re-suspended in or dialysed against 15 mM 
Tris/500mM NaCl, pH7.5, to protect against aggregation. Some evidence of 
aggregation was observed in case of the Pichia supernatants analysed here, which 
quickly took on a cloudy appearance. Aggregates have been common in the 
production of other PfEMP-1 domains and this makes their handling and analyses 
problematic (Dr. Graham Bentley, Institute Pasteur, personal communication). 
The affinity purified CIDR1 protein was used in ELISA using sera from malaria 
endemic areas and comparing this with the reaction obtained with malaria naive sera 
using an MSP119 control. There were different levels of reactivity; the MSP-1 was 
almost always recognised more strongly than the PfEMP-1 derived product. 
Following rabbit immunizations an anti-CIDR antiserum was also tested for 
reactivity to P.falciparum infected RBCs. A panel of previously characterised cross-
reactive monoclonal antibodies to iRBC surface (Dr Jana McBride and Dr David 
Cavanagh, Edinburgh University) was used as a positive control. Whilst the 
monoclonal antibody controls were seen to strongly recognize acetone-fixed RBCs 
infected with late stage parasites, none of rabbit sera from this immunization study 
was shown to recognize RBCs. This finding was somewhat disappointing although 
probably to be expected as it is commonly observed that raising polyclonal 
antibodies to the iRBC surface antigens is difficult and has been achieved by few 
groups (Chen et al, 2004; Gamain et a!, 2004). 
Chapter 2 	 50 
The fact that the antisera did not recognize 3D7-infected red blood cells indicates 
that we have no reagent which reacts with this specific CIDR domain on the infected 
erythrocyte surface. This may be due to the fact that we have no way of selecting for 
an enriched population of infected red blood cells specifically expressing the CIDR 
domain that we have raised the antisera against or that the CIDR1 is not expressed on 
the surface. Thus there is no direct evidence that the PIEMP-1 molecule containing 
this CIDR antigen is on the surface of a significant proportion, or indeed any, of the 
continuously antigenically varying parasites in our unselected cultures. 
The methylotrophic eukaryotic expression host, P. pastoris, has been successfully 
developed as an alternative to the E.coli system (Hollenberg & Gellessien 1997: 
Cereghino & Cregg 2000). For Plasmodium proteins, the P. pastoris system is 
already being successfully used in the production of a recombinant form of Pfs25H, a 
cysteine rich 25kDa P. falciparum surface antigen of zygotes and ookinetes and a 
candidate for a transmission —blocking malaria vaccine (Zou et al., 2003). Protein 
expressed in P. pastoris has been shown to be superior to that produced in E. coli 
based on its ability to bind to red blood cells. The antibodies generated against the 
Pichia-produced protein prevented the binding of recombinant EBA to red blood 
cells. These antibodies recognize EBA-175 present on merozoites (Yadava & 
Ockenhouse, 2003). Codon optimization has proven successful for the expression of 
other malaria genes (Nagata et al, 1999; Narum et al. 2001: The production of 
recombinant P. falciparum proteins in Pichia have been shown in MSP-1 (Morgan 
et al, 1999) and AMA-i (Kocken et al, 2002). 
The recombinant CIDR1, Produced during this part of thesis, enabled us to test the 
usefulness of the used expression system (Pichia) and the importance of recodoning 
the Plasmodium antigens. This recombinant protein will be used as a His-tag protein 
positive control and a negative control for glycosylation assays. 
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Chapter 3. Characterisation and screening of antigen 
arrays from PfEMP-1 domain expression libraries. 
3.1. Aims. 
The P. falciparum genome project has aided approaches such as the use of antigen 
arrays whose objective is to rapidly identify promising gene targets and thus 
accelerate the development of new drugs and vaccines (Young & Winzeler, 2005). 
Previously studies of protein or antigen activity have been conducted by studying a 
single protein at a time, which is time consuming and expensive. With the 
sequencing of entire genomes, large-scale 'proteome' analysis using protein micro-
arrays has become possible (Thu & Snyder, 2001). One of several current schools of 
thought with regards to the choice and subsequent production of an anti-malarial 
vaccine is that it should be based on the immuno-dominant parasitized erythrocyte 
antigens that play a role in the acquisition of natural protective immunity against the 
disease (Smooker et al, 2000, Jensen et al, 2004). In order to test the hypothesis that 
a major source of such immuno-dominant epitopes is encoded in the parasite's cell 
surface antigen genes, several known surface antigen specific genomic DNA 
(gDNA) expression libraries were produced in a form suitable for screening with 
human malaria immune serum. 
A great deal of previous work has shown that differential screening with malaria 
immune sera can be used to identify parasite antigens that can be tested as vaccine 
candidate antigens (see, for example, Watanabe et al, 2001, Sowa et al, 2004). 
Genomic DNA expression libraries were chosen in preference to cDNA libraries 
because stage specific expression of some surface antigens may result in the 
production of biased libraries that exclude sequences absent, or present in very low 
abundance at the point of RNA extraction from cultured parasites. The use of 
genomic DNA thus increases the chances of expressing all surface antigens present 
in the genome, regardless of whether such genes are switched on in culture or not. 
There are clearly technical and scientific problems with protein array technologies, 
sometimes caused by individual protein characteristics although some are common to 
high throughput methods in general. They include the problem of obtaining high 
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efficiencies of functional protein expression in a dense array and of selecting the best 
membrane for optimal signal-to-background ratios. A further consideration is that 
arrayed proteins should be correctly folded and functions as the naturally presented 
antigens as much as possible. Correlating in vitro with in vivo is difficult and requires 
assays that can compare the two states, which is certainly not always possible but can 
often be facilitated by comparing expression in different host cells which process 
recombinant protein in different ways. The simplest way of achieving such a 
comparison is by using a dual expression system in which the same plasmid vector 
has promoters for expression in two different host cells. 
To achieve both aims, PfflMP-1 specific Duffy Binding-Like (DBL) domain 
expression libraries were constructed from the extracted DNA of the P.falciparum 
clone, FCR3CSA. There are estimated to be around 60 var genes per parasite 
genome. Each parasite clone is believed to have a repertoire of polymorphic but 
ancestrally related var genes and most (not all) var genes that have been sequenced 
have DBL-alpha domains upstream of CIDR domains. In this chapter, methods to 
optimise conditions for analyzing an expression array of P.falciparum PIEMP-1 var 
gene fragments are presented 
3.2. Dual Expression Vectors. 
To carry out the preliminary library-screening experiments a dual expression 
vector capable of expressing P. falciparum proteins in both prokaryotic (E. coli) and 
eukaryotic (P. pastoris) cells was chosen. The pPICHOLI dual expression vector (a 
gift of its inventor, Dr. Dolores Cahill) (Figure 3.1) combines both eukaryotic and 
prokaryotic promoter elements and drug selection appropriate for both hosts. A 
phage T7 promoter promotes bacterial expression. Protein expression in yeast is 
controlled by the alcohol oxidase promoter. Expression in yeast is completely 
repressed when grown on glucose and maximally induced when grown with 
methanol as the carbon source (Lueking et a!, 2000). pPICHOLI has a multiple 
cloning site permitting insertion in three different reading frames within a 3.6 Kb 
plasmid genome. Genes cloned in pPICHOLI can be expressed in E. coli and P. 
pastoris as fusion proteins, with a hexa-histidine tail (the HIS tag) enabling a simple 
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purification step via affinity chromatography and detection by commercially 
available specific anti-HIS Tag antibodies. These vectors do not target the 
recombinant sequence into the yeast secretoary pathways. This has the disadvantage 
that purification is more difficult but the advantage that glycosylation during 
secretion is much less of a problem. 
AOX-Promoter 
CoIE1 On 
Zeocin 	 AOX Terminator 
PARSI 
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Figure 3.1. The pPICHOLI dual expression vector. It includes the 6xHis tag 
for detection and purification of the expressed protein. The vector contains an 
inducible (yeast) alcohol oxidase promoter and an E. colt T7 promoter as well as 
sequences allowing autonomous replication in both P. pastoris and E. colt. 
3.3. DBL domain library construction. 
The physical production of the gDNA expression libraries is a two-step process 
involving first amplification of PCR fragments of PfEMP1 DBL domains using 
FCR3CSA as the PCR template. Recombinant clones are then produced by ligating 
PCR products into pPICHOLI prior to transformation into BL21 codon plus cells for 
the E. colt expression library or X33 yeast cells for the P. pastoris library. 
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3.3.1 PCR amplification of PfEMP-1 specific DBL domains from FCR3CSA. 
Fragments that correspond to our current estimates of where the boundaries 
between different DBL domains are likely to be were amplified from FCR3-CSA 
using degenerate primer combinations whose sequences were based on short 
conserved motifs within the flanking conserved blocks (see Materials and Methods 
for oligonucleotide sequences). All primers were designed with 5' Sal I and 3' Not I 
restriction sites to enable cloning into the Sal I and Not I pre-digested dual 
expression vector. 
The PCR products (obtained using Pfu polymerase) were run on I % agarose gels to 
confirm the presence of the amplified bands within the expected size range of 400- 
650hp (Figure 3.2). 
650 hp  
NI 	1M31.lu. 	I)BL3 	l)BLy 
Figure 3.2: PCR products for amplified DBL domains using domain-specific 
degenerate primers. For DBLa domains, the PCR products are about 650bp. For 
DBL3 and DBL-y domains, the PCR products amplified are approximately 400-
600bp. M is the 1Kb Plus DNA ladder (Invitrogen). 
3.3.2 Preparation of expression plasmids. 
To sub-clone into the expression vector, PCR products (flanked with sal 1 and Not 
1) were first sub-cloned into the TA cloning vector. This was done to facilitate the 
digestion with the restriction enzymes. Double restriction digest with Sal I and Not 
1 was used to excise the fragment from the TA cloning vector immediately prior to 
ligation into the same sites in the expression vector (Figure 3.3). To optimize 
ligation, different molar ratios of the vector and DNA were tested vector to insert 
ratios of 1:1, 1:3 and 1:5 were generally used. Ligation with 1:3 ratios usually 
generated the greatest number of clones. The ligation products were transformed into 
E. coil BL2I RIPL Codon Plus strain. 
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To obtain reasonable P. pastoris X33 strain transformation efficiency, two 
protocols for transformation were tested. When using freshly prepared competent 
yeast cells, electroporation using the Bio-Rad Gene Pulser was more efficient, with 
improvements in transformation efficiency of 3-10 folds when compared with the 
chemical method. Stored frozen cells were also used but sometimes give poor 
transformation results. 
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Figure 3.3. Cloning into the pPICHOLI dual expression vector. 
3.3.3 E. coli and P. pastoris gDNA DBL expression libraries. 
Using the method summarized in Figure 3.4, six different P. falciparum gDNA 
expression libraries were made using degenerate DBL domain primers. All libraries 
were stored as frozen glycerol cultures in 96-well plates at -80°C until required. 
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Degenerate primer design 
FCR3CSA gDNA isolation 
PCR amplification and ligation into TA cloning vector 
Excision of inserts from TA vector & ligation into pPICHOLI 
Transformation 
E. coli expression library ] 
	
P. pastoris expression library 
Figure 3.4. Flowchart summarizing production of protein expression libraries in 
either E. coli or P. pastoris. 
3.3.4. Protein expression of selected clones of DBL domains in both bacteria 
and yeast. 
After the libraries construction, a proof of concept was carried out to test whether 
the recombinanat plasmid is capable to express the recombinanat proteinthe and gave 
a strong signal with anti His tag antibodies. 
The DBLa-6 clone was expressed first in bacteria and a protein band of expected 
size was detected by using the anti-His antibody. The Pichia pastoris produced 
recombinant also gave a strong band but of slightly higher than the expected size 
when probing with anti-His Tag and pooled male Ghanaian serum. A smaller band 
(fainter) has also been detected in these gels (Figure 3.5).This size shift could be due 
to glycosylation although this was not tested. 







Figure 33: Western analysis of DBL1a-6 clone. A. The induced bacterial 
recombinant protein detected with anti 6XHis antibody as compared to the uninduced 
(1) and induced (2) clones. B. P. pastoris recombinant protein was detected with anti 
6XHis antibody when the same plasmid was shuttled into yeast. C. Yeast 
recombinant proteins probed with sera from Ghana. It showed 2 bands, the stronger 
corresponded to the expected size. 
3.4. Library characterisation. 
To determine library quality before starting large-scale sequencing and protein 
expression studies it was necessary to characterise the libraries, based on the 
following criteria; 
1). Percentage number of clones with inserts. 2). Size of inserts. 3). Sequence of 
inserts. 4). Number of domains cloned. 5). Orientation. 
3.4.1 Number of recombinant clones. 
Direct colony PCR was performed on 50 clones from each of the 3 E. coli libraries, 
giving results for a total of 150 clones. With the dual expression vector containing an 
insert in E.coli, only one band is expected to be amplified as E. coli lacks the AOXI 
gene. The 3' AOX1 and 5' AOX1 primers will therefore only amplify the cloned 
fragment in the plasmid. Direct colony PCR was also performed on DNA isolated 
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from colonies from the 3 P. pastoris libraries. For the transformed yeast cell two 
PCR products were expected, a) an approximately 2.2kb fragment, equivalent to the 
size of the AOXI gene amplified from the yeast genome and b) the insert in the 




Figure 3.6: Direct colony PCR of (A) 12 bacterial clones and (B) 12 yeast 
clones. PCR products were separated on 1% agarose gels. M is the DNA molecular 
standard. 
3.4.2. Insert Size. 
Direct PCR screening revealed that there was size polymorphism between cloned 
domains and this was later confirmed by sequence analysis. In general, the current 
estimation of a full-length DBL domain is 900-1200bp encoding 300-400 amino 
acids. The degenerate primers used in this project amplified only a portion of that 
domain. The approximate sizes expected for DBLaI, DBL32 and DBL13 are 0.6 Kb, 
0.4-0.65 Kb and 0.55 Kb respectively (Figure 3.7). 
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Figure 3.7. Size range of inserts for each DBL domain. 
3.4.3. Sequence Representation. 
A good library should have a large number of unique inserts. The nucleotide 
sequences were determined with a PRISM/S BigDye Terminator Cycle Sequencing 
Reaction Kit and the Applied BioSystems 377 DNA sequencer. Each set of primers 
tested amplified a number of variants whose sequences indicated that they were 
derived from different PfEMP-1 loci in the FCR3CSA genome. These were grouped 
into sub-classes according to their degree of homology to DBL domain sequences in 
the database. It was found that, as expected, the primers used were domain-specific 
in the sense that all products amplified with a particular pair of degenerate primers 
did amplify sequences that appeared to belong to the expected domain type. 
98% of the clones with inserts gave useful sequence data. A total of 18 different 
DBLa, 21 different DBLI3 and 23 different DBLy sequences were isolated and 
sequenced from the FCR3CSA libraries. After sequencing, homology searches of the 
sequence databases were performed at the National Center for Biotechnology 
Information (http://www.ncbl.nlm.nhm.gov  and www.plasmodb.net). Sequences 
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obtained were confirmed as var fragments by BLAST analysis in both the general 
database (NCBI) and the P. falciparum database (PlasmoDB). Deduced amino acid 
alignments of obtained sequences with the 3137A DNA sequences and other var gene 
fragments available in the databases were made using MacVector Clustal functions 
(data not shown). There were three general categories of homology, identity (100%) 
with previously described domains, matches with between 80-100 % identity and 
matches with less than 80% homology (Table3.1). Specific homology of some 
sequenced clones are summarized in table 3.2. 
Domain name 100% homology) > 80% homology. <80% homology 
DBL1 4 12 3 
DBL2 3 7 5 
DBL3 3 5 12 
Table 3.1: The DBL domain sequence homology results compared with 
database DBL domain sequences. 
Comparisons between sequences within each domain show that there is marked 
conservation of the positions of certain residues in the DBL-1 domain. Large 
numbers of DBL-1 sequences share short (10-20 amino acid) regions of sequence, an 
observation that has been reported previously (Ward et al, 1999). These 
observations support the view that the structural framework of the DBL-1 domains in 
most, if not all, of these molecules is highly conserved. Multiple amino acid 
alignments showed that DBLa and DBL3 are somewhat more similar to each other 
than either is to DBL'. This may reflect ancestral relationships between domains 
based on ancient gene duplications. In general, full-length DBL domains are 
approximately 900-1200bp. The degenerate primers only amplify a portion of that 
domain. 
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Clone Acc. No. Reference Isolate 
DBLa /TA1 AF366354 Oguariri, et al, 2001. Isolate from Gabon 
DBLa TTA3 AJ3 19689 Duffy, et al, 2002. CSA binding CS2 
DBLct /TA1O AF050740 Voss, et al, 2000. FCR3 
DBL /TA4 AY248887 Kraemer, et al, 2003. A4 
DBL 	/TA12 AF193424 Smith J., et al, 2000b. A4 
DBL /TA7 AY248886 Kraemer, et al, 2003. A4 
DBLy /TA 3 AY248879 Kraemer, et al, 2003. A4 
DBLI /TA 7 PFA133811 Buffet, et al, 1999. FCR3CSA 
DBLy /TA 13 AF465509 Fried and Duffy, 2002. Placental isolates. 
Table 3.2: Clones with 100% identity to DBL domains obtained from the 
database. 
3.4.4. Insert Orientation. 
To confirm the directionality of these libraries, a total of 150 clones from the E. 
coli library were sequenced from both ends. None of the clones were inverted, 
thereby making the libraries 100% unidirectional, an important factor when 
considering transcription, translation and protein expression. 
3.4.5. Total number of domains cloned and arrayed for screening. 
The libraries made in E. coli comprise 475, 570 and 570 clones for DBLa1, DBL2 
and DBL13 respectively, arrayed in 96-well plates. Yeast expression libraries for 
these domains comprise 37, 55 and 73 clones respectively, arrayed in one 96-well 
plate/domain (Table 3.3). 
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Expression system DBLa1 DBLf2 DBLy3 
37 55 73 
P. pastoris  
475 570 570 
E. coli  
Table 3.3: Number of colonies for each DBL domain in E. coli and P. pastoris 
expression libraries. 
3.5. Creation of antigen arrays from the FCR3CSA gDNA library. 
Membranes are currently the only practical surface for screening microbe derived 
protein arrays. Colonies from the bacterial and yeast libraries were picked from the 
master plates into 96-well growth plates (in duplicate) (Figure 3.8). The wells 
contained LB medium supplemented with 50.tg ml -1 Zeocin (and 37jig mV' 
chioromphenicol for E. coli libraries). BMGY containing 100tg mV' Zeocin was 
used in the case of P. pastoris libraries. Colonies were incubated overnight at the 
appropriate temperature and used in inoculating membranes for subsequent growth. 
Colony arrays were initially prepared by application of the liquid culture to High 
Bond-C Extra (Amersham) nylon filter membranes for E. coli expression. Protran 
membranes were used in the case of P. pastoris. Using the Replicator (a 96 prong 
steel pin tool) to seed the microbial cells onto the membranes and following the 
procedure outlined in Figure 3.9, both types of colony arrays were grown by placing 
the appropriate filter on either LB agar or BMGY agar. All expression arrays were 
grown overnight at 30°C and protein expression was induced the following day. 
E. coli filters were induced for recombinant protein expression by transfer of 
overnight filter from 'LB agar only' plates to LB agar plates supplemented with 
1mM IPTG and 50tg ml -1  zeocin, at 37°C for 4 hours. Yeast library induction was 
carried out by transferring the filter array to BMGY agar plates supplemented with 
0.5% methanol and 100 j.tg ml—1 zeocin, for 3 days at 30°C (with addition of 500.ml of 
methanol every 24 hours). After the appropriate protein induction period, the cells 
were lysed in situ to liberate intra-cellular recombinant protein; the filters were 
blocked overnight in 3% BSA with 0.1mM of the protease inhibitor PMSF. If 
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necessary, after this procedure the filters may be removed from the washing buffer, 
wrapped in Saran Wrap and stored for up to 24 hours at 4°C. 
Protein immobilized on these membranes can be remarkably stable and after 
incubation with one set of antibodies, these antibodies can be stripped off with strong 
ionic detergents and the membrane re-incubated with alternative antibodies. Some 
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Figure 3.8. Colony printing procedure adapted from http://www.vp-
scientific.com . 1. The Replicator. 2. & 3. Assembly of the membrane and the pad in 
a preparation tray. 4. Applying the colony array from the 96-well plate into the 
membrane. 5. Schematic of colonies growing on a membrane. 
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3.5.1. Optimisation of colony growth on different membranes. 
The selection of an appropriate surface for colony seeding is the key step in 
recombinant protein array design. Such arrays require combining strong and durable 
attachment of relevant recombinant proteins with low non-specific binding of other 
host-derived proteins. Several membrane types were tested for this purpose. 
Following application colonies were arrayed' onto filters and grown on agar plates 
until clear colony growth was visible. The applicability of several different colony 
support filters was tested, as summarized in Table 3.4. 
Table 3.4. The effect of different membrane types on colony growth. Five 
different membranes were spotted with the same number of colonies from each 
library and other controls. HybondTM- C Extra was chosen for E. coli array and 
Protran®for P. pastoris. 
After comparison of their capacity to support optimal growth of 
microbial colonies, a Hybond-C Extra membrane was chosen for the E. coli array. 
Protran membranes for the P. pastoris array proved to be superior to other 
membranes. Neither the Hybond-N nor the cellulose nitrate membranes resulted in 
clear and distinct colony-protein signals. This may be due to the lack of efficient 
binding of the proteins to the membranes. The PVDF based membranes could not be 
used for yeast or bacteria array screening as pre-soaking the membrane in 100% 
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methanol is required, making it impractical for use as it would kill bacteria and yeast 
arrays before growth and induction could commence. 
3.5.2. Optimisation of signal to background ratios. 
Liquid cultures were spotted onto membranes and grown on plates until colony 
growth was visible. 1-ugh-level expression of recombinant protein was induced and 
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Table 3.5. Selection of membranes for antigen arrays. Membranes were spotted 
with E. coli and P. pasroris arrays and probed with the IgG from Ghanaian donors. 
Goat anti-human lgG-HRP(Dako) was used to detect antibodies. 
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Experiments were performed to optimize antibody concentration with respect to 
background, substrate color intensity and substrate color retention. For primary 
antibodies an appropriate dilution was chosen (generally 1:50-1:5000) and filters 
were incubated for 1 hour at room temperature on a shaking platform. 
3.6. Preliminary screening of Pichia DBL libraries using anti-6XHis 
antibody. 
When membranes containing a selection of clones from each library with controls 
were incubated with Anti-6X his antibody, it was found that there were strong 
signals for some clones and no reactivity at all for other clones. The background and 
signal were optimised readily (Figure 3.9). To detect intracellular expression clones 
of each DBL yeast expressor were grown on Protran membranes and induced on 
BMMY (Buffered Methanol-Complex Medium) agar plates. Cell lysis was carried 
out using YeastBusterlM detergent reagent for 30 minutes at room temperature. 
Lysed cells were removed by rinsing with PBS. 
The membrane was blocked with PBS containing 0.05% Tween-20 and 5% nonfat, 
dry milk overnight at 4°C. Anti-6XHis-HRP was added (1:4000 dilution in PBS/5% 
nonfat, dry milk) for 1 hour at room temperature with moderate shaking. The blot 
was washed three times with PBS containing 0.05% Tween-20 (PBST) for 15 
minutes each time. Positive and negative controls were clones expressing the 
recodoned CIDR and a clone containing the plasmid without insert. Duplicated 
spotting is the main means of controlling the screening results and only duplicate 
signals are considered as true positives. 
5 DBLa clones were detected successfully, as pairs of spots for the same clone, 
with strong signals (42%). 5 clones were detected as one spot (42%) which 
considered being not true positives. The remaining clones (2 clones) could not been 
detected (16%). For the DBL3 clones, 5 out of 12 were detected as pairs of spots 
with strong signals (42%). 2 clones were detected as one spot (16 %). The remaining 
clones (5 clones) could not been detected (42%). In the case of DBLi, it was found 
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that 7 clones were true positives (59%). One clone (7%) was detected as single spot, 
while the remaining clones (4 clones) could not been detected (34%). 
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Figure 3.9: High throughput screening of a Pichki array of expression clones 
from the DBLt, 0 and y  libraries. Some clones gave strong signals (boxed) when 
probed with the anti 6XHis antibody. Controls include the positive control C1DRI 
recombinant protein, while the negative control was the expression vector plasmid 
without insert. A blank growth medium spot was also included. Expressing colonies 
were detected using the ECL chemiluminescence detection kit (Amersharn). 
3.7. Screening the antigen arrays. 
After optimising the conditions required for bacterial and yeast growth on filters 
and the antibody concentrations needed for Western blots, the antigen arrays were 
ready to be immuno-screened. In the final part of this chapter, 1 will discuss the steps 
taken to treat the sera in order to ensure that the results obtained from the screening 
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process were due to actual recognition of the expressed protein by the human 
immune sera. 
3.7.1 Removal of anti-bacterial and anti-yeast antibodies from human sera for 
improved screening. 
To decrease the possibility of obtaining 'false-positive' results due to non-specific 
cross-reactivity, it is imperative that the antibodies responsible for such cross 
reactivity be removed. Previous studies have shown that there are naturally acquired 
anti-bacteria and anti-yeast antibodies in some human sera. Pellets of live E. coil and 
P. pasioris with the expression plasmid (but without inserts) were used for the 
absorption of 0.1 volume of serum from a patient after dilution of the serum (1:100) 
in PBS-Tween 20. The mixture was incubated at 20°C for 2 h and spun at 10,000g 
for 15 minutes. The serum was also absorbed with lyophilized bacterial material (1 
mg/ml of serum) and sonicated yeast material (Figure 3.10). 
Duplicated clone 	 Detection 
A. 	 +++ 
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IN 
Figure 3.10. Depletion of anti E. coli antibodies from human serum. A. Clone 
without insert probed with undepleted human serum (before incubation with E. coli 
pellet and/or lysate). B. Clone without insert probed with 1X depleted serum. C. 
Clone without insert probed with 2X depleted serum. 
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Human serum antibodies from malaria endemic areas depleted of anti-bacterial and 
yeast antibodies were used to screen the membrane bound antigen arrays at serum 
dilutions from 1:50 - 1:5000 dilutions (Figure 3.11). The signals were visualized 
using an ECL plus detection kit with exposure times ranging from I to 30 minutes, 
the intensity of the signal was adjusted according to exposure times. Experiments 
were also performed to determine the best blocking agents. Different blocking agents 
in the blocking buffer were tested, including fetal bovine serum, non-fat dried milk 
and bovine serum albumin (BSA). BSA gave the lowest backgrounds with both 
primary and secondary antibodies and was therefore used in subsequent screening 
assays. 
Signal Intensities 	 Primary antibody dilution. 
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Figure 3.11. Sensitive detection of serum antibodies with goat anti-human IgG 
(Dako) in the antigen arrays. The membranes were incubated with varying 
concentrations of human serum from malaria endemic areas and then used to test the 
detection limit in array format. 
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3.7.2. Controls and extra precautions. 
Both positive and negative controls were used in each assay and processed in the 
same manner. Pooled Scottish sera were used as negative controls. It was found that 
there was faint reactivity to some negative controls. Antigen arrays were also 
incubated with just the secondary antibodies conjugated to HRP. There was no 
reaction when incubated with only the secondary antibodies -IIRP conjugate. The 
negative controls were used to confirm the specificity of the test and to assess the 
degree of non-specific sero-recognition present by omitting the primary antibody. 
Omitting the primary antibody and using antibody diluent (PBS) alone is usually 
sufficient for assessing the degree of nonspecific binding by the labelling (secondary) 
antibody. 
3.8. PCR-based screening of DBLy bacterial antigen array. 
To make use of the optimised conditions an E. coli DBL1 expression array was 
tested. A clone containing the empty expression plasmid was the negative control. 
189 clones were spotted in duplicate and grown by placing the filters on LB agar 
supplemented with glucose (1%), zeocin (25igIml) and chioramphenicol (34.ig/ml) 
at 30°C overnight. Protein expression by colonies on filters was induced and 
expressers were detected by chemiluminescence. 19 randomly picked positive clones 
were cultured in 3 ml LB medium/clone overnight at 37°C. Plasmid DNA was 
prepared from each clone using the plasmid Qiaprep Kit (Qiagene) and sequenced 
using the ABI sequencer (Figure 3.12). 18 out of 19 clones that gave strong signal in 
the blot revealed a band of the expected size. A number of clones displayed sequence 
polymorphism. In fact these clones produced a diverse list of candidate antigens. The 
primary results indicated that the library is both representative and reliable and 
reliably amplifying the desired target domains. (The clones with empty vectors were 
removed from the master plates in preparation for immunoscreening.) 
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Figure 3.12: E. coli DBLy array showing correlation between recombinant 
clones and detection of expressed protein. These clones were arranged in duplicate 
and contained inserts with size and sequence polymorphism. A negative control was 
used consisting of a cell containing the vector but no insert. Arrays were produced on 
High Bond-C Extra filters (Amersham) using an applicator with 96 steel pins. After 
induction and lysis, filter was incubated with pooled male serum from Ghana and 
was detected by goat anti-human IgG-HRP (Dako). Mark boxes clones were the 
randomly picked colonies from which plasmid DNA was prepared. 
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3.9. Conclusions. 
Protein arrays allow high-throughput screening using manual or robotic methods 
after immobilization of antigens onto membrane. Six different P. falciparum gDNA 
expression libraries based on DBL domains from PfEMP-1 var genes were 
successfully constructed in the E. co/i and P. pastoris expression systems. The 
shuttle library approach was exploited here in order to gain maximum flexibility and 
choice in optimizing the expression system. However, shuttling is not without 
problems and there is significantly reduced transformation efficiency in the yeast 
system. Transformation by electroporation became necessary for yeast work, as was 
the use of freshly prepared competent cells as stored frozen cells sometimes gave 
poor transformation results. 
There was also a significant difference in the number of clones obtained from the 
Pichia libraries. In addition to reduced yeast transformation efficiencies, this may 
also be influenced by uncorrected codon usage differences between the two 
organisms (yeast and P.falciparum). Codon usage differences between Plasmodium 
and E. coli were compensated for by the use of BL2I cells which contain a plasmid 
that expresses a number of tRNAs that are rarely used by wild type E.coii. An 
equivalent plasmid, to compensate for the small pools of certain tRNAs in Pichia is 
not available and therefore could not be used in this project. 
The primers used were able to amplify a variety of different DBL type-specific 
sequences from the FCR3CSA clone even although they were based on the PfEMP-1 
sequence data from P. falciparum clone 3137. A total of 18 DBL I alpha, 21 different 
DBL beta and 23 different DBL gamma sequences were isolated and sequenced. It is 
likely that more such ' var gene tags' could have been isolated if more clones had 
been sequenced but the primary objective here was to show that the libraries 
constructed had a good representation of different var genes, not to completely 'tag' 
label every FCR3CSA var gene. The indication that semi-conserved primer 
sequences can be used to amplify specific domain tags from a different parasite 
genotype provides further confirmation of earlier observations that there is extensive 
sequence conservation between PIEMP-1 var genes and some structuring of the 
sequences into related sub-classes. (Ward et a!, 1999, L.avstsen et a!, 2003). 
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Optimisations of antibody-based protein array format for analysis of protein 
expression libraries were described. To optimize the immunoscreening of antigen 
arrays, various membranes, antibody concentrations, and hybridization times were 
evaluated. The membranes were evaluated on the basis of background color reaction, 
retention time of the color reaction, and the durability of the membrane throughout 
the course of the procedure. Various problems were encountered when using 
antibodies to screen an expression library. Many factors should be considered if no 
positive clones or abundance of positives are noticed. 
The antibodies used may not recognise the antigen when the latter is expressed in 
E. coil. These problems can occur when screening for eukaryotic cell protein that 
have posttranslational modifications such as carbohydrates, lipids and disulfide 
bonds. Each of these modifications is antigenic and not generally present on proteins 
expressed on E. coil. Monospecific polyclonal antibodies that recognise fully 
denatured, deglycosylated proteins should be used whenever possible to avoid these 
problems. 'This can be circumvented by utilizing a eukaryotic expression system (e.g. 
P. pastoris). The use of excess primary or secondary antibodies in the screening 
reactions can lead to the detection of too many positive clones. Diluting the antibody 
may eliminate or reduce cross-reactions without significantly affecting the binding of 
the antibody to its two targets. By varying the concentration of antibodies on 
different filters one should also be able to identify the optimal conditions and/or 
improved expression characteristics. Too many positives can sometimes reflect a 
problem with the blocking reagent; one of the other blocking reagents should be 
tried. Increasing the concentration of tween or the non-ionic detergent Nonidet P-40 
in the rinsing and washing buffers reduced the number of seropoitives. The 
temperature at which the blocking, rinsing and washing steps are carried out can be 
increased to as high as 50°C. 
One of the problems faced in the development of antibody-based protein arrays is 
the cross-reaction among different antibodies. This problem may be overcome by 
careful incubation of antibodies, and pre-absorption of antibodies with the expression 
systems of choice antigens. Automated screening of antibody or scaffold libraries 
against arrays of target proteins will be the most rapid way of developing the 
thousands of reagents required for protein expression profiling. The antigen assay 
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may be the most specific and easiest way to detect antibody. Other potential 
applications of protein array technology include identification of specific markers 
(antigens) for disease, and determination of differential protein expression in two 
different states. The antigen arrays will be screened for capacity of the target 
antigens to be recognized by sera collected from clinically distinct cohorts of 
individuals naturally exposed to malaria (Doolan et a!, 2003). Protein microarrays 
are a powerful technology, which allows the protein of an organism to be screened in 
a single experiment. The array consists of protein released from the selected 
expression system after lysis and screening their immunogenecity. These assays have 
been used in the human malaria parasite (Sowa et al, 2004, Hayward et at, 2000) 
The combination of DNA library construction and antibody screening methods will 
facilitate identification the antibody responses to immunogenic antigens of P. 
faicipa rum and help identify epitopes that could be exploited in malaria vaccine 
development (Anders, 1988). The libraries are ready for the next steps in immuno- 
screening. 
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Chapter 4. Immuno-screening DBL domain libraries 
with malaria immune sera. 
4.1. Aims. 
The experiments described in this chapter use the optimised methods for bacterial 
and yeast expression library construction described to identify immunogenic, 
, vaccine-candidate'-type epitopes. Immuno-screening for vaccine candidate antigens 
in parasitology developed from antibody recognition of SDS gel fractionated parasite 
antigens in Western blots. This developed into a recombinant protein screening 
method using mono- or polyclonal anti-sera to immuno-screen cDNA or gDNA 
expression libraries. 
A novel method to identify key PfEMP-1 genes, based on up-regulation of 
transcription after selection for a particular adhesion property, has recently been 
developed. Using gene-specific primers for all var genes (based on the genome 
sequence of 3D7) and quantitative real-time PCR. the levels of var gene transcription 
before and after selection for adhesion to CSA were measured (Salanti et a!, 2003). 
The var gene PFU0030c (var2CSA) of the NF54 isolate (now thought to be identical 
to its daughter clone 3D7) showed a higher level of expression following CSA 
selection (NF54CSA). Var2CSA was subsequently shown to be expressed on the 
surface of CSA-selected parasitized cells and certain recombinant domains of this 
antigen were recognized by antibodies from the serum of individuals living in 
endemic malaria zones in a gender and parity-dependent manner (Salanti et a!, 
2004). 
'Mini-libraries' of var2CSA domains from unselected 3D7 parasites have been 
constructed in P. pasioris. Yeast clones were induced for protein expression and 
preparations of induced protein were purified. ELISA studies were carried out to 
identify epitopes that can react with a panel of human serum samples from Eastern 
Sudan. The reactivity of expressed recombinant protein from var2CSA domains was 
also tested with serum antibodies from a malaria endemic region in Ghana. 
Chapter 4 	 76 
4.2. Var2CSA yeast expression library constructs. 
The var2CSA P.pastoris expression required designing specific primers, using both 
the P.falciparum 3D7 isolate genome sequence and DNA to amplify regions encode 
different domains of the var2CSA gene from that isolate. Both forward and reverse 
primers have similar annealing temperatures calculated using the Tm determination 
programme (http://alces.med.umn.edulrawtm.html ). Each primer pair has a stop 
codon (UAA) incorporated into the 3' sequence. 5' primers were designed to be in-
frame with an ATG codon in the vector (pPICHOLI1) that initiates transcription of 
cloned sequences. Purification/detection tags that are thus incorporated onto the N-
terminus of translated recombinant proteins. Primers usually gave a single band in 
1% agarose gel separations of the amplified products. The sizes of the amplified 
fragments and of the expected molecular weight of P.pastoris produced recombinant 
proteins transcribed and translated from the pPICHOLI1 vector are given in Table 
4.1. 
Domains PCR products Expected Molecular Weight 
DBL1X 650 bp 30.5 kDa 
DBL2X 670 bp 46 	kDa 
DBL3X 930 bp 40.5 kDa 
DBI-As 711 bp 31.5kDa 
DBL5E 633 bp 32.5kDa 
CIDR1 1000 bp 29.5 KDa 
Table 4.1. Expected sizes of DNA fragments and molecular weights of the 
expressed proteins from the var2CSA gene, using the different primer pairs. 
Potential N-linked glycosylation sites were avoided during the primer design. For 
asparagine to be N-glycosylated in most mammalian or yeast systems, it requires the 
context of the amino acid motif N-X-S/T (Marshall, 1974). X can be almost any 
amino acid although a motif will not be glycosylated if it contains or is followed by a 
proline (Gavel & von Heijne, 1990). Creating N-glycosylation sites at either end of 
the var gene fragments was therefore minimised and least one potential site was 
avoided in each of the var2CSA domain-fragments amplified (Table 4.1). Potential 
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internal N-glycosylation sites were not removed as the fragments were not subjected 
to a complete internal re-codonisation. 
P. pastoris strain GS1 15 was used to express the var2CSA fragments after 
cloning into the pPICHOLI vector. The vector expresses heterologous sequences as 
fusion proteins, purified from the cytosol of the yeast cell after induction then cell 
lysis. The hexa-histidine 'tag' sequence is followed by a peptide sequence that can 
be biotinylated to facilitate purification via affinity chromatography. However this 
adds 34 amino acids of molecular weight (4.2kDa) to each yeast expressed 
recombinant protein. Rabbit anti-sera raised against bacterial recombinant material 
derived from var2CSA protein domains was also used to characterise the yeast 
derived recombinant proteins (a gift from Dr. Ali Salanti, Copenhagen University). 
Bacterial recombinant proteins, (made in RosettaTM  E. coli strains designed to permit 
enhanced formation of disulphide bonds) were used to immunise the rabbits. 
Immunising constructs corresponded approximately to the DBL3X, DBL4E and 1D2 
(CIDR-like) DBL5c domains. 
Of these rabbit antisera, the anti-DBL3X and anti-DBL5E were surface reactive 
with two laboratory parasite isolates and the DBL5E antisera reacted positively with 
3 tested laboratory isolates and 1/3 field-collected placental P. falciparum isolates 
(Dr. Ali Salanti, unpublished observations). Because of the high backgrounds often 
observed with rabbit antisera in Western Blots, the antisera have not been used in 
Copenhagen in Western blots and a major effort to make monoclonal antibodies 
against this protein is underway in this laboratory (Dr. A. Salanti pers.com ). 
Figure 4.1 shows the results of Western Blots carried out here using the anti-His 
tag mouse monoclonal antibody (2 plates) and the anti-var2CSA, recombinant 
domain polyclonal rabbit antisera (3 plates). To test for cross reactivity of rabbit 
serum, extracts from the yeast cells without plasmids, yeast cell with the plasmids 
without insert and the yeast cell with the insert that has been grown in the glycerol 
(i.e. before induction of recombinant protein expression) were included as controls. 
The data obtained indicate that there is a problem of cross reactivity with the rabbit 
anti-sera. Western Blots with the anti-DBL3X antibodies indicate that there are 
strongly cross reactive products in all four lanes, even although only Lane 4 contains 
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the methanol-induced pPICHOLI plasmid containing DBL3X. The expected size of 
the recombinant fusion protein from this plasmid is 40.5kDa. A band of around 42-
47kDa is visible in Lane 4 of plate A.1 but the rabbit antisera also cross-reacts 
strongly with Lanes 1-3. The Coomassie stained gels of these preparations are full of 
protein in this molecular weight range and this size of induced band was not easily 
distinguished in stained gels (data not shown). 
However, when the induced material in lane 4 was purified using affinity columns 
and the fractions eluted off the Nickel column were run on SDS PAGE (plate B.1.1) 
and then Western blotted with the mouse monoclonal anti-His tag antibodies (plate 
B.1.2), a single -42-45kDa band was detected. It is therefore concluded that a protein 
of approximately, or slightly larger than the size expected, with a hexa-His Tag 
sequence is being produced from the pPICHOLT 1IDBL3X plasmid vector. 
The second Pichia expressed domain construct analysed was that containing 
DBL4E. In this case the size of the induced product is expected to be 31.5 kDa. 
Again the rabbit antisera give background staining (somewhat less marked than in 
the previous experiment) but this time a distinct reaction is seen with an 
approximately 32735kDa band in the methanol-induced preparation containing the 
pPICHOLI1IDBL4E plasmid (Lane 4 of plate A.2). When this material was grown in 
larger cultures to make more protein and the Nickel column elution fractions were 
run on SDS PAGE gels (plate B.2.1) and Western blotted with the anti-His Tag 
antibodies then a distinct purified band of approximately the expected molecular 
weight (31 .5kDa) was seen (plate B.2.2). Thus a protein of the size expected, with a 
hexa-His Tag sequence appears to be produced from the pPICHOLI 1/DBL4E 
plasmid vector. 
The third Pichia domain construct analysed contained DBL5a, whose induced 
product is expected to be around 29.5 kDa. Again the rabbit antisera give cross-
reactive binding (somewhat less marked than in the previous experiment but again 
showing the -50kDa cross reacting band of unknown origin) but this time a distinct 
reaction is seen with an approximately 29-32kDa band in the methanol-induced 
preparation containing the pPICHOLI1/DBL4E plasmid (Lane 4, plate A.3). 
Unfortunately, after scaled up production no His tagged product could be detected on 
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Western Blots (data not shown). In this case although a protein of the size expected 
was detected with the rabbit antibodies, no hexa-His Tag sequence appears to be 
attached (or free to bind detection antibody) and it can thus neither be purified on 
affinity columns nor detected with the antibody. A similar situation was observed 
with the pPICHOLI1/CIDR plasmid constructs. This is unfortunate as it is very 
difficult to purify and analyse these products. 
These experiments demonstrated that two yeast clones with var2CSA/pPICHOLI1 
plasmids, those containing the DBL3X and DBL4c domains, yielded products that 
were both 'His-tagged' and recognised by the rabbit polyclonal domain-specific anti-
sera. These were grown in larger quantity for further purification (1) litre cultures in 
2 litre baffled culture flasks). 
After following the growth protocol used for the smaller cultures, the larger 
samples were concentrated into pellets by centrifugation and lysed using the Yeast 
Buster Protein Extraction Reagent (Novagen) (with addition of benzonase nuclease 
to decrease viscosity of the lysate). The resulting insoluble debris fraction was 
pelleted by centrifugation and the lysate was then passed through a 0.2 micrometre 
filter. The insoluble fraction, crude and filtered lysates were fractionated by SDS 
PAGE. Proteins were transferred to membranes by Western blotting, which showed 
that recombinant proteins are present mainly in the soluble fractions. 
Using the filtered lysate material, the DBL3X and DBL4c recombinant proteins 
were further purified by liquid chromatography using the AKTA prime system. This 
exploits binding of the N-terminal histidine 'tag' to metallic nickel ions on the 'Hi-
Trap' chelating column. The HiTrap column (capacity of lml of column material) 
was washed with distilled deionised water, loaded with 100mM NiSO4, then washed 
again with water prior to loading the protein sample which was pre-dialysed into the 
binding buffer (20 mM sodium phosphate, 0.5M NaC1 pH 7.4). The sample was 
filtered through a 0.2 micrometer filter before loading onto the Aktaprime column at 
a rate of 2mllmin. Bound protein was eluted with column elution buffer (washing 
buffer with 500mM imidazole added to compete for Ni binding) and collected in 
twenty fractions. The protein content of the fractions was measured by a Bradford 
assay. Fractions containing protein were run on SDS PAGE prior to Coomassie blue 
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staining. These gels show the presence of the expected band s for the DBL3X and 
DBL4E constructs (as shown above in Figure 4.1). 
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Figure 4.1: (see next page) 
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Figure 4.1: Western blot analysis of P. pastoris expressing pPICHOLII 
plasinids containing DBL3X, DBL4E and DBL5E domains. The proteins were 
separated by SDS-PAGE using 4-12% gels and then transferred to PVDF 
membranes, incubated with rabbit polyclonal anti-sera (1:250) raised against 
recombinant var2CSA DBL domains (plate A), followed by detection with HRP-
conjugated anti-rabbit immunoglobulins (Dako) (1 :1,000)(plate B). Plate A: Plate 
A.1. Pichia expression of pPICHOLII containing a DBL3X domain, probed with an 
anti DBL3X antiserum. Plate A.2. Pichia expression of pPICIIOLI 1 containing a 
DBL4E domain, probed with an anti I)BL4e antiserum. Plate A.3. Pichia expression 
of pPICHOLII containing a DBL5E domain, probed with an anti DBL5E antiserum. 
Lane 1, Untransformed P.pastoris extract. Lane 2. P.pastoris extract transformed 
with the pPICHOLII expression vector without cloned insert, grown on glycerol. 
Lane 3. P.pastoris extract transformed with the pPICHOLII expression vector with 
cloned insert, before methanol induction. Lane 4. Extract of transformed P.pastoris 
containing the inserts of interest, lysed after methanol induction of plasmid 
expression. Plates B: fractions eluded from scaled up protein preparations 
purifications, run on SDS PAGE gels and then Western blotted with mouse 
monoclonal anti-His Tag antibody. Plate B.1.1: gel analysis of the expression of 
pPICHOLI1 containing a DBL3X domain stained by Coomasse stain and by Western 
blot using 6Xflis tag antibody (B.1.2) (Qiagene). Plate B.2.1: gel analysis of the 
expression of expression of pPICHOU1 containing a DBL4E domain attained by 
Coomasse stain and by Western blot using 6XHis tag antibody (B.2.2). All 
molecular weights are estimated from (BioRad) markers and are given in kilo 
Daltons. 
4.3. Human antibodies to the purified DBL3X and DBL4E 
recombinants. 
To investigate whether humans mount an antibody response to these var2CSA-
derived recombinant proteins following malaria infections, an ELISA assay was set 
up using antibodies from malaria infection samples collected in Sudan. These 
samples were collected by Dr. Nasreddin Abdulahi during the course of a study 
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investigating immune responses to P.falciparum antigens in 'sickling' (HbAS) and 
'non-sickling' (HbAA) individuals. The serum samples were collected from 
adolescents and adults of both sexes as they presented with malaria symptoms at 
clinics in and around Gedaref, a large town in Eastern Sudan, during 1989. These 
samples were part of a batch that Dr. Abdulahi brought to Dr. Arnot's laboratory for 
analysis during a research visit in 1990. Dr. Arnot accompanied Dr. Abdulahi on a 
collection trip around the Gedaref health posts in 1989 and thus knows the setting 
and study plan. Dr. David Cavanagh identified a subset of this collection (around 
20% of the samples) that had moderate-to-high levels of antibodies that recognised 
the C-terminal recombinant fragments of MSP-l. 
The binding of antibodies to recombinant DBL3x and DBL4s in these 'Gedaref 
infection sera' was assayed, in duplicate, on microtitre plates, each coated with 100 
ng of purified recombinant-derived antigen prior to assay by ELISA. MSP119 was 
used as positive control and measure of that individual serum's reactivity to a defined 
P.falciparum merozoite antigen. Because a pooled malaria naïve serum was used a 
negative control, without standard positive serum or monoclonal antibody control it 
is not possible to create a standard curve for either positive or negative control sera. 
Nonetheless with these sera and controls it is certainly possible to detect a fairly 
strong and specific level of reactivity to all three recombinant antigens with the great 
majority of Sudanese infection serum. No such malaria antigen reactive antibodies 
are present in the Scottish malaria naïve serum pools. 
In some ways this is a surprising result. It was not unexpected that the Sudanese 
serum, taken from individuals attending clinics during the malaria season, actually 
had quite high levels of anti-malaria major merozoite antigen antibodies. In fact these 
'Gedaref clinic' sera were pre-selected because they were known to be 'high-
responder' anti-MSP-1 samples, with antibody levels similar to those found in many 
Sudanese infection and post-infection samples from the nearby village of Daraweesh 
(Cavanagh et at, 1998). What was less expected is that so many of these individuals 
appear to have significant levels of antibodies to domains of a particular PfEMP-1 
erythrocyte surface antigen which is known to be up-regulated by in vitro selection 
of parasites for CSA adhesion (Salanti et a!, 2003) and probably also by in vivo 
selection for placental adhesion (Salanti et a! 2004). Few or none of the donors of 
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these original blood samples were pregnant, many were males and pre-adolescent 
children and the low intensity transmission conditions of Eastern Sudan are not 
thought to lead to high levels of anti-var2CSA antibodies. Such antibodies have been 
proposed to protect adult females from the pathogenic effects of pregnancy malaria 
(Salanti et a!, 2004). 
2/20 samples gave low or negative responses to all three recombinant antigens 
(serum 11 and 20). In one third of the positive samples (6/18), responses to MSP119 
were stronger than those to the var2CSA-derived antigens. However in two third of 
the Gedaref clinic acute infection samples (12/18) the antibody response to at least 
one of the var2CSA derived antigens was equal to or greater than that to the major 
merozoite antigen MSP1 fragment. In 7 samples, the response of both the var2CSA 
derived recombinant proteins was greater than that observed to MSP1 19 (Figure 4.2). 
Figure 4.2: Reactivity of three recombinant produced malaria antigens (C-
terminal MSP-119, PfEMP-1 var2CSA DBL3X and PfEMP1 var2CSA DBL4e) 
with malaria infection serum from Sudan and pooled Scottish malaria naïve 
serum. Samples 1-20 are individual Sudanese sera reacted with the three antigen 
coated wells and a blank well. Sample 21 is the Scottish serum pool reaction with 
these antigens. bOng of each antigen preparation, dissolved in PBS, was used to coat 
the wells (overnight) of a 96 well Thermo Dynex Inc. microtitre plates. Absorbance 
was measured at 492nm in a Labsytems Multiscan Ascent plate reader. 
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4.4. Recognition of the purified yeast recombinant DBL3X and 
DBL4 proteins by pooled male and pregnant female malaria 
immune serum from Ghana. 
To further test the antigenicity of the purified yeast recombinant proteins they were 
then tested with a three pools of antisera to further investigate immunogenicity of the 
two recombinant produced var2CSA domains. 
The experiment also assayed whether these var2CSA derived recombinant proteins 
are recognised in a sex and parity dependent fashion. The phenomenon of sex and 
parity dependent antibody recognition of placental-type P.falciparum parasites was 
first reported by Ricke el a! (Ricke at a!, 2000). Currently var2CSA is considered to 
be the leading candidate antigenic target of such antibodies (Salanti et a!, 2003, 
2004). 
The serum pools used were the same as those previously used in studies that 
showed CSA binding parasites express trypsin resistant variant surface antigens 
(VSA) that bind the female-specific antibodies induced by pregnancy associated 
malaria (Sharling et a! 2004). The pools are a 'male serum pool' of 20 serum 
samples from men living in a malaria endemic region of Ghana. The 'pregnant 
female serum pool' consists of pooled serum from 15 Ghanaian women, collected at 
delivery. This pool included 5 primigravidae (even not likely to have Abs against 
var2CSA binding domains), nine secundigravidae and one multigravid woman. Six 
Scottish malaria naïve individuals donated sera to create the 'malaria negative pool' 
serum. The bacterially produced MSP1 1 9 GST fusion recombinant protein was 
included as a positive control (the Ghanaian sera were the gift of Dr. Mike Ofori and 
Dr Trifle Staalsoe, University of Copenhagen and the MSP-119, used above, was from 
Dr. David Cavanagh,). 
When the PfEMP- 1 var2CSA derived antigens were probed with both the male and 
the pregnant female serum pools sera, there was fairly strong reaction with both sera, 
although the response was stronger to the MSP-1 antigen. Thus no parity and gender 
specific reactivity was observed in the response to these var2CSA derived 
recombinant antigens (Figure 4.3). Again this finding is not exclusive as if we are to 
conclude a clear gender specific recognition, reasonable number of individual male 
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and pregnant sera should be tested . then a statistically conclusion could be reveal 
whither an antigen is recognised in gender specific manner. 
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Figure 4.3: ELISA readings from pooled male, pooled pregnant female serum 
and Scottish sera incubated with the purified DBL3x and DBL4e domains from 
var2CSA protein. All sera were used at a dilution of (1:1000). 
4.5. Differential screening of arrayed expression libraries with male 
and pregnant female sera from Ghana. 
As well as var2CSA, the DBL3 (also known as DBL1) domain of the varlCSA 
encoded protein has been implicated in CSA binding and proposed to have a role in 
the pathogenic processes involved with PAM (Buffet et a!, 1999). Therefore an 
experiment was designed to investigate if this class of sequences in the P.falciparum 
FCR3CSA isolate might be expressed and differentially screened with male and 
pregnant pooled sera from Ghana. 
Colonies (90 different clones, arrayed in duplicate pairs) from a library of 
sequences amplified from FCR3CSA genomic DNA with 'degenerate primers' 
flanking a semi-conserved sequence in the DBL3 type domain were picked from the 
original transformation master plates into 96-well growth plates (in duplicate). The 
methods used in the creation of this domain sub-library were described in Chapter 3. 
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The pPICHOLI plasmid was used as the transformation vector. Colony arrays were 
prepared by seeding colonies to High Bond-C Extra (Amersham) nylon filter 
membranes. The E.coli filters were induced for recombinant protein expression and 
then lysed to liberate intra-cellular recombinant protein; the filters were blocked with 
non fat dried milk (5%) in PBS overnight. One of the membranes was then incubated 
with Ghanaian male sera, while the other was incubated with Ghanaian pregnant 
female sera. Two identical membranes containing the DBL3 type domain arrays 
were first tested with Scottish sera. No positive, antibody-binding colonies were 
observed with malaria naïve sera. 
Figure 4.4 A&B shows that the Ghanaian pregnancy serum always reacted slightly 
more strongly with expression products than the Ghanaian male sera (a dilution of 
1:5000 for the pregnant women and 1:2000 for the male sera was used to compensate 
for this). This stronger reactivity of infection sera from pregnant women is probably 
because these samples are taken from women with an active placental malaria 
infection who thus had significantly higher levels of anti-malaria antibodies than the 
relatively immune adult male who probably have not had any recent active clinical 
malaria infection. 
Interestingly, when the duplicated expression clone arrays were screened with the 
different sera, there was a clear differential recognition of some clones. Certain 
clones are clearly reacting with the Ghanaian pregnancy serum but not with the 
Ghanaian male serum (Figure 4.4). 
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Figure 4.4: Immuno-screening of duplicated bacterial expression arrays of 
DBLy type domains.A. Pooled Ghanaian male sera. B. Pooled Ghanaian pregnancy 
sera. After lysis, the membranes were first incubated with the primary sera at dilution 
of 1:5000 for the pregnancy sera and 1:2000 for the male sera. This was followed by 
HRP-conjugated rabbit anti-human IgG immunoglobulins (1:1,000) (Dako). 
Differential recognition of pairs of colonies binding female pregnancy derived 
antibodies but not male endemic serum antibodies is illustrated by boxes. 
4.6. Characterisation of the PfEMP-1 var-gene fragments encoding 
epitopes that are differentially recognised by male and multigravid 
female endemic area serum antibodies. 
The DBLy expression library has been described in Chapter 3 (samples of these 
sequences are listed in the Appendix 1). 
The three differentially recognised (i.e. pregnancy + / males -) clones were 
sequenced and two of the three were found to be identical (the DBL13/5 clone). This 
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serves as a good internal confirmation that the observed gender specific serum 
recognition is a repeatable phenomenon. The sequence of this fragment, and an 
identical sequence from the database, is shown in Figure 4.5. This sequence that is 
identical to the DBLy3/5 over 481 nucleotides and 160 amino acids is a previously 
described var gene fragment (Accession number AY248877, from the P.falciparum 
isolate ff412515 (Kraemer et a!, 2003). 
This immuno-detected 'gender-specific' clone from an FCR3CSA genomic DNA 
derived library is thus identical to a sequence originally identified using a novel 
series of type specific primers for the DBL-beta, gamma and delta types (Kraemer et 
al, 2003). The paper by Kraemer and his colleagues also states that the A4 clone used 
in their study as a DNA source is a derivative of the P.falciparum line 1T4/25/5. The 
authors then state that, "the ff4125/5 isolate is one of a series of isolates including 
the FVO, FCR3 and Palo Alto parasites that appear to have a common genetic origin 
due to a laboratory cross-contamination event [33]".  The reference 33 is to the paper 
of Robson et a! (Robson et al, 1990). It seems likely that part of the explanation for 
the 100% match with Kraemer and colleagues' sequence is that rather than working 
with two different isolates, we and they are actually working with the same clone. 
Why this clone might appear 'gender-specifically' recognised by our serum pools 
will be discussed later. 
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Query: 108 AAATTATGTGTAATTAATACAACATTAAAGAGAATACAT 	GAAGAAAA 167 
1111111111111111111111111111 I I 11111111111 liii Illillillil 	ill 
Sb jct: 	1 AAATATGTGTAATTAATTTACAACA TAAAAGAATACATCGTT 	 60 
Query: 168 GCTTTTATTcAATGCGCTGCCGCAGAAACTTTTTTACTATGGCATAAATACAAAACGGAT 227 
Iii 	1111111111111 111111111 I 1111111111 I lIIIIlIII1llIlI1lII Ill 
Sb ]ct: 	61 GCTTTTATTCAATGCGCTGCCGCAGAAACTTTTTTACTATGGCATAAATACAAAACGGAT 120 
Query: 228 AACAATGGTGGTGAAGAACTACAAAACCAATTAGAAAGTGGAATAATccCTGAAGATTTT 287 
I lilIlIllillIlIll I 111111111 I 	I Illillilill I 
Sb] Ct: 121 AACAATGTGGTGAAAACTACAAAACCAATTAAAATGGAATAATCCC 	TT?1 180 
Query: 288 AAGCGCCAIATGTTCTACACAT'J.TGGCGATTACAGAGATTTGTGTTTGGATAAAAATATA 347 
111111111111111111111111111111111111111111 1 lililIllillilli Ii 
Sb jct: 181 AAGCGCCAAATGTTCTACACATTTGGCGATTACAGAGATTTGTGTTTGGATAAAAATATA 240 
Query: 348 GGTAGTGATGTGATGAAGTAGAAAAAAATATAAAACGTGTCTTCTC TAATGGAAC 407 
1111111111111 llllllIllllllIlllIlIlll 111111111111111111111111 
Sb jct: 241 GGTAGTGATGTGAGTGAAGTAGAAAAAAATATAAAACGTGTCTTCTcAAGTAATGGAGAC 300 
Query: 408 AAAACACCTAATGGCCAATCACGTCTAGACTGGTGGGGAAAAACTGTCATATAT 467 
1111111111111 III 	II 11111111111 liii 
Sb jct: 301 AAAACACCTAATGGCCAATCACGTCTAGACTGGTGGGGAAAAAACTGTCAAGATATAT 360 
Query: 468 CAAGGAATGTTATGTGGCCTATCACACGCTAGTGGAAATATAAGTAACGTAGAAACTATC 527 
11111111 I 	IIIIIIIIIIIIIIIIIIIIIIIIIIIIII I 
Sb Ct: 361 CAAGGAATGTTATGTGGCCTATCACACGCTATGGAAATATATAACGTAGAAACTATC 420 
Query: 528 AAAAACAACAACACCTACTCCCTCGTCAAATTCATGGTGACAATAGAGGCCCCACCC1 587 
Sb JCt: 421 AAAAACAACAACACCTACTCCCTCGTCAAATTCATGGTGACAATAGAGGCCCCACCC 480 
Query: 588 GAGGAATTCTCTAAACGA 605 
1111111 1111111111 
SbjCt: 481 GAGGAATTCTCTAAACGA 498 
Figure 4.5. Nucleotide sequence alignment of DBLy-5 and DBLy type domain 
(Accession number AY248877) of isolate 1T4/25/5 revealed that they have 100% 
homology. 
The other sequence is a named DBL37-13 which, to date, has no exact homology 
with any sequence in the databanks, although it is has homology of (98%) of 546/55 3 
nucleotides (Accession number AF1 93424) with the DBLi domain of a PffiMP-1 var 
gene (Smith, J et al, 2000a), again of the IT isolate (clone A4tres), a gene encoding a 
protein that has been described to bind ICAM1 which has been implicated in cerebral 
malaria (Smith et al, 2000a) (Figure 4.6). 
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Query: 	83 TGTATGCCTccTAGTAGACAAAATTTATGTGTAcATTATTTAACAAAATTGAATGACGAC142 
111111 I I 	II 	II 	11111 1111 I 111111 I IIII1IIIIIIIIIIIIIIIIIIIIII I 
Sb jct: 5246 TGTATGCCACCAAGAAGACAAAAT TATGTGTACATTATTTAAC 	TTGAATGACGAC 5305 
Query: 143 TCCAAAGAAGAAATTTAAGAAGCATTTATTAA 	 GAAACA1TCTT 202 
111111111111111111111111111111111111111 I 11111111111111 	11111 
Sb jct: 5306 TCCAAAGAAGAAGATAAGAGAGCATATTAAC 	 CATrrC!1 5365 
Query: 203 CTACGGCAATATTATAATAGTA GAATGTTG GACGATAAAATAW.CAT 	TATG 262 
liii 111111111111111111111111111111 	I 111111111111111111 I 11111 
Sb jct: 5366 CTACGGCAATATATAATAGTAGAATGTTGA ACGATAAATATTACATAGAATAT 5425 
Query: 263 ATCCCTCCCGAAI TTCAGATCCATGTTCTATACATGGAATTATGTATATGT 322 
11111111111111111111111111111111111111111111111111111111111 1 
Sb jct: 5426 ATCCCTCCCGAA TTCAGATCCATGTTCTAThCATTTGGAATTATTATATGT 5485 
Query: 323 TTAGATACAGATATATCTGAAAAAATTGCAGATCATGATGTAACTACGGcAAAAAAGAAA 382 
11111 I 11111 I 11111 	11111111 I 11111111111 liii 	11111111111111 	II 
Sb jct: 5486 TTAGATACAGATATATCTGAAAAAATTGCAGATCATGATGTAACTACGGCAAAAAAGAAA 5545 
Query: 383 ATAACTGCTGT TrCCAAAAAATTGGCTCCAAAACTACTAA 	 GTGCTAGAA 442 
I I 	IIIIIIIIIIIIIIII III 1111111111111111111111111111111 I 111111 
Sbj Ct: 5546 ATACTGCTGTTrTCCAAAAAATTGGCTCCAAAACTACT 	 TGCTAAA 5605 
Query: 443 CGCGAAGGGTGGTGGAAAGAATATGGTCTATCTAT 	GGAATGTTATGTGCTTTA 502 
11111111 I I I I 	11111111111111111111111111111111111 	111111111 I I 
Sbjct: 5606 CGCGAAGGTGGTGGAAAGAATATGGTCTATCTAT 	 TGTTATGTGCTTTA 5665 
Query: 503 AGTTAThATACTGAAACAAAAAAAATGGATGAA 	TG 	CATACC1ATGAATAT 562 
III 	I I 11111 	III IIIIIIII11IIIIIII I III 	III IlillIllIllIll III 
SbjCt: 5666 AGTTATAATACTGAAACAAAAAAAATGGATGAAGGAGTGCGCACATACCATCTAT 5725 
Query: 563 ATATACNAAAACAACGACNTANAAGAATATCTCGAGGAGTTTCGT 	ACCCCCATTT 622 
111111 	1111111 liii 	II 	11111111 	III 	1111111111111111 I 111111 	I 
Sb jCt: 5726 ATATACAAAAACAACGACATAAAAGAATATCTCG GTTTGGTCAGACCCCCATTT 5785 
Query: 	623 TTACATGG-TTA 634 
111111111 	III 
SbjCt: 5786 TTACGATGGGTTA 5798 
Figure 4.6: Nucleotide sequence alignment of DBLy-13 and a fragment of var 
gene implicated in binding to ICAM1 domain (Accession number AF193424) of 
isolate IT revealed that they have 98% homology. 
This identification of a var gene fragment that encodes an antigenic epitope that 
is recognised by multigravid female serum but not by male endemic serum is 
interesting. This is one, probably important, characteristic of the type of sequence 
that is a candidate antigen for inclusion into a malaria in pregnancy vaccine designed 
to give women who have never been pregnant a vaccine-induced immune response 
which mimics that of multigravidae who are protected against PAM. This will be 
discussed further in the Conclusions in Chapter 5. 
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4.8. Conclusions. 
The sequencing of the genQme of the malaria parasite P. falciparum has permitted 
much more rapid genomic and proteomic studies of this pathogen which have clearly 
made it easier to identify novel potential drug and vaccine targets (Hanash, 2003). 
The use of gene expression micro-arrays has permitted us to identify certain protein 
epitopes that appear to be recognised by antibodies present in pregnant women 
infected with P. falciparum but which are not recognised by compared with males. It 
has also been confirmed that dual expression - shuttling between two conventional 
expression systems can be useful in expression research. Using this vectors, and the 
fact it produces intracellular recombinant proteins, the glycosylation can be 
circumvented. Glycosylation is carried out in the endoplasmic reticulum(ER) and 
processed further in Golgi body to form the glycoprotein. There is, however, 
evidence concerning N- linked glycosylation of the extracelluar P. falciparum 
protein is contentious. Although it is suggested that it is not possible in situ due to the 
supposed lack of glycosylation site (Dieckmann-Schuppert et al, 1992), protein 
expressed in eukaryotic systems have in fact been shown to be glycosylated (Hodder 
et al, 1996). 
When using rabbit antisera with CIDR1, DBL1X and DBL2X, rabbit antibodies 
appear to bind these Pichia expressed domains in Western blots. When using the 
purified recombinants for DBL3X, DBL4c in ELISA studies, these products showed, 
in some individuals, strong antibody reactions to all three recombinant antigens. The 
purified yeast recombinant proteins were tested to further investigate whether the two 
yeast recombinant produced var2CSA domains are recognised in a sex and parity 
dependent fashion. When the PfEMP- 1 var2CSA derived antigens were probed with 
both the male and the pregnant female serum pools sera, there was strong reaction 
with both sera and thus no parity and gender specific reactivity was observed. 
An experiment was designed to investigate if DBL3y class of sequences in the 
P.falciparum FCR3CSA isolate could be expressed and differentially screened with 
male and pregnant pooled sera from Ghana. When the two identical expression clone 
arrays were screened with the different sera, there was a clear differential recognition 
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of small group of the duplicated clones. Some clones are clearly reacting with the 
pooled pregnancy serum but not with the pooled male serum. 
This identification of a var gene fragment that encodes an antigenic epitope that is 
recognised by multigravid female serum but not by male endemic serum is 
interesting. Maternal and neonatal immune responses directed to peptides 
corresponding to conserved regions of the DBL-i3 domain of PfEMP1 have been 
analysed by other workers. It has been found that two of the four peptides were 
particularly immunogenic, associated with both B- and T-cell responses in pregnant 
women and their offspring (Bmstoski et al, 2005). 
The antigen arrays when screened for capacity of the target antigens to be 
recognized by sera collected from clinically distinct cohorts of individuals naturally 
exposed to malaria. The anticipated outcome of these studies will facilitate the 
identification of those proteins that correspond to immunodominant antigens and will 
prioritise the investigation of those antigens and epitopes on the basis of immune 
reactivity and according to their potential association with protection against P. 
falciparum challenge. (Doolan et a!, 2003). 
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Chapter 5. Conclusions and Future Directions. 
The overall aim of this study was to investigate, both singly and in a combined 
'dual expression' system, the heterologous expression of P.falciparum PfEMP-1 
antigen fragments in E.coli and P. pastoris. If this could be achieved it would be 
possible to first characterise and then scale—up production of candidate antigens that 
can be used in anti PfEMP-1 mediated cytoadhesion blocking blood stage malaria 
vaccines. The choice of a CIDR domain as an initial test of the Pichia expression 
system was based primarily on the fact that the CIDR1-type domains of PfEMP1 has 
been identified as capable of binding to CD36 (Baruch et al, 1995, Newbold et al, 
1997, Beeson et al, 1999). It has also been shown that the same region can also 
mediate binding to chondroitin sulfate A (CSA) on the surface of Chinese Hamster 
Ovary (CHO) (Degen et al, 2000). It was then aimed to express this domain for 
parsitefhost adhesion assays. 
Choosing a suitable expression system for a particular protein depends primarily 
on the properties of the protein, the amounts required, and its intended purpose. For 
malaria vaccines based on PfEMP-1 the following seem to be the most important 
considerations; 
Recombinant protein conformation. As near native conformation of the product 
as is possible is required in order for the recombinant protein to elicit antibodies that 
will recognise the native antigen in vivo. 
The method must be high yielding and capable of being scaled up. This is 
important for the long-term goal of producing a GMP quality antigen for vaccination 
trials. Large amounts of pure material are also important for structural 
characterisation. Excessive modification (e.g. glycosylation) by the production cell 
must be avoided. 
There are several protein expression systems in prokaryotes and eukaryotes. They 
include: bacteria - e.g. E. coli, Yeast (e.g. P. pastoris and S. cerevisiae), cultured 
insect cells and cultured mammalian cells. The advent of recombinant DNA 
technology makes it technically feasible to produce any protein of interest in a 
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number of different organisms. However technical feasibility does not guarantee 
production success. Factors affecting expression include initiation of transcription, 
RNA elongation, RNA stability, initiation of translation, translational elongation, 
polypeptide folding and post-translational processing including amino-terminal 
modification of polypeptide, disulphide bond formation, proteolytic cleavage of 
precursor forms, glycosylation and modification of amino acids within proteins. 
Production is also affected by the rate of degradation (Rai and Padh, 2001) 
The expression of proteins in E. colt is an important and frequently used tool 
within malaria research although the method remains problematic. Due to lack of an 
appropriate redox environment within the cytoplasmic compartment that rendered it 
difficult to produce correctly folded molecules that require the disulfide bonds 
formation. Recombinant protein expression in E.coli can yield insoluble and 
misfolded or poorly expressed protein. (Yadava & Ockenhouse, 2003). Although 
methods have been developed to obtain correctly folded proteins from these 
inclusion bodies, the process of refolding cannot be successfully applied to all 
proteins (Pandey et al, 2002; Singh et al, 2003). 
The methylotrophic eukaryotic expression host, P. pastoris, has been 
successfully developed as an alternative to the E. colt system (Hollenberg & 
Gellessien 1997, Cereghino & Cregg 2000). Yeasts are simple eukaryotes and the 
most frequently used alternative to bacteria. The main advantages of yeast cells are 
that they perform many eukaryotic, post-translational modifications. The main 
disadvantage of yeast cells is the presence of highly active proteases that degrade 
foreign proteins, so that reducing their yield. Yadava and Ockenhouse have produced 
two synthetic genes coding for part of the 175-kDa P. falciparum erythrocyte-
binding antigen (EBA-175) to determine the effects of codon alteration on protein 
expression in homologous and heterologous host systems (Yadava & Ockenhouse 
2003). Synthetic genes were designed based on P. falciparum, E. coli, and Pichia 
codon usage. Compared to the expression of the native sequence, conversion to E. 
colt- or Pichia-based codon usage dramatically improved the levels of recombinant 
protein expression in both E. coli and P. pastoris. 
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The majority of the protein expressed in E. coli, however, was produced as 
inclusion bodies, whilst the P. pastoris-expressed protein was secreted and soluble 
and (unlike the its E. coli-expressed counterpart) was functionally active (able bind 
to red blood cells). Consistent with these observations, antibodies generated against 
the Pichia-produced protein prevented the binding of recombinant EBA to red blood 
cells and recognize EBA-175 on merozoites and in sporozoites by IIFA. Protein 
expressed in P. pastoris has been shown to be superior to that produced in E. coli 
based on its ability to bind to red blood cells (Yadava & Ockenhouse, 2003). 
Glycosylation in eukaryotic expression systems is carried out in the endoplasmic 
reticulum (ER) and processed further in the cis-Golgi to form a glycoprotein. This 
occurs in 0.5-1% of eukaryotic translated proteins. However, evidence concerning N-
or 0- linked glycosylation of extracellular Plasmodium proteins is contentious. 
Although it is suggested that it is not possible in situ due to the supposed lack of 
glycosylation sites (Dieckmann-Schuppert et al, 1992) proteins expressed in 
eukaryotic systems have in fact been shown to be glycosylated (Hodder et al, 1996). 
It is often the case that the same protein can be recognised by different glycosylation 
enzymes which creates a population of oligosaccharide heterogeneity (Yan et al, 
1999). The formation of disulphide bonds and protein folding occurs in the ER and 
systems have been optimised with the yeast P. pastoris (Daly and Hearn, 2005). 
The expression vector that allows protein expression in both prokaryotic and 
eukaryotic systems greatly reduces workload, time and costs, a good and tested 
examble is the dual expression vector (Leuking et a!, 2000). It has been confirmed, to 
some extent, that the dual expression system is a potentially valuable reagent in 
malaria vaccine industry as it can be shuttled between two conventional expression 
systems. Due to high A[F content and frequent lysine and arginine repeats in the P. 
falciparum genome are thought to be the main reason for the frequent problem of 
early termination in the mRNA translation process. The majority of P. falciparum 
derived recombinant proteins are expressed only as truncated forms or as insoluble 
inclusion bodies within the bacterial cells and the expression of P. falciparum 
derived proteins, especially membrane-bound proteins, is still a considerable 
challenge (Flick et al., 2004). Malaria genes to be expressed in heterologous 
expressition system, one has to consider the recodoning of the gene of interest to 
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improve the protein yield or even start the translation. Two other main methods are 
available to increase the expression levels of proteins which containing rare codons 
in host cell, which are the site-directed mutagenesis and the co-expression of the 
genes which encode rare TRNAs. So far, this system is perhaps the most promising 
one for GMP (industrial scale and guaranteed quality) productions. 
The results from the first phase of this project indicate that the Pichia expression 
system can express a P.falciparuin CIDR-domain derived cysteine-rich recombinant 
protein fragment. The quantity and quality of product obtained notably improved 
after performing a scaled-up automated fermentation run. Using this system, a time 
dependent increase in the amount of CIDR-like product of the expected MW 
(-28kDa) was consistently produced. This product was provisionally confirmed as 
the intended CIDR product following in Western blot using antibodies to the 
engineered poly-histidine tag epitope. Now that mass spectroscopy based sequencing 
and protein characterisation methods have become available to us in the Department 
of Chemistry in Edinburgh, a full sequence characterisation of this candidate product 
could be carried out. 
Detection of the candidate CIDRI decreased with the time, suggesting that some 
degradation was taking place. Some evidence of aggregation was observed in the 
Pichia derived protein solutions analysed here, which quickly took on a cloudy 
appearance. Aggregates have been common in the production of other PfEMP-1 
domains and this makes their handling and analysis problematic (Dr. Graham 
Bentley, Institut Pasteur, personal communication). In fact, this problem affected 
material that was sent to Dr. Bentley and little progress was made in the X-ray 
crystallographic analysis of this material, despite the fact that it was being made in 
sufficient quantity to carry out crystallisation experiments. 
The affinity purified CIDR1 protein was also used as the target antigen in 
ELISA assays using MSP1 19  positive sera from malaria endemic areas. Scottish 
malaria-naive sera served as a negative control that was not expected to show 
reaction to the P.falciparum antigen. The positive control, expected to be recognised 
by most malaria infection sera, was the most conserved fragment of the major 
merozoite surface antigen, MSP1 19  .Results showed that most of the Sudanese sera 
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tested recognised both this merozoite antigen and the PfEMP- 1 CIDR1 antigen 
fragment. The implication is that this antigen, or a similar structure which elicits 
antibodies which cross-react with this antigen, has been expressed during the 
ongoing or recent malaria infection suffered by this Sudanese malaria season acute 
infection cohort. Given that the CIDR domain is implicated in CD36 binding and that 
CD36 binding is thought to be a common adhesion phenotype, it is certainly possible 
that cross reactive antibodies recognising a range of different but related CIDR 
sequences are commonly elicited by malaria infections. 
When this recombinant CIDR antigen was tested as the target antigen in another 
ELISA experiment using two particular pools of male and multi-gravid female sera 
from Ghana, each pool recognised the target antigen equally well. Given that each 
member of the groups used to make the serum pool must have had many different 
malaria infections, it is not surprising that there are antibodies in each serum pool 
capable of recognising this recombinant protein and the result is in accordance with 
what would be expected given the previous results showing widespread reaction to 
this antigen in the Sudanese acute infection sera. It also shows that Ag has epitopes 
similar to those seen by malaria exposed individuals. 
An antiserum was raised in rabbits against the recombinant CIDR and the 
antibodies from this immunization were tested for reactivity to P. falciparum 
infected RBCs. Monoclonal antibodies to MSP-1 (a gift of Dr Jana McBride and Dr 
David Cavanagh, Edinburgh University) were used as positive controls. The 
monoclonal antibody controls were seen to strongly recognize acetone-fixed RBCs 
infected with late stage parasites. However none of rabbit sera from the 
immunization study was shown to surface label any stage of intra-erythrocytic 
malaria parasites (3D7) in IFA following acetone fixing of the cells. This finding was 
disappointing, but it has been found by many groups that it is difficult to raise 
antibodies that recognise PfEMP-1 on the infected erythrocyte. A few groups have 
however, reported success (Chen et a!, 2004; Gamain et a!, 2004). That the rabbit 
sera did not recognize 3D7 parasites infected may be due to our uncertainty that the 
immunising antigen is structured in its in vivo conformation and can thus induce 
'conformation dependent' antibodies or the lack of transcription of the var gene that 
contains the nucleotide encoding this domain. 
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Six different sub-libraries were constructed using primers designed to hybridise to 
regions flanking the different PfEMP-1 domain types in the E.coli and P.pastoris 
expression systems. This was atchived by desingning degenerate primersfor DBLa, 
DBLI3 and DBLy domain of PfEMP1. These primers were able to recognize a great 
variety of different sequences and have also amplified DBL type-specific products. 
These primers could be used broadly and were found to be less biased against 
particular sequences. Even these primers based in different P. falciparum clone 
(3D7), thus, these degenerate primers could be used for other falciparum parasite 
genotypes (e.g. FCR3CSA). This could be even improved by including other specific 
or degenerate primers to make these libraries much representative ones, which in turn 
will help in generation of more collection of var gene fragments. The dual 
E.coli/yeast expression shuttle vector (pPICHOLI1) has been shown to be useful for 
quickly alternating between two conventional expression systems. Direct PCR 
screening and sequencing of clones showed that different variants of each of the 
domains in the FCR3CSA genomic DNA are present and growth on the filters, 
induction, lysis and immunoscreening of these libraries has been optimized. Various 
membranes, antibody concentrations, and hybridization times were evaluated. 
Various problems associated with high background reactivity were encountered 
when using antibodies to screen an expression library. These were mainly resolved 
by diluting the antibody and increasing the temperature at which the blocking, 
rinsing and washing steps are carried out (to as high as 50°C). Pre-absorption of 
antibodies with the the lysates from expression systems of choice also helped to 
remove cross-reacting specificities. 
In addition to making the domain specific sub-libraries, a series of constructs were 
made using the sequence of a particular PfEMP-1 var gene, the pregnancy associated 
malaria vaccine candidate, var2CSA. Some of these domains were expressed in P. 
pastoris and when using rabbit anti-sera raised in Copenhagen (a gift of Dr. Ali 
Salanti) against the so-called CIDR1, DBL1X and DBL2X domains, these rabbit 
antibodies bound the Pichia expressed domains in Western blots, although there 
were clearly problems with high background and widespread cross-reactivity of yeast 
proteins with these rabbit antisera. When using purified recombinant antigen 
corresponding to the DBL3X and DBL4 domains in ELISA studies, these products 
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bound some antibodies present in most Sudanese acute infection sera but did not 
react to Scottish malaria naïve serum pools. This could be due to the existence of 
serological cross-reactivity between VAR2CSA antibodies with other PfEMP-1 
antigens. It is certainly not likely that any of these serum donors had recently 
suffered from pregnancy-associated malaria. There are few reports in the literature 
that appear to shed further light on this phenomenon but it should be followed up by 
testing with further groups of well characterised antisera, such as samples from the 
Daraweesh study. 
These purified yeast recombinant proteins were tested to further investigate 
whether the yeast recombinant produced var2CSA domains are recognised by serum 
pools that are derived from individuals living in a much higher malaria transmission 
zone than Sudan, such as rural southern Ghana. When the PfEMP-1 var2CSA 
derived antigens were probed with both the male and the pregnant female serum 
pools, there were clearly antibodies in both serum pools that recognised the target 
PfEMP-1 antigens and gave quite strong reactions in the ELISA assays when 
compared to the Scottish malaria naïve serum pool. This experiment, using different 
var2CSA derived antigens than those previously used in a study by Salanti and co-
workers (Salanti et al 2004), gives a somewhat different result than that observed in 
this earlier work. This earlier work showed some evidence that anti-VAR2CSA 
domain antibodies against DBL3X and DBL5E were significantly more strongly 
recognised in ELISA assays by plasma antibodies from women, particularly term-
pregnant women, than male Ghanaian plasma antibodies (Salanti et al 2004). The 
results presented here can tentatively be interpreted as indicating that the two 
different Var2CSA derived recombinant antigens used here (DBL3X and DBL4e) 
can induce either specific or cross-reactive antibodies that occur at some frequency 
throughout the population, regardless of sex or pregnancy and parity status. 
However, these results using pooled serum are more difficult to interpret than results 
obtained using well-characterised individual sera. These experiments with these 
constructs should be repeated using individual male and female serum although these 
were not available in quantity during this study. 
To explore the parity dependent antigen recognition phenomenon from a different 
perspective and to use the system and optimised conditions worked out in the course 
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of the thesis work, an experiment was designed to investigate if DBL3y class of 
sequences in the genome of the P.falciparum FCR3CSA isolate might be expressed 
and then differentially screened with the male and pregnancy serum pools from 
Ghana used in the ELISA experiments. Interestingly, when duplicated FCR3-
Db13'y domain expression arrays were screened with the different sera, there was a 
clear differential recognition of a small subset of the clones such that on the first 
screening, three clones clearly bind antibodies present only in the pooled pregnancy 
serum. 
Further sequencing showed that two of these three 'gender-specifically 
recognised' clones are identical, a useful internal control showing that the 
phenomenon is repeatable. The sequence is called DBLy3/5 has been shown to be 
identical sequence with a previously described var gene fragment (Accession number 
AY248877, from the P.falciparum isolate ff412515 (Kraemer et al, 2003). The other 
sequence is a named DBL3y-13 which has no exact homology with any sequence in 
the databanks, although it is has homology of (98%) of 546/553 nucleotides 
(Accession number AF193424) with the DBL3'y domain of a PfEMP-1 var gene 
(Smith et al, 2000a), again of the IT isolate (clone A4tres), a gene encoding a protein 
that has been described to bind ICAM 1. 
The significance of these apparently 'gender specifically recognised' DBLy 
derived fragment expression proteins is not clear. Time did not permit carrying out 
more definitive experiments in which first the induced expression clones, and then 
recombinant, antigen purified from these expressors, was tested against a large panel 
of individual endemic male and endemic pregnancy malaria derived antibodies. It 
seems unlikely that no adult male would be able to mount an antibody response 
against an epitope of an ICAM-binding PfEMP-1 protein. At the risk of over-
interpreting the data, these results do seem to support the view that DBLy regions of 
PfEMP-1 genes can give rise to cross-reactive antibodies. 
For various reasons including time constraints and difficulties encountered the 
possible directions that could be pursued are continue to investigate the gender 
specific clones. This could be done by screening the whole DBL31 library, in 
automated way, screening for target proteins will be the most rapid way then isolate 
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the clones that are recognised in sex pattern. These antigens are now ready, together 
with the DBL3X, DBL4E and CIDR fragments already expressed in Pichia pastoris 
to be used in scaled-up production runs in fermentors for purification of the large 
quantities of recombinant antigen required for further structural analysis and 
vaccinological studies. This work and the possibility of constructing larger 
recombinant antigens which may more closely mimic the complex epitopes that seem 
to be formed by these large parasite adhesion proteins could form the logical next 
phase of this work. 
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Chapter 6: Materials and Methods. 
This chapter describes all of the materials and methods used during the course of 
this project. 
6.1 Materials. 
This section lists all materials used in this research. Unless stated, all reagents were 
purchased from Sigma. Suppliers can be found in Appendix 1. 
6.1.1 P.falciparum parasites: 
Name 	 Phenotype 	 Source 
3D7 	 standard laboratory clone, 	cloned and maintained in 
Amsterdam Airport strain 	Edinburgh 
FCR3CSA 	CSA binding parasite 	 selected 	in 	Amot 
laboratory from FCR3 
6.1.2 E. coli strains: 
Different E. coli strains have been used in this project for different purposes. 
Name 	 Application 	Genotype 
XL1 blue 	Cloning plasmids 
(recAl endAl gyrA96 thi-1 hsdRl7 supE44 relAl lac [F' 
Stratagene 	 proAB lacIqThM15 TOO (Tetr)]) 
TOP10 	Cloning plasmids 
Invitrogen (F-mcrAA(mrr-hsdRMS-mCTBC)(p80IadZLM 15 
araleu)7697 ga/U ga/K rpsL (StrR) endAl nupG) 
BL21RIPL 	Protein expression 
Stratagene 
(E. coli B F— ompT hsdS(rB— mB—) dcm+ Tetr gal 
A(DE3) endA Hte [argU proLCamr] [argU ileY leuW 
Strep/Specr) 
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6.1.3 P. pastoris strains: 
Two P. pastoris strains have been used in this project for protein expression 
experiments. 
Name 	 Application 	 Source 
X33 (Invitrogen) 	Protein expression 	
wild-type 
 
GS1 15 (Invitrogen) 	Protein expression 
his4 
6.1.4 Vectors. 
Three different vectors were used during this work. Two of these vectors are 
commercially available, while the third was a kind gift from Dr. Dolores Cahill 
(Berlin). 
Name 	 Purpose 	 Source 
The TA Cloning® Holding vector for sequencing and Invitrogen. 
vector 	 sub-cloning. 
pPICZa.A 	Protein expression. 	 Invitrogen. 
Gift 	from 
pPICHOLI 	Protein expression. 	 Dolores Cahill. 
6.1.5 Monoclonal and conjugated monoclonal antibodies: 
Primary and secondary antibody reagents are listed below. These antibodies have 
been used in Western blots and in immuno-histochemical assays (ELISA and IFA). 
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Host Specificity Conjugate source 
Rabbit Human IgG HRP DAKO 
Mouse 6X His tag HRP Qiagen 
Swine Rabbit IgG HRP DAKO 
6.1.6 Polyclonal sera: 
Polyclonal sera were used in Western blots, in immuno-histochemicaJ assays 
(ELISA and IFA) and in the immuno-screening of the expression libraries. 
host 	 Source 
Pooled human sera 	 Malaria exposed adults from Sudan and 
Ghana. 
Individual human sera 




Rabbit polyclonal sera against the yeast Rabbits 	immunized 	with 	the 
recombinant CIDR1. 	 recombinant CIDR1 antigen. 
Individual Scottish sera 
	 Dr. David Cavanagh lab. 
6.1.7 Reagents, Equipment and consumables. 
The majority of chemicals and reagents were purchased from Sigma. Reagents 
supplied by others are listed in Appendix A. 
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6.1.8 Media, buffers and solutions. 
Media, buffers and solutions for culture work were prepared with Millipore water, 
and sterilized by filtration through 0.22 micrometre filters. Uncompleted 
(Incomplete) medium was stored for up to 3 months at 4°C. A list of all prepared 
media, buffers and solutions is given in the following Table. 




Soc medium, 1 litre 5 g Bacto yeast extract 
0.5 gNaCl 
10 nil 250 mM KC1 
20 g Bacto tryptone 
Make up to: 1 litre with 
water and adjust to pH 7.0, 
autoclave then add: 
20 ml 1 M Glucose 
Culture medium for 
E. coli. 
LB medium 	 10 g Bacto tryptone 
5 g Bacto yeast extract 	Culture medium for 
10 g NaCl 	 liquid 	E. 	coil 
Make up to: 1 liter with cultures 
water and autoclave. 
LB-Agar 1 litre 	 15 g LB medium Agar, 	Solid 	culture I 
make up to 1 litre with water, medium 	 I 
then autoclave. 	 I for E. coil cultures I 
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LB I 50% Glycerol 
	
50% Glycerol, 	 Freezing medium 
50% LB 
	 for 
E. coli cultures 
Minimal Dextrose Medium 
+ Histidine (1 liter) (MD and 
MDH) 
Minimal Methanol + 
Histidine (1. liter) (MMH or 
MM)  
800 ml of water then add: 
100 ml of lOX YNB 
2mlof500XB 
100 ml of lOX D 
To make MDH, add 10 ml 
of 100 X H stock solutions. 
800 ml of water then add: 
100 ml of lox YNB 
2mlof500XB 
100 ml of 1OXM 
To make MMH, add 10 ml 







Buffered Minimal Medium 690 ml water 	 Protein expression 
containing methanol and/or 	100 ml 1 M potassium using Pichia 
histidine plates (BMGH and phosphate buffer, pH 6.0 
BMMH) 
100 ml lOX YNB 
2ml500XB 
100 nil 1OXM 
Add 10 ml of 100X(H) 
histidine stock solution. Mix 
and store at +4°C 
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Buffered 	Methanol- 
complex Medium (1 liter) 
(BMMY) 
Dissolve 10 g of yeast 
extract and 20 g peptone in 
700 ml water. 
Autoclave, then add: 
100 ml 1M potassium 
phosphate buffer, pH 6.0 
100 ml lox YNE 
2 mI500XB 
100 mI lox GY 
100 ml lox  
Protein expression 
Using Pichia 
Yeast Extract Peptone 	Dissolve 10 g yeast extract General growth and 
Dextrose Medium (YPD) (1 and 20 g of peptone in 900 storage of Pichia 
liter) 	 ml of water. Autoclave, then 
add: 100 ml of lOX D. 
Yeast Extract Peptone 	Dissolve 10 g yeast extract, 	Selection of Pichia 
Dextrose Sorbitol Medium 20 g of peptone, 182.2 g of Zeocin 	resistance 
with Zeocin(YPDS with sorbitol in 900 ml of water. transformants. 
Zeocin) (1 liter) 	 Autoclave, then add: 
100 ml of lOX D. 
Then add 1.0 ml of 100 
mg/ml ZeocinTM.  Pour plates. 
Store YPDS plates with 
ZeocinTM at +4°C in the 
dark. 
1OxPBS 	 1.37MNaC1 	 Various 
27mMKC1 	 or 
	
General I 
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120 mM Na2HPO4 	laboratory reagent 
15 mM KH2PO4 
adjust to pH 7.0 
5 x TBE running 	 5 M Tris base 	 Gel electrophoresis 
buffer 	 4 M boric acid 
10 mM EDTA, pH 8.0 
Gel loading buffer 	 30% glycerine 	 Gel electrophoresis 
(blue juice) 	 10 mM Tris-HC1, pH 8.5 
10 mM EDTA, pH 8.0 
0.1 mg of bromophenol 
blue 
0.1 mg of xylene cyanollO 
mM Tris-HC1, pH 8.5 
1 mM EDTA 




lox YNB 	 Dissolve 134 g of yeast Media component 
nitrogen base (YNB) with required for Pichia 
ammonium sulphate in 1000 expression system 
ml Of water and filter 
sterilize. 
Lysis buffer 	 50 mM NaH2PO4 	 Protein purification 
300 mMNaC1 
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adjust to pH 8.0 
500X Biotin 	 Dissolve 20 mg biotin in Media component 
100 ml of water and filter required for Pichia 
sterilize, 	 expression system 
100X Histidine. 	 Dissolve 400 mg of L- Media component 
histidine in 100 ml of water. required for Pichia 
expression system 
lox Dextrose. 	 Dissolve 200 g of D- Media component 
glucose in 1000 ml of water required for Pichia 
then autoclave, 	 expression system 
lox Methanol. 	 Mix 5 ml of methanol with Media component 
95 ml of water. Filter required for Pichia 
sterilizes, 	 expression system 
iox Glycerol. 	 Mix 100 ml of glycerol Media component 
with 900 ml of water. required for Pichia 
Sterilize by autoclaving 	expression system 
1 M potassium phosphate 	Combine 132 ml of 1 M Media component 
K2HPO4, 868 ml of 1 M required for Pichia 
KH2PO4 and confirm that expression system 
the pH =6.0. 
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Buffer B 	 8 M Urea 	 Protein purification 
100 mM NaH2PO4 
10 ruM Tris-HC1, pH 8.0 
Adjust to pH 8.0. 
2 x SDS-PAGE 	 2.5 ml 0.5 M Tris-HO, pH Protein separation 
sample buffer 	
6 
2.0 ml glycerol 
0.4gSDS 
0.31 gDTT 
1 mg bromophenol blue 
add to: 
10 ml with Millipore water. 
x running buffer 	 15 g Tris base 	 Protein separation 
72 g Glycine 
5 g SDS 
Make up to: 
1 litre with Millipore water 
1 x transfer buffer 	 5 mb. 1 M CAPS, pH 11.0 	Western blot 
5mlMeOH 
40 ml Millipore water. 
Giemsa solution 	 Azure ll-eosin 3g 	 Staining of malaria 
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Azure II 0.8g 
	 parasites 
Glycerol 200 ml 




Storage of iRBCs 
3% sorbitol or maimitol 
	with P. falciparum. 
0.65% NaCl 
l%agarose gel 	 Measure 1 g Agarose DNA 
powder and add it to a 500 electrophoresis 
ml flask 
Make up to 100 ml with 
TAE. Melt the agarose in a 
microwave or hot water bath 
until it has fully dissolved. 
Ethidium bromide solution 	Dissolve 10mg of ethidium DNA 
bromide in 1 ml of ddH20). 	electrophoresis 
6X DNA loading buffer 	Combine 1 ml sterile H20 	DNA 
And 1 ml Glycerol. Add electrophoresis 
bromophenol blue powder. 
TAE Buffer 	 4.84 g Tris Base 	 DNA 
1.14 ml Glacial Acetic electrophoresis 
Acid 
2 ml 0.5M EDTA (pH 8.0) 
Complete RPIVH 1640 	74.75m1 of RPMI 1640 and Culturing 
add: 	 P. falciparum. 
SOmls human serum 
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12.5m1 HEPES buffer 
5th! 200mM L-glutamine 
5m1 20% glucose 
1.25m1 	of 	10mg/mi 
gentamicin 
imi of 1M NaOH (pH to 
approx 7.2-7.4) 
6.1.9 Commercially available kits. 
During this work, several kits were used. The kits are listed the table below: 
Kit name 	 Source 
Mega plasmid purification kit 
	
Qiagen 
Qiaprep Spin Plasmid 
	
Qiagen 
Kit Qiaquick Gel Extraction Kit 
	
Qiagen 
Pro-Q Fuchsia Glycoprotein Gel Stain Kit 
	
Molecular Probes 
Qiaquick PCR purification kit 
	
Qiagen 
Quick ligation kit 
	 New England Biolabs 
ECL Plus Detection System 
	 Amersham 
6.1.10 Filter membranes: 
Different filter membranes have been used in this work as support matrices for 
growth and high-throughput immunoscreening. 
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Colony support filter 	Supplier 	 Purpose 
Hybond'-N+ 	 Arnersham 	 Growth support filter. 
Cellulose Nitrate(E) 	Schleicher Schuell 	Growth support filter. 
Polvinylidene Difluoride 	Sigma 	 Growth support filter. 
Hybond- C Extra 	Amersham 	 Growth support filter. 
ProtranTM 	 Schleicher Schuell 	Growth support filter. 
6.1.11 Enzymes. 
A. Restriction enzymes. 
Most restriction enzymes and corresponding buffers used in this work were 
obtained from Promega. A list of all used enzymes used is given in Table below: 
Enzyme 	Recognition site 	Source 	Usage 
Sail 	GATCGAC 	Promega 	When using pPICHOLI cloning 
strategy requiring an upstream 
primer containing a Sal I site and 
Noti 	GCA GGCCGC 	Promega 	A 	downstream 	primer 
containing a Not I site. 
Sacl 	GAGGCTA C 	Promega 	Linearization of vector for 
efficient integration into the 
Pichia genome. 
fable 2.10: List of restriction enzymes used in this project. 
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DNA polymerases and dNTPs. 
To perform PCR reactions, three different DNA polymerases were used: Taq DNA 
polymerases (Promega), Pfu DNA polymerase (Stratagene) and KOD Hot Start DNA 
Polyrnerase (Novagen). 
Other enzymes. 
Name 	 Supplier 
Lysozyme 	 Sigma 
Proteinase K 	 Qiagen 
T4 DNA Ligase 	 Promega 
Lyticase 	 Sigma 
RNAase 	 Sigma 
DNAase 	 Sigma 
Benzonase 	 Novagen 
6.1.12 Primers. 
A. Custom-made primers. 
The Oligonucleotides were synthesized by MWG Biotech, at the 40nmol or 
O.lnmol synthesis scale and HPLC purified. A complete list of the primers used is 
listed below: 

























NOT 1/DBL-4 s IR AAAAAGCGGCCGCTAACTCGCAAAACTCAmGT 
CCATI'C 
SAL1JDBL-5 c IF 	AAAAGTCGACCTGGAATGATGTGGATATGCGAGA 
T 
NOT1IDBL-5 s IR  AAAAAGCGGCCGCTAACGATI'CTTGTGCCCCTAA 
A111'AGT 
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SAL1IDBL-5 IF 	AAAAGTCGACCTGGAATGATGTGGATATGCGAGA 
T 




SAL1IDBL-6 s IF AAAAGTCGACCATCGGAAATGAAGCAmAAGCA 
A 
AAAAAGCGGCCGCTAAATCmGAAATACTGG 
NOT 1IDBL-6 sIR 
GGATTC 
	
DBLaIF 	 TGYGCNCCNTAYMGNMGN 
DBLxIR 	 TTTNCKRCAAAARTCI1TC 
DBLf3IF 	 WSAACAHWTKTGTACMTC 
DBLI3IR 	 TCDTTGNGGDATRTARTC 
DBLyIF TATGCCWCCHAGDAGAVAA 
DBLyIR CATCKHARRAAYKGDGG 
DBL IF CCVMGSAGRCGAMRANTATA 
DBL /R GCCCCATTCWTVWARSYAWCG 
Abbreviations 
R=AIG 	Y=CIT 	M=AIC 	K=G/T 
S=G/C 	W=AIT 	H=A/CIT 	B=CIGIT 
V=AICIG D=A/G/T N=A/CIGIT 
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B. Commercially available primers: 
Primer name 	sequence 5'-3 	 Purpose 
M14/17 GTAAAACGACGGCCAG Primers for 
sequencing from any 
A/T E. coli cloning 











6.1.13 Molecular weight markers: 
All markers were used according the supplier's instructions. 
Marker 	 usage 	 Source 
Ready-load 1 K plus DNA Estimation of the size of DNA. 	Invitrogen 
ladder 
Estimation of the size of BlO-RAD 
Precision plus protein standards 	proteins. 
6.2 Methods.. 
This section describes all the methods used during the course of this project. Unless 
stated, all centrifugation was carried out in a bench top centrifuge. All media and 
experimental materials were pre-warmed to 37°C before use. Liquid waste was 
disinfected in 1% Virkon before disposal. Contaminated consumables were disposed 
of by incineration or inactivated by autoclaving.. 
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6.2.1 Preparation of the serum. 
Serum was removed from coagulated bloods pack using sterile technique into 
sterile centrifuge tubes. It was centrifugated at 690g(using a centrifuge IEC/ Centra® 
MP4R from International Equipment Company, rotor 215 ans radius of 15.4) for 5 
minutes to spin down any remaining red cells. Serum from at least 6 patients' blood 
was pooled and aliquoted and stored frozen at -70°C. 
6.2.2 Preparation of Red Blood Cells. 
Blood (0+) was taken into a pack containing anticoagulant. Aliquots of blood were 
removed from the pack using sterile technique into sterile centrifuge tubes. It was 
then spun at 690 g for 5 minutes to remove serum and as much of the Buffy coat as 
possible. An equal amount of incomplete medium was then added, mixed well and 
centrifuged again at 690 g for 5 minutes. this wash was repeated twice more. After 
the last wash, red cells were re-suspended in an equal volume of complete medium to 
obtain a 50% haematocrit stock. 
6.2.3 Asexual parasite culturing. 
Cultures may be started from patients' blood, from deep-frozen samples or from a 
sub-culture of an existing live culture. Normally a sub-culture is obtained from an 
existing culture and set up as follows: a stock of 5% haematocrit blood is prepared in 
complete medium i.e. from the washed 50% haematocrit blood prepared as above, 
take 1 ml and dilute this in 9 ml complete medium. The parasitaemia of the original 
culture is measured and diluted with the stock 5% haematocrit red cells to make the 
required sub-culture. e.g. from an original culture of 5% parasitaemia take lml and 
add 4 ml stock red cells to make a new flask 'of 1% parasitaemia. The flask is then 
gassed (10 seconds for small, and 20 seconds for large flask)with a gas mixture of 
1% oxygen, 3% carbon dioxide and 96% nitrogen, then incubated at 37°C with 
culture medium being changed daily. Parasitaemia is checked using a Giemsa-stained 
thin blood smear. (Smears are fixed for 30 seconds in methanol and stained with 10% 
Giemsa in PBS pH 7.2 for 45 minutes). Cultures were diluted as necessary using 0+ 
red blood cells (pre-washed 3 times in incomplete medium). 
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6.2.4 Deep-freezing. 
For preservation, samples of PRBCs were frozen in cryoprotectant in liquid 
nitrogen. Mature stage parasites undergo modifications that render the PRBC 
membrane relatively inflexible. This means that only young, ring stages can be 
successfully frozen. Cultured cells were pelleted by centrifugation and the 
supernatant drawn off. The pellet was slowly re-suspended in an equal volume of 
deep-freeze solution (28% glycerol, 3% sorbitol, 0.65% sodium chloride) at room 
temperature and transferred in 0.5m1 aliquots to freezing vials, which were then 
plunged in to liquid nitrogen (-196°C). Addition of the solution should be done at 
room temperature for efficient penetration of the glycerol into the red cells. Aliquots 
of the final mixture were pipetted into small screw-topped ampoules - 0.5-imi per 
ampoule and rapidly frozen by plunging into liquid nitrogen. Parasites were 
maintained in continuous culture in human red blood cells (obtained from the 
Scottish Blood Transfusion Service, Edinburgh, UK), incomplete RPMI-1640 
medium (cRPMI) supplemented with 10% human serum, 37.5mM HEPES, lOOpiM 
hypoxanthine, 20mM glucose, 2mM glutamine, 2mg/m1 NaHCO3, 25ilg/ml 
gentamycin sulphate and sodium hydroxide to pH 7.2. 
6.2.5 Thawing of deep frozen P. falciparum. 
Thawing was performed carefully using a series of salt solutions to minimise lysis 
and return the cells to normal osmolarity. Samples were thawed at 37°C and 
transferred to 50m1 centrifuge tubes. 0.2 volumes for every 1 ml thawed blood of 12% 
(wlv) sodium chloride were added drop-wise over 5 minutes, with continuous 
mixing. After incubation at room temperature for 3 minutes, 10 volumes of 1.6% 
(w/v) sodium chloride was added drop-wise over 5 minutes. Following centrifugation 
at 690 g for 5 minutes, supernatant was removed and 10 volumes of 0.2% 
dextrose/0.9% (wlv) sodium chloride was added drop-wise over 5 minutes. After a 
final centrifugation at 690 g for 5 minutes, the supernatant was removed and cells 
were re-suspended in complete RPMI-1640 to 5% haemtocrit and the culture 
maintained under normal conditions 
Chapter 6 	 120 
6.2.6 Synchronisation of Asexual Parasite Cultures. 
PRBCs older than 18-20 hours post invasion undergo changes that render them 
permeable to sorbitol. A method for the preferential lysis of older forms was, based 
on osmotic stress using sorbitol (developed by Lambros and Vanderberg, 1979) was 
used. To maintain parasites within a narrow age range for experiments, parasites 
were enriched for ring stages by treatment with sorbitol. Parasite cultures with a high 
proportion of young ring stages were centrifuged at 1000 g in a microfuge for 5 
minutes at room temperature and the medium removed by aspiration. The culture 
was washed by adding 10 volumes incomplete RPMT-1640, followed by 
centrifugation at 690 g. The cells were then re-suspended in 5% (vlv) sterile 
sorbitollPBS and incubated at 37°C for 10 minutes. The suspension was centrifuged 
at 690 g and washed twice in incomplete RPMI-1640. The parasites were then 
transferred back to culture and examined by blood smear after 24 hours by which 
time they should all be large parasites (trophozoites). 
6.2.7 CSA Selection. 
Sterile Chondroitin Sulphate A solution was made up at iO microgram/ml in PBS. 
2.5m1 of this solution was added to Petri dishes and incubated for at least 3 hours at 
RT or at 4 degrees C overnight. Immediately prior to selection, the CSA was 
aspirated off and the plate surface blocked with 2% BSA in PBS for at least 30 mins. 
Parasites to be selected were synchronized and used when the parasitaemia of 
trophozoites was at least 5% but preferably over 10%. The 2% BSA blocking 
solution was aspirated off and 2-3m1. of trophozoite-enriched culture added. The 
plates were incubated for 60 minutes at 370C, with gentle rocking every 10 minutes 
by hand. After binding, the parasite suspension was gently removed and the plate 
washed again gently 5-7 times with PBS until the plate was visibly clear and, when 
viewed under the inverted microscope showed a homogeneous distribution of the 
expected density of parasitised cells. 3 ml of uninfected erythrocytes at 5% HCT was 
added, and the dish placed at 37 degrees C, under normal parasite culture conditions, 
i.e. placed in an incubating chamber and gassed with 1% 02, 3% CO2 and 96% N2. 
(If a chamber not available it is possible to culture in a 5% CO2 incubator). Culture 
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were left for 20-24 hours and then harvested into a normal culturing flask and grown 
under normal conditions. 
6.2.8 Preparation of Parasites for Fixed IFA. 
Cells at 5-10% parasitaemia were pelleted by centrifugation at 1000g for 5 minutes, 
washed twice in incomplete RPMI-1640 and re-suspended to 5% haematocrit. 250 
of this suspension was spotted onto each spot of clean, multi-spot microbiological 
glass slides (Hendley-Essex) and left to dry at room temperature. Slides were 
wrapped in Paraflim, sealed in plastic bags with dry silica gel as desiccant and stored 
at -20°C. 
6.2.9 Parasite DNA. 
5m1 of asexual culture at 5-10% parasitaemia were centrifuged at 690 g for 5 
minutes to pellet pRBCs then re-suspended in lml of 0.15% saponin in incomplete 
RPMI 1640 medium and mixed until lysis was observed. An equal volume of 
incomplete RPMI-1640 was added and the mixture spun at 1000 g for 10 minutes. 
DNA was extracted from the parasite pellet using QIAampR DNA Minikit, 
according to the manufacturer's instructions. 
6.2.10 Plasmid DNA. 
Plasmid DNA from 5m1 overnight bacterial and yeast cultures was prepared using 
the QiAprep Spin Miniprep kit according to manufacturer's instructions. Final 
elutions were made in 50i.tllbuffer EB (QlAprep). For the yeast cell, acid washed 
glass beads were added to the P2 slusion of the kit. The QlAprep Midiprep kit 
(Qiagen) was used for transformation quality plasmid recovery with 25m1 overnight 
culture and final resuspension in 200 il water. 
6.2.11 DNA quantification. 
Plasmid DNA concentration was estimated by measuring its absorbance at 260nm. 
It was assumed that an 0D260 of 1.0 is equivalent to a concentration of 50p.g/ml for 
double stranded DNA. 
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6.2.12 Agarose Gel Electrophoresis. 
Agarose gels were used to check the quality of genomic DNA and plasmid 
preparations and to analyse PCR products and restriction digests. 1% agarose was 
dissolved in TAE buffer by boiling. After cooling, ethidium bromide was added to a 
concentration of 0.5.L.lg/m1 and the mix poured into an gel plate and left to set at 
room temperature before being placed in TAE buffer in an electrophoresis gel tank.. 
DNA was mixed with 6X DNA loading buffer and loaded into the submerged gel. 
Electrophoresis was carried out in TAE at 80-120 volts for an appropriate time. 
Fluorescence from DNA-bound ethidium bromide was visualised by short 
wavelength UV light and photographed. 
6.2.13 Primer design. 
Degenerate PCR primers were designed based on known nucleotide sequences. 
With the release of the genome sequence for P. falciparum (isolate 3D7) it has been 
possible to design degenerate primers to identify almost every var gene. To design 
type-specific primers to DBLa, DBL3, DBL7 and DBL, var genes were 
downloaded from the databases. Primers were based on a total of 41 var genes from 
the 3137 genome and other var genes from other parasite genotypes. Their predicted 
protein architectures were obtained. Protein motifs on each domain were determined 
then the nucleotide sequences rechecked to identify the codon. After codon 
determination, degenerate primers were designed in order to amplify the maximum 
numbers of each domain. As far as possible, GC content was adjusted to about 50% 
and Tm to above 60°C, by extending the matching regions. Sequences were analysed 
for hairpins, homoduplexes and Tm. Pairs of oligos were designed to be of equal (+1-
2°C) Tm. Where a restriction site was incorporated, this was at the 5' end. 
6.2.14 TA cloning. 
To obtain sequence for the inserts and to prepare the amplicons to be digested, PCR 
products were cloned into TA vectors. Using the Pfu polymerase, PCR products from 
P. falciparum DNA were obtained using universal degenerate primers. The Taq 
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polymerase was then used to produce amplicons with A-overhangs which are 
compatible with TA cloning vector. 
6.2.15 Automated DNA sequencing. 
Automated sequencing of plasmid DNA was carried out using dye terminators with 
the PRISMS/S cycle sequencing kit (Applied Biosystems Inc.) and the 377 
automated sequencer (ABI). Reactions were set up using 4 .tl Big Dye, 1 .6pmol 
appropriate sequencing primer, 2ig plasmid DNA and made up to 10iI with PCR 
grade water. Cycle sequencing was performed with the following conditions: 25 
cycles of 95°C for 30 seconds, 50°C for 20 seconds, 60°C for 4 minutes. PCR 
products were precipitated by centrifugation in a spin column for 2 minutes at 1500 g 
in a microfuge and run on an acrylamide gel. Chromatograms were viewed and data 
edited using the SeqEdTM program (ABI). 
6.2.16 Digestion of ainplicons and vector. 
Restriction sites for Sail and Noti in each pair of primers and in the vector were 
digested by Sail and Noti enzymes according to the recommended protocol. To set 
up double digestion, lOU of each restriction enzymes were added to 16.ml DNA with 
2pi of the appropriate lox buffer and the mixture made up to 201ilwith water. The 
digestion mixtures were incubated at 37°C for 3 hours, followed by a heat 
inactivation step (65°C, 15 minutes), this achieves 95% inactivation of the enzymes. 
BSA was added to enhance the activity of the restriction enzymes 
6.2.17 De-phosphorylation of cut vector prior to cloning. 
To prevent re-circularisation of cut vector during cloning, the 5' terminal 
phosphates were removed using SAP (shrimp alcohol phosphateas). 1 W of enzyme 
and. Sill  lox CLAY buffer (NEB) were added to 20picut vector. The mixture was 
made up to 50tl with water and incubated at 37°C for 2 hours, followed by 
inactivation of phosphatase activity at 75°C. 
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6.2.18 Purification of DNA fragments. 
DNA fragments from restriction digests or PCR reactions were purified from 
agarose gels prior to cloning using a Gel Extraction kit, according to the 
manufacturer's instructions. PCR products were cleaned using QlAquick PCR 
purification kit. 
6.2.19 Ligation reactions. 
Typically, a 3:1 molar ratio of insert to vector results in the highest yield of 
transformants with a single inserts. A lower amount of insert reduces the efficiency 
of ligation; a higher amount increases the probability of obtaining transformants with 
multiple inserts. Cutting both the amplicons and the vector with the same restriction 
enzymes produces compatible sticky ends so that these amplicons can be inserted in 
the correct orientation. The ligation protocol which demonstrated the best result was 
Quick LigatknTM  Kit (New England Biolabs). This kit uses T4 DNA ligase to 
catalyse the formation of phosphodiester bonds between neighbouring 3'-OH and 
5'phosphate ends in double stranded DNA. Linearised vector and inserts were 
purified by gel-extraction and lOOng vector DNA was incubated with a 1:1, 1:3 and 
1:5 molar ratio of vector:insert DNA. Controls were included using linearised vector 
alone. 1Otlreaction mixtures were set up, with 1-3U T4 DNA ligase (Promega) and 
T4 DNA ligase buffer and incubated at 16°C for 12 hours, followed by 37°C for one 
hour and 65°C for another one hour to denature the ligase and prevent further 
activity. Ligation was carried out at room temperature for 5 minutes 
6.2.20 Recodoning of the CifiR1 fragment. 
This part of the work was done by Toby Feagin and Peter Lawrence as part of an 
unpublished 4th year Honours project in the Arnot laboratory. The method for 
synthesizing a codon optimized version of the gene was based on the established 
methods (Stemmer et al., 1995; Withers-Martinez et al., 1999). The following 
parameters were taken into consideration: reduction of the AlT richness of the 
sequence by replacing rare by more common codons used in the host system (this 
was achieved with help of http:// www.kazusa.or.jp/codon),  removal of potential N- 
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glycosylation 	sites 	(this 	was 	achieved 	with 	help 	of 
hup://www.cbs.dtu.dk/services/fletNGLYC)  and removal of restriction sites that may 
affect downstream cloning techniques. 
6.2.21 Creation of expression library. 
To create an expression library i.e. a library that not only contains the DNA 
fragments of interest but one that can manufacture the protein so that it may be 
detected by the antibody. Essentially the process involves isolation of genomic DNA 
and insertion of PCR enriched fragments into an appropriate expression vector. After 
transformation of bacteria or yeast, growths then induction were carried out. The 
final step involves library screening to select particular clones from the library. For 
the current work, an expression vector that can be used in two expression systems, E. 
coil and P. pastoris, was used. 
6.2.22 Transformation of Bacterial Strains. 
XL-1 Blue and XL-10 Gold strains were used for cloning and propagating DNA. 
Based on the manufacturer's recommended protocols, cells were transformed 
chemically. Briefly, mercaptoethanol (lil) was added to the cells for 10 minutes 
whilethe cells were kept on ice. The ligation product (2tl) was added to the cells and 
left for 30 minutes. The cells were subjected to heat shock for 45 seconds and 
transformed cells were then re-suspended in SOC medium at 37° for one hour before 
being spread on an agar plate containing zeocin (25.tg/m1) and incubated overnight at 
37°C to allow colonies to form. 
6.2.23 PCR colony screening of bacterial Clones. 
Successfully transformed clones were identified by direct colony PCR screening 
and by restriction digest of plasmid DNA. For PCR screens, a standard reaction mix 
was made up with PCR buffer, appropriate forward and reverse primers, 2.5mM each 
of dATP, dCTP, dGTP and dllI'P, 1U Taq polymerase and lOOtillJnil DMSO. liilof 
cell suspension was added to 9piof reaction mix. PCR was carried out under standard 
conditions (94°C for 10 minutes for 1 cycle, followed by 30 cycles of 94°C for 30 
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seconds, 55°C for 30 seconds and 72°C for 90 seconds with a final extension cycle of 
72°C for 1 minute). Amplified DNA was analysed by agarose gel electrophoresis. 
When necessary, PCR conditions were optimised for different primer pairs. Clones 
with inserts in the correct orientation were identified using a standard PCR, with 
primers selected to only allow amplification of an insert in the correct orientation. 
A cell suspension was first prepared using a sterile pipette tip to transfer a bacterial 
colony to 100pJPCR grade water. A 5-950 of the cell suspension was used to 
inoculate 5m1 LB with the appropriate selective antibiotic and incubated overnight at 
37°C, with shaking. Plasmid minipreps were carried out on overnight cultures to 
recover plasmid DNA, using the QiAgen miniprep kit, according to the 
manufacturer's instructions. Recovered DNA was incubated with appropriate 
restriction enzymes to release the insert or to produce a band pattern characteristic of 
a particular insert when analysed by agarose gel electrophoresis. 
6.2.24 Expression of in E. coli in liquid medium. 
BL21-Codon Plus-RIPL competent cells were transformed with an appropriate 
concentration of DNA and transformed bacterial colonies were selected with zeocin 
(50dg/ml and 70 .t1g/m1 chloramphenicol in the LB). Various colonies were picked 
and cultured separately in 50m1 LB medium at 37°C, with shaking, overnight. This 
culture was then used to inoculate 1 litre of pre-warmed LB and incubation continued 
until the 0D600 had reached 0.4-0.6. To induce expression, IM WIG was added to a 
final concentration of 0.1mM and the culture incubated at RT for 4 hours. Bacteria 
were pelleted by centrifugation at 1000 g for 20 minutes at 4°C. The supernatant was 
discarded and the cell pellet resuspended in 50m1 BugBuster® Protein Extraction 
Reagent (Novagen). 50piBenzonase® Nuclease (Novagen) (25u/ml) was added to 
the lysate to degrade bacterial DNA and decrease viscosity. After a spin at 1000 g for 
30 minutes at 4°C, the supernatant was filtered and loaded onto the Aktaprime 
column at a rate of 2mllmin. Bound protein was eluted using elution buffer and 
collected in 2.5m1 fractions. Fractions with the highest peaks of absorbance were run 
on an SDS gel and stained with Coomassie Blue and those fractions containing the 
most protein were pooled and buffer-exchanged. 
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6.2.25 Culture and storage of the expression library. 
Individual colonies were picked from the spread plate. The picked colonies were 
transferred into wells of a 96 well plate containing deep-freezing LB media with the 
appropriate antibiotics to maintain the plasmids, and then stored at -70°C. 
6.2.26 Growth and induction on filters. 
Samples of DBL-a, 0 and y  expression libraries were cultured overnight from the 
frozen libraries. The colonies were grown at 30°C in a 96 well plate in LB media 
supplemented with glucose (1%), glycerol (8%) and zeocin (25ig/rnl). Colonies 
were arranged in duplicate as a control measure for the Western blot to follow. A 
negative control was used consisting of a cell containing the vector but no insert. 
Following the protocol of Sowa et al.,(2004), High Bond-C Extra filters (Amersham) 
were spotted with bacterial colonies using an applicator with 96 steel pins. Colonies 
were grown by placing the filters on LB agar supplemented with glucose (1%), 
zeocin (25.tg/nil) and CAM (34j.tg/ml) at 30°C overnight. For induction of protein 
expression, the arrayed filters were transferred from the glucose/ zeocin 
supplemented medium onto LB agar plates supplemented with IPTG (0.2%), zeocin 
and chioramphenicol. Induction was for 4 hours at 37. 
6.2.27 Lysis of bacterial host strains. 
Lysis was initiated by incubation of filters on Whatman paper pre-soaked with 
BugBusterTM HT (Novagen), supplemented with PMSF (0.1mM) for 20 minutes. 
This was to ensure that the colonies were not displaced from the filter. Following this 
initial lysis, each filter was incubated in 50m1 of lysis buffer; Tris HCl (50 nilvl Tris 
HC1, pH 7.5), NaCl (0.15M), MgC12 (5mM), PMSF (0.1mM), lysosyme (40j.tg), 
Benzonase (300 units/1) and BSA (3%). The filters were incubated with gentle 
agitation for 3 hours at room temperature. Filters were blocked overnight at 4°C in 
PBS-TT, PMSF (0.1mM) and BSA (3%). After overnight blocking, filters were 
washed 3 times in PBS-TT, 15 minutes per wash, then once in normal PBS (lOOmi 
per filter). 
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6.2.28 Removal of Anti-E. Coli and Anti-P. pastoris antibodies from antiserum. 
For removing antibodies that react with either bacterial or yeast encoded proteins, a 
method adapted from De Wet et al., 1984 was used. This contains two steps. Briefly, 
both expression cells were induced with appropriate inducer (IPTG for E. coli and 
methanol for P. pasroris). Live cells of both expression systems that contain just the 
expression vectors (i.e. ones without inserts) were pre-incubated with the panel of 
human sera that were to be used in the immuno-screening, to remove non-
specifically binding antibodies. 
6.2.29 Screening of protein arrays using Anti-His tag antibody and human sera 
from malaria endemic area. 
Filters were probed with HRP- conjugated anti-His tag antibodies (1:2000 dilution) 
for one hour at room temp in the blocking buffer provided. The ECL plus Western 
Blotting Detection System (Amersham) was used to detect positive colonies. After 
lysis, blots were blocked with PBSTM (PBS, 0.5% powdered non-fat milk, 0.1% 
Tween-20) for one hour at RT or overnight at 4°C with gentle agitation. Antibodies 
were made up in PBSTM at appropriate dilutions. Membranes were incubated with 
antibodies for one hour at RT, with agitation, followed by three washes of 15 
minutes each in PBST. Those filters to be tested with human Sera were treated as 
above. The primary antibody was blood sera collected from adults in malaria 
endemic areas, the secondary Ab was Anti-human IgG- HRP (dilution of 1:5000.) 
Blots were developed using an enhanced chemi-luminescence system according to 
the manufacturer's instructions. 
6.2.30 Transformation of P. pastoris. 
Wild-type (X33) P. pastoris and GS1 15 cells were made competent and 
transformed according to the manufacturer's instructions. Briefly, 1 OOml YPD was 
inoculated with 1 colony of P. pastoris and incubated overnight at 30°C with shaking 
at 250 rpm, to an OD at 600nm of 1.3-1.5. Cells were centrifuged at 1500g for 5 
minutes at 4°C and re-suspended successively with lOOmI, then 50m1 ice-cold sterile 
water followed by 4ml, then 0.5ml ice-cold 1M sorbitol. Competent cells were kept 
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on ice and used the same day. 80  cells per transformation were mixed with 5-10ilg 
of linearised DNA (in 5-10pi sterile water), transferred to an ice-cold 0.2cm 
electroporation cuvette and incubated on ice for 5 minutes. Electroporation was 
carried out using a BioRad GenePulser, at 1,500V, 25vF and 200R. After 
electroporation, 1 ml of ice-cold 1M sorbitol was added immediately to the cuvette 
and the contents transferred to a sterile 1 5m1 tube. The cells were then incubated at 
30°C without shaking for 1-2 hours, after which time 10, 25, 50, 100 and 100pJ were 
plated on separate YPDS Z eocinTM (1001lg/m1) plates. Plates were incubated at 30°C 
for 2-3 days until colonies formed. 
6.2.31 	E. coli transformation with expression plasmids isolated from P. 
pastoris. 
To prepare plasmid DNA from selected P. pastoris expression clone from each 2-
ml cultures were grown for 2 days at 30°C. Cells were harvested by centrifugation at 
maximum speed for 5 mininutes. Pelleted yeast cells were incubated in 100 ml lysis 
buffer (1 M sorbitol, 10 mM EDTA, 5 mM DYF, and 2 mg/ml lyticase) for 30 
mininutes at room temperature. Cells were lysed by the addition of 150 ml P2 buffer 
(Qiagen lysis buffer) and incubated on ice for 30 mm. After addition of 500 ml P3 
buffer (Qiagen) the suspension was further incubated on ice for 15 min and 
centrifuged at maximum speed for 10 minutes. The supernatant was purified 
according to the manufacturer's protocol (Spin Miniprep kit; Qiagen). Plasmid DNA 
was electroporated into XL1B1ue cells and plated onto selective medium. Plasmids 
of each clone were isolated (QlAquick Spin Miniprep kit; Qiagen) and transformed 
into the bacterial expression strain. 
6.2.32 Direct Screening of Pichia Clones. 
In order to establish the presence of an insert in transformed yeast cells, a PCR 
screen was carried out. Yeast cells were lysed by lyticase, tolloweci Dy 
freezing/heating treatment to release gDNA which was then used as a PCR template, 
according to the manufacturer's recommendations. Briefly, half of the colony was 
resuspended in lOpi ddH20. 5pi of a 5U/pi lyticase solution was added, and then 
incubated at 30°C for 20 minutes. The PCR reaction was set up in 150pi as follow: 
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-H20 85il 






-Cell lysate 5il 
-Taq polymerase. 3tl 
Total: 	150t1 
Then 30 cycles as follows; 
94° C 1 minute 
55° C 20 seconds 30 X 	30X 
72° C 1, 20 minute 
72° C7minutes 1X 
PCR positive colonies were re-streaked on YPD plates containing lOOp.lg/ml, 
200ilg/ml and 500pig/ml ZeocinTM. Direct PCR screening of Pichia was performed. 
6.2.33 Selection of Pichia for the Methanol Utilisation (Mut+) Phenotype. 
Two media were used, Minimal Dextrose with histidine (MDH) plates and 
Minimal Methanol with histidine (MMH). Using a sterile toothpick, one colony was 
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picked, and streaked on both MMH and MDH plates. The plates were incubated at 
30°C for 2 days. Mu•t+ strains will grow normally on both plates, while Mut- strains 
will grow normally on MDH plate but show little or no growth on the MMH plates. 
6.2.34 Screening Recombinant Pichia for Expression. 
Three levels of induction experiments were carried out. These included small 
induction experiment, scale-up of expression and expression through fermentation. 
A Small induction experiment. 
Selected colonies were picked into lOml (in a 50m1 centrifuge tube) or 50m1 (in 
250m1 a baffled flask) BMGY and incubated overnight at 28-30°C in a shaking 
incubator at 250-300rpm. When the cultures reached an 0D600 of 2-6 (indicating 
log-phase growth), they were harvested by centrifugation at 1,500-3,000g and 
washed in sterile PBS to remove traces of glycerol that may adversely affect 
methanol induction. Cells were then re-suspended to an OD600nm of 1.0 in 100-
200m1 of BMMY, in a 1 litre baffled flask, to induce expression. Incubation was 
continued and 100% methanol was added to a final concentration of 0.5% every 24 
hours for 4 days to maintain induction. 500iiJ samples were removed at appropriate 
time points, centrifuged for 2 minutes at maximum speed in a bench-top microfuge 
and supernatants transferred to fresh tubes. Both supernatants and cell pellets were 
frozen quickly in a dry ice I ethanol bath and stored at -80°C. 
B Scale-up of Expression. 
This involved the same set up as for the smaller inductions except that the initial 
inoculum (25 ml of BMGY) was added to 1 litre of BMGY in a 3 or 4 litre baffled 
flask and grown at 30°C with vigorous shaking until the OD = 2-6. The culture was 
harvested and the pellet was used to inoculate a 2-6 litres of BMMY to start 
induction. 
C Fermentation. 
The fermentation run consisted of the following stages: 
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• 	Glycerol Batch Phase —20 hours 
• 	Glycerol Feed Batch phase - 20 hours 
• 	Starvation phase - 1 hour 
• 	Methanol Feed Batch - 70 hours 
Harvest 
Six litres of Basal Salts Medium were added to the fermenter. After sterilization 
and cooling, the temperature was set to 30°C, agitation and aeration were set to 
routine operating conditions (maximum rpm and 1:10 volume of gas: volume of 
liquid) and the pH was set to 5 with 28 % ammonium hydroxide. Maintaining 
sterility, 4.35m1/1 of PTM was added and the inoculum seed flask was added to the 
fermenter culture. The culture was incubated until complete consumption of the 
glycerol (approximately 20 hours), after which initiation of glycerol-feed was started 
using 50% glycerol containing 12m1 of PTM. The feed rate was adjusted to 
18.15m1/hour per litre of initial fermentation volume. Glycerol feeding was 
terminated and 30 minutes of carbon source starvation was carried out before the 
production phase of the culture was started. The production phase started with 1 2mlJl 
PTM in methanol, and the feed rate was set to 3.5m1/h/l for 3 hours. After adaptation 
to methanol utilization, the feed rate was set at 7.3 mI/l/h for 2 hours. The methanol 
feed rate was changed to 11 mI/l/h to the end of the run (65 hours), at which point the 
culture was collected into 500 or 1000ml centrifuge bottles and centrifuged at 5000g 
for 30 minutes at 4° C to separate cells from supernatant. 
6.2.35 Overlay Assay of P. pastoris colonies on the filters. 
The following procedure has been optimised to screen recombinant colonies 
expressing the proteins of libraries of interest. After transformation, grow the cells on 
YPDS with 100 j.tg/ml ZeocinTM plates. Grow each of the growing cells on either 5 
ml of MGY, BMG, or BMGY broth in 24 deep-well plates supplemented with 
100.t1I/ml Zeocin for (approximately 16-18 hours.) at 28-30°C in a shaking incubator 
(250-300 rpm) until the culture reaches an 0D600 = 2-6. Patch transformants onto 
Minimal Dextrose with histidine agar plates and YPD plates using replicating 
devices carrying 96 steel pins (25-50 colonies per plate) supplemented with 
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l00i11Im1 Zeocin and incubate at 30°C for 2-3 days. Replica plate from the MD (H) 
plates onto MM(H) Minimal Methanol with histidine. Wet the nitrocellulose filter in 
0.5% methanol for 1 minute. Lay a nitrocellulose filter over the colonies with a 
Whatman filter on top (or paper towels, to draw liquid through the nitrocellulose 
filter). Invert the plates and incubate for 2 to 3 days at 30°C. Add 1 ml of 100% 
methanol to the lid of each plate every day. 
To assay for expression, peel the nitrocellulose membrane off the plate with 
tweezers. To detect intracellular expression, lyse the cells by incubating the filter in 
Lysis Buffer. Lysis Buffer (prepare fresh, 0.1% SDS, 0.2 M NaOH, 35 mM 
dithiothreitol) for 30 minutes at room temperature. Remove lysed cells with rapidly 
flowing distilled water and rinse the filter with PBS. Block the membrane with PBS 
containing 0.05% Tween-20 and 5% nonfat, dry milk (PBSTM) or 2% BSA 
(PBS/BSA). For lOOml, lOOml PBS+50.tl Tween-20+5g nonfat dry milk for 1 hour 
at room temperature or overnight at 4°C. Add Anti-His-HRP (1:4000 dilution in 
PBS+2%BSA) in blocking solution and incubate for 1 hour at room temperature with 
moderate shaking. Wash the blot three times with PBS containing 0.05% Tween-20 
(PBST) for 15 minutes each time. Detect expressing colonies using 
chemiluminescence (following the manufacturer's instructions). Circle the high 
expressing clones and compare with the colonies that were patched onto the YPD 
plate. Select the appropriate patched colonies for further expression experiments. The 
most promising clones (those that stained the most intensively) will be picked for 
scale up expression in liquid culture in 50 ml plastic tubes containing 5 ml of 
medium. 
6.2.36 SDS-PAGE. 
Samples were added to 4X sample buffer and heated at 90°C for 5-10 minutes. 4-
12% Bis-Tris polyacrylamide NuPAGETM Novex high-performance pre-cast gels 
were removed from packaging and washed three times with water, before transfer to 
500m1 per tank of either MOPS or MES running buffer. 60SeeBlue® Plus 2 Pre-
stained Protein Standard (Invitrogen) and 20-30j.tl of each sample were loaded in 
each well and electrophoresis was carried out at 200V, constant voltage for 
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approximately 50 minutes, or until the loading dye front had reached the bottom of 
the gel. 
6.2.37 Staining of SDS-PAGE Gels. 
Two methods were used to stain the gels, Coomassie Brilliant Blue stain and Silver 
Salts stain. In the former the gels were fixed and stained for 1 hour in the stain 
solution (10% (vlv) methanol,l0%(v/v) glacial acetic acid and a pitch of Coomassie 
Brilliant Blue). Destaining was performed in the same buffer without the dye. In the 
silver stain method which is more sensitive 1000-fold than the Coomassie stain. 
Simply this kind of stain includes fixation of the gels by the fixation solution 
(Ethanol: glacial acetic acid: H20 in ratio of 30:10:60). Then sensitizing was 
performed by sensitizing solution (30% Ethanol, sodium thiosulphate 5%, and 
sodium acetate). Silver nitrate is added to the gel for 30 minutes. Developing solution 
is then added (2.5% sodium carbonate, 0.02% formaldehyde). Stopping solution is 
then added to stop the reaction (1% acetic acid or EDTA-N2 .2H20). 
6.2.38 Protein Concentration Determination. 
Two assays were used: Bradford Assay and Bio-RadIDC Protein Assay (based on 
the Lowry assay). In the Bradford assay (maximum 100.tl of sample and 1 ml of 
Bradford Working Buffer) were added to the sample. Readings were taken after 2 
minutes at 595nm. We prepared a series of BSA standard solution between 0.2mg/mi 
and 2mg/mi. In Bio-Rad DC Protein Assay we added 5 of 3-5 dilutions of protein 
standard containing 0/2 mg/ml to 1.5mg/mi of BSA, and an appropriate dilution of 
the protein samples. 25 of Reagent A is added to each well, 200 of reagent B is added 
and mixed well. After 15 mins, readings were taken at the absorbance of 750nm. 
6.2.39 Concentration of the protein sample. 
Vivaspin concentrators, ammonium sulphate precipitation, and a Speed-vac 
concentrator were used in this project. Vivaspin concentration was used directly with 
molecular weight cut-off of 5000Kda. Speed-Vac concentration was also used 
directly for the appropriate times. 300 ml supernatant was mixed with 1200.tl of 
saturated ammonium sulphate and left on ice for 20 minutes, followed by 
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centrifugation for 15. minutes at maximum speed in a microcentrifuge. Supernatant 
was discarded and the pellet was re-suspended in PBS. 
6.2.40 Western blot. 
Wet transfer of proteins to PVDF was carried out in a BioRad Mini Trans-Blot cell, 
according to the manufacturer's instructions. Briefly, SDS-PAGE gels were placed in 
a sandwich of blotting paper sheets and filter pads saturated in transfer buffer and run 
at 30V for 1 hour. After transfer, blots were blocked with PBSTM (PBS, 0.5% 
powdered non-fat milk, 0.1% Tween-20) for one hour at RT or overnight at 4°C with 
gentle agitation. Antibodies were made up in PBSTM at appropriate dilutions. 
Membranes were incubated with antibodies for one hour at RT, with agitation, 
followed by three washes of 15 minutes each in PBST. Blots were developed using 
an enhanced chemiluminescence system (Amersham Pharmacia, Uppsala, Sweden) 
according to the manufacturer's instructions and placed between clear acetate sheets 
for exposure to film. 
6.2.41 Desalting and buffer exchange the purified His Tag Protein. 
Dialysis and D-Salt Excellulose Plastic Desalting columns (from Pierce) were used 
in this project. In both methods, we have chosen the appropriate dialysis tubing for 
the former, and the appropriate matrix. In dialysis, the protein samples were poured 
into the dialysis tubing and were dialysed against PBS buffer overnight with 2 to 3 
buffer exchanges. The desalting column was used to apply the sample into the gel. 
An aliquot of PBS buffer then was used to elute the sample. This column was used 
for buffer exchange as well. 
6.2.42 Purification of His Tag Protein. 
For small scale purification, Ni-NTA His Bind ® Risins, Hi Trap Chelating 
column, and gel filtration were used for purification. We incubated the clarified 
supernatant with Ni-NTA His-Bind Resins, which are divalent Ni++ cations. The His 
Tag will bind, while the other proteins which should not bind are discarded. Finally 
an elution buffer can be added to the beads to elute the His Tagged protein in a 
purified concentrated form. In the large scale purification, Hi Trap chelating columns 
Chapter 6 	 136 
(imi) was used as follows; the column was washed with H20, loaded with NiSO4 
(100mM NiSO4), then washed again with 1120, meanwhile the protein sample was 
dialysed against the binding buffer (20 mM Sodium phosphate, 0.5M NaCl pH 7.4). 
The supernatant was filtered and loaded onto the Aktaprime column at a rate of 
2ml/min. Bound protein was eluted using elusion buffer and collected in 2.5ml 
fractions. Fractions with highest peaks of absorbance were run on an SDS gel and 
stained with Coomassie Blue and those fractions containing the most protein were 
pooled and buffer-exchanged. 
6.2.43 Glycosylation assay. 
To test for glycosylation, the Pro-Q Fuchsia Glycoprotein Gel Stain Kit (from 
Molecular Probes) was used. After fixing the gel with fixation solution (250 ml of 
methanol and 250 ddH20), it was washed with ddH20 and incubated in oxidizing 
solution (Periodic acid). In the dark, the gel was washed in Pro-Q Fuchsia reagent, 
before being incubated in the reducing agent (Metabisulfate). After staining with 
glycoprotein staining kit, the recombinant expressed in Pichia then to be compared 
with the four positive controls in the marker provided with kit. The glycosylated 
recombinant should stained fushia. 
6.2.43 Enzyme —Linked Immunosorbent Assay (ELISA). 
Wells of 96-well plates (Immulon 4, HBX Thermo Dynex) were coated with 0.5, 1 
and 5 .tIg1m1 of antigen to be assayed in lOOml coating buffer (15mM Na2 CO3, 35 
mM NaCO3 pH 9.3). The wells were then washed 3 times in washing buffer 
(0.05 %Tween 20 in PBS). The adherent antigens were blocked with blocking buffer 
(1% skimmed milk powder in washing buffer). Human plasma diluted 1:500 in 
blocking buffer was added in duplicates and incubated overnight at 4°C. After 3 
washes, the wells were incubated for 3 hours at room temperature with horseradish 
peroxidase-conjugated rabbit anti-human IgG (diluted 1:5000 in washing buffer). 
The wells were then washed again 3 times and incubated for 15 min at room 
temperature with the substrate (0.1 mg -1 0-Phenylendiamine +0.012 H202) in 
developing buffer (24.5 mM citric acid monohydrate and 52 mM Na2HPO4 pH 5). 
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The reaction was stopped by addition of 250 2M 112SO4 and OD measured at 
492nm. 
6.2.44 Rabbit immunization. 
The antigen concentrations required for each immunization was 50 - 200ug which 
was administered with complete Freund's adjuvant to ensure a high quality/quantity 
response Immunisations were carried out by the Harlan Bio-Sera Company 
according to their rabbit immunisation Protocol: 
Day Action 
0 Pre Bleed + Immunisation 
14 Boost 1 
28 Boost 2 
35 Test Bleed 1 
42 Boost 3 
49 Test Bleed 2 
56 Boost 4 
63 Test Bleed 3 
70 Boost 5 
77 Terminal Bleed approx. 50-70 ml serum 
6.2.45 Live Immunofluorescence Assay on iRBCs. 
Infected red blood cells at 5-8% parasitaemia (4% trophs) were washed and 1 Op.l 
cell pellet per sample was re-suspended in 100.tlPBS/1% BSA containing primary 
antibody at the appropriate dilution. Samples were incubated on ice for 30 minutes 
with flicking every 10 minutes to re-suspend cells. Between incubations, cells were 
washed three times in lml PBS/i %BSA and re-suspended in lOOiil FITC-conjugated 
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secondary antibody, at the appropriate dilution in PBS/ 1% BSA. Incubation with 
secondary antibody was as previously described but in the dark to prevent bleaching 
of fluorescence. Cells were washed three times as previously and re-suspended at 20-
40% haematocrit with 50:50 glycerol: PBS containing 0.1% Evans Blue, 1: 100 000 
DAPI and 1.25 mgm1-1 DABCO. A drop of each sample was spotted onto a clean 
glass slide, mounted for observation using a 9:1 solution of glycerol/PBS conatining 
the anti-fade reagent (Citifluor) and sealed with nail varnish to prevent drying out. 
6.2.46 Fixed Immunofluorescence Assay on iRBC5. 
Microspot slides were transferred from storage at —20°C and allowed to equilibrate 
to RT, for 15 minutes. For dry IFA they were used thus. For fixed IFA they were 
covered in 2% paraformaldehydefPBS for 5 minutes, followed by 90% 
methanoll10% acetone for 1-2 minutes. Slides were then air-dried and re-equilibrated 
in PBSTIO.l% Tween-20. Antibodies were made up in 1% BSA/PBS at appropriate 
dilutions and 30-50i11 per spot was used for each incubation. To stain parasite nuclei, 
DAPI was added to secondary antibody solutions at a dilution of 1:1000. Incubations 
were for 30 minutes at 37°C followed by 3 washes in PBS, 10 minutes each, with 
gentle agitation. After the final wash, slides were mounted using 2-3 drops of 
Vectashield® and sealed with nail varnish. 
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Appendix 1. 
A.the native and recodoned CIDR1 in the nucleotides and amino 
acids levels. 
A.1. The native sequence: 
CI F FL W L 	Q ML D D S 	E W R K K 
3 
	
	tgca tttttttcctttggctaaCaCaaatgttagatgattCtatagaatggagaaaaaaa 62 
L K T CI N NE K PIN XI R G C K K P 
63 	cttaaaacctgtataaataatgaaaaaccaactaattftatacggggttgtaaaaagccc 122 
CE CF ER WV E 	K E E E WI S 	E K 
123 tgcgaatgttttgaaagatgggttgaacaaaaagaagaagaatggatttcaattgaaaaa 182 
H F D K Q RD IS E E ER Y IT L E Y I 
183 cattttgacaaacaaagagatatatcagaagaagaaCgttatataacacttgaatatatt 242 
L 	E F F MD K I E KAY G I E K SK E 
243 ttgaatgaattttttatggat aaaattgaaaaagctt atggaatagaaaaatcaaaagaa 302 
L K E K L K S N KG H Gil RD I E H S 
303 ttaaaggagaaattaaaatcaaataaaggtCaCggaatt at aagagatacagaacattca 362 
Q 	A 1K ILL E H EL ED A K K CT E 
363 caggatgcaat aaaaatattgct agaacatgaattagaagatgCaaaaaaatgCaCagaa 422 
I H ND E K C K E 	E ES G G R S L NP 
423 acccataatgatgaaaaatgtaaagaacaagaagagagCggaggtCgCtCtttaaaCg 482 
D P ES D D E E El D NV KEN P C A V 
483 gat ccagaatccgacgacgaagaagaaaCggataatgtaaaagagaacccgtgtgctgta 542 
G K K L 	K TV K Q IA R Q M H Q A A K 
543 gggaaa aaactcactaaaaCtgtgaaaCaaatCgCtagaCagatgCatCaagcggaag 602 
K 	L G S S S SR AL K A H 
603 aaacaattgggtagtagtagtagtagggCattgaaggCtCat 	 644 
A.2. the recodoned CIDR1 sequence: 
P L E K RE K Q K IMP F 0 A F F F LW 
1 	ccgc t cgagaaaagagagaagcagaagatCatgCCattCgaCgCCttCttctttgtgg 60 
L 	Q ML D D S 	E W R K K L K IC IN 
61 	ctgactcagatgctggacgactccatCgagtggCgtaagaagCtt aagacctgcatcaac 120 
NE K P INC I R G C K K PC E C F ER 
121 aacgagaag ccaaccaactgtatCCgtggttgtaagaagCCttgcgagtgtttcgagaga 180 
WV E 	K E 	E WI S 	E K H F D K Q R 
181 tgggttgaacagaaggagcaggagtggat ct ccattgagaagcactttgaCaagCagaga 240 
DI SEE ER Y IlL E Y IL NE FF1 
241 gacat ct ccgaggaagagCgttaCatCaCCCtggagtaCatCCtgaaCgagttctttc 300 
0K I E KAY G I E K SK ELK E K L K 
301 gacaagatcgagaaggctt acggaattgagaagtccaaggagttgaaggagaagCtgaag 360 
S 	KG HG II RD I E H S 	D A 1K I 
361 tccaac aagggtcacggaatcatccgtgaCaCtgaaCaCtCCCaagacgccatcaagatc 420 
LW SIN W RI L R SAP K PITT R S 
421 tt gt ggagcacgaattggaggacgCtaagaagtgCaCCgaaaCCCaCaaCgaCgaggt 480 
V R SR RE S G G R S L N PD P ES D D 
481 gt aaggagcaggagggagtccggtggtagatCCCtgaacCCtgatccagaatccgacgac 540 
E E E 	D N V KEN PC A V G K K L 	K 
541 gaagaggagactgacaacgtcaaggaaaaCCCatgtgCtgtCggaaagaagCtgaCCg 600 
IV K Q IA R Q M H Q A A K K Q L G SS 
601 accgt c aagcaaatcgctagacaaatgcaccaagCtgCcaagaagcagttgggttcctct 660 
S SR AL K A H H H H H H * 
661 tcctctagagccttgaaggctcaccaCCatCacCatCattaa 702 
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A.3. Alignment of the native and the recodoned version of CIDR1 using T -
COFFEE, Version,1.41 (1=The native sequence, 2= the recodoned version and 
C= the Consensus) 
a: 99 99 








2 	- 	 I.IHHHR 
C 
B. Samples of sequences obtained from DBLa, P and 'y expression 
libraries 
B.!. DBLa sequences. 
B.I.I. 
L I I L E R S K T I N Y S K D P 'T Y S R 
2 	cttacgacacttgagagat caaaaacaactaattattcgaaggatcctaCgtatt caaga 61 
I R LII F AL R AD N NY N R F N CE 
62 	atacgactcactatatttgctttgCgagCggataacaattataatagattcaattgtgag 121 
RI TI S H RI H Y 	GE IN YE RI A 
122 cggataacaatttcacacagaattCattatagaggagaaattaaCtatgagaggatcgca 181 
S PS P S RIPER H L R S S E N R ME 
182 tcaccatcaccatcacggatccCtgaaCgaCatCttCgaagCtcagaaaatcgaatggaa 241 
K V D NE A DL LA E V C MA A K YE G 
242 aaagtcgacaacgaagcagatttgttggcagaagt atgt atggcagccaaatacgaaggg 301 
G S 	K THY I PH Q H KY G 	SD S  
302 ggctcaataaaaacacattatacaccacatcaacacaaatatggtgattctgattctcaa 361 
IC TV LA R SF A DIG D I I R G K D 
362 atatgt act  gtattagcacgaagttttgcagatattggagacattataCgaggaaaagat 421 
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L Y L G 	K K K A K S N R KR K L E 	K 
422 ct gt at ct cggtga taaaaaaaaagcaaaatCaaaCCgaaagagaaaattagaacagaaa 481 
L K El F K K I H SE VI TN GEL Q K 
482 ttgaaagaaattttcaagaaaatacatagtgaagtgacgacaaatggggagctacaaaaa 541 
R Y G Q D G Q N F Y Q L RED W WY A N 
542 cgct acggacaagacggtcaaaatttttatCaattaCgagaagattggtggtatgctaat 601 
R E T V N K A MICE APES AS Y FR 
602 cgagaaacagt atggaaagccatgacatgtgaagCaCCagaaagtgCttcatattttcga 661 
K IC D G GE N P TAT Q G N C K C IN 
662 aaaaca tgtgatggtggagaaaatCcaaCtgCgaCtCagggtaactgcaaatgcattaat 721 
G 	VP H 1ST ISA VS S V V R GM G 
722 ggagat gtcccccatatttCgaCtaCgtCCgCagtatCttcggtggtccgaggaatgggc 781 
P K IF V 
782 ccgaagacttttgta 796 
B.1.2. 
L R 	L R R SKIT NY S K DPI Y L Y 
2 	tt acgacacttgaggagatcaaaaaCaaCtaattattCgaaggatcctacgtatttatac 61 
D SLY L L C ER 11111 D S 	VS G 
62 	gactcactatatttgctttgtgagCggataaCaattataatagattcaattgtgagcgga 121 
Y Q F HI E F I K E E K L 	MR G S H H 
122 taccaatttcacacagaattcattaaagaggagaaattaactatgagaggatcgcatcac 181 
H H H HG S L N DI FE A Q K I E W K K 
182 ca tcaccatcacggatccctgaaCgaCatCttCgaagCtCagaaaatcgaatggag 241 
ST A K H DL L L E V C MA A K YE GE 
242 tcgacggct aagcatgatttgttgttagaggtgtgtatggCagCCaaatatgaaggagaa 301 
S L 	R F NP KY P El Y S G ST MCI 
302 t cttt aacacgttttaatccaaaatatCCagaaatatattCtggttCtaCaatgtgtt 361 
ML AR SF A DIG D I V R G RD IF R 
362 atgttggcacgcagttttgcagatataggagatattgtaagaggaagagatatatttcgt 421 
G N D E E K K K RD EL EN K L K El F 
422 ggtaatgatgaagaaaaaaaaaaaagagatgaattagaaaataagttgaaagaaattttc 481 
K K I H S G L SK N GA K D 	Y Q DEN 
482 aagaaaatacatagtggattgtCgaagaaCggCgCaaaagactactaccaagatgaaaat 541 
GE N F F K L RED N 
542 ggtgaaaatttttttaaattacgagaagattgg 574 
B.1.3. 
F A Y 0 1 C E I K N I N Y S K D PT Y S 
2 	tttgcttacgacacttgtgagatcaaaaacactaattattcgaaggatcctacgtattca 61 
Y N SLY L L C ER 111110 S IV S 
62 	tacaactcact at atttgctttgtgagcggataacaattataatagattCaattgtgagc 121 
G N Q F HI E F I K E E K L 	MR G S H 
122 ggatggcaatttcacacagaattCattaaagaggagaaattaaCtatgagaggatcgcat 181 
H H H H HG S L N DI FE A Q K I E W K 
182 caccatcaccatcacggat ccctgaacgacatcttcgaagctcagaaaatcgaatggaaa 241 
K SIT K H DL LA E V C MA A K YE G 
242 aagt cgacaacgaagcatgatttgttggCagaagtatgtatggCagCCaaatacgaaggg 301 
0 S I K THY I PH Q H KY G 	SD S  
302 ggctcaataaaaacacattatacaccacatcaacacaaatatggtgattctgattctcaa 361 
IC IV LA R SF A DIG D I I R G K D 
362 at atgtactgtattagCaCgaagttttgCagatattggagaCattataCgaggaagat 421 
L Y L G 	K K K KS KM K P K E K N L N 
422 ct gtatctcggtgataaaaaaaaaaaaagCaaaatgaaaCCgaaagagaaaaatttgaac 481 
RN SK K F SR KY IV KR R L MG S Y 
482 agaaattcaaagaaatttt caagaaaatacatagtgaagagacgaCt aatggggagctac 541 
K N AID K TV K IF IN YE K I G GM 
542 aaaaacgctacggacaagacggtcaaaatttttatCaattaCgagaagattggtggtatg 601 
LIE K Q Y G K P L H V K H Q K V L HI 
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602 Ct aatcgagaaacagtatggaaagccattaCatgtgaagCaCCagaaagtgCttcat att 661 
FE K H V MV E K I Q L Q L 
662 ttcgaaaaacatgtgatggtggagaaaatCCaaCtgcaaCtC 703 
B.1.4. DBLus amino acids Sequences alignment. 
AVGw- 
* 
1 	: 42 
I: 	50 
3 	: 48 
1 -LTTLERSKTTNYSKDPTYSRIRLTIFALR.ADNN 
2 -LRHLRRSK—T N—ys. K_P.,T?YL-.- -a. 
-----  
 IDS IVSGYQFHTEFIKEEKLTMR 




3 GSHRHHliHGSLNDI----- - 
C 	. ::.: 	 ...... * 
1 
2 McRSFADIGDI1rRG1DIFRGNDEKK--KRDELENKLKEIFKKIB --------------------  
3 S , -4;p~"LYLGDKKKKS--KMKPKEKNLNRNSKKFSWI~rlvmmics 
C  
1 







B.2. DBLP sequences. 
B.2.1. 
R F TI L GE D Q K TINY S K DPI Y 
2 	cgctttacgacacttggagaagatcaaaaaaCaaCtaattattCgaaggatCCtaCgtat 61 
I Y D SLY L L CE RI 11110 S 	V 
62 	tattacgactcactatatttgctttgtgagCggat aacaattataatagattcaattgtg 121 
S G S 	F HI E F I K E E K L 	M R•G S 
122 agcggatcacaatttcaCaCagaattCattaaagaggagaaattaaCtatgagaggatCg 181 
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H H H H H HG S L N DI FE A Q K I E W 
182 catcaccatcaccatcacggatccctgaacgacatcttcgaagctcagaaaatcgaatgg 241 
K K ST RE H V CT S 	L KY L L S G R 
242 aaaaagtcgacccgagaacacgtgtgt acct caaatttagaat atttactttctggt aga 301 
G G Q F E 	V 	D D K A SD SF L G 	V 
302 ggcggacaatttgaacaagtt ccagatgataaagctagcgaCt cattcttgggcgatgtt 361 
L VA AR Y 	SR K H K E T G W N SC P 
362 cttgttgcagcacga t at agaagcagaa aaCataaagaaactggatggaactcatgcccg 421 
MK P N SC KR R S Y Y L PC Y T L Q X 
422 atgaagccgaa tt catgt aaaagaCgaagCtaCtatttgCCgtgCtatacgttaagrtt 481 
C R Y W R' Y Y S R N R F V G Y K W L C N 
482 tgcagatattggcgat att att CgaggaaCagatttgtgggatataaatggttatgtac 541 
RCA K SF1 N G Y LETS KS 
542 aggt gt gcaaagt catttaCaaaCgggtatttggaaaCttCaaaaagc 589 
B.2.2. 
R 	IT L E K 1K K Q L I I R RI L P W 
1 
	
	cgcttt acgacacttgagaagatcaaaaaaCaaCt aattattcgaaggatcctaCCatgg 60 
Y Y Y D SLY L L C ER 11111 D S  
61 	tat t att acgact cact at attt gCtttgtgagCggataacaattataatagattctt 120 
VS G S 	F HI E F I K E E K L 	MR C 
121 gtgagcggatcacaatttCaCaCagaatt catt aaagaggagaaattaactatgagagga 180 
S H H H H H HG S L N DI F K A Q K I E 
181 tcgcatcaccatcaccatcacggat ccctgaacgacatcttcgaagctCagaaaatCgaa 240 
WK K ST SE H L CT S 	LEN L DV C 
241 tggaaaaagtcgaccagtgaacaCttgtgtaCatCCaattt agaaaatttagatgttggt 300 
S 	1K ND K AS H S L L G 	V Q LA A 
301 agtgtcact aaaaatgataaggctagccact catt attgggagatgttcagCtCgCagCa 360 
KT D A A Eli KR Y K D Q N NI Q L  
361 aaaact gat gcagct gagat aat aaaaCgCtataaagatcaaaataatatacaactaact 420 
D P I, Q Q K D Q K A M C R A V R Y S F A 
421 gat ccaat acaacaaaaa gaCcaggaggCtatgtgtCgagctgtacgttat agttttgcc 480 
DL G 	II R G RD MW D ED K SST D 
481 gatttaggagacatt attcgaggaagagatatgtgggatgaggat aagagctcaacagac 540 
MET R LIT G F K N 1K D K H D GIl 
541 atggaaacacgtttgat aaccggattt aaaaacattaaagataaacatgatggaatCaCa 600 
D NP KY T GAY K Q Y A RI L  
601 gacaaccc t aaat at accggtgCatataagCaataCgCCCgcatattaata 651 
B.2.3. 
FIT PR ED Q K T TN Y SK DPI Y Y 
3 	tttacgacacctagagaagat caaaaaacaactaatt attcgaaggatcct acgt attat 62 
SD SLY L L CE RI TI lIDS I VS 
63 	tccgac t cact at attt gcttt gtgagCggataaCaattataatagattcaattgtgagc 122 
G Y Q F H 1K F I K E E K L 	MR G S H 
123 ggat at caattt cacacagaa tt Cattaaagaggagaaattaactatgagaggatcgcat 182 
H H H H HG S L N DI FE A Q K I E W K 
183 caccatcaccatcacggat ccctgaacgacatctt cgaagctcagaaaatCgaatggaaa 242 
K SIRE H F C IS N L KY L L S G R G 
243 aagt cgacccgtgaacactttt gtaCCtCaaatttagaatatttactttctggtagaggc 302 
G Q F E 	VP D D K A SD SF L G 	V L 
303 ggacaattt gaacaagtt ccagatgataaagctagcgactcattCttgggcgatgtt ctt 362 
VA A K K K A EN 1K K LYE INN R K 
363 gttgcagcaaaaaaagaagcagaaaacataaagaaactgtatgaaacaaataaccgaaaa 422 
SKID V ND EAT I C R Al R Y SF A 
423 agcaaaatt gat gt aaatgacgaagcaactatttgCCgtgCtatacgttacagttttgca 482 
DIG D I I R G ID LW DING DVI G 
483 gat att ggggat att att cgaggaa cagatttgtgggatataatggtgatgtaaCaggt 542 
V Q S 	L Q TV F G K 1K K Q F N G KY 
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543 gtgcaaagt aatttacaaacggtttttggtaaaatCaaaaagcaatttaatggcaaatat 602 
TN D S 	H T Q L R AD W WEAN R K Q 
603 accaat gact cccaacataCaCaattaCgagCagattggtgggaggctaatagaacaa 662 
IN Q A MT C P Q N G 1K CD K D pp 
663 atatggcaagccatgacatgtccacaaaatggt atcaagtgtgataaagatCCaCCaC 720 













B.3. DBL7 sequences. 
B.3.1. 
R L Y D T TED Q K T TN Y S K D PT Y 
1 	cgcctttacgacact acagaagatcaaaaaacaactaattattCgaaggatCCtaCgtat 61 
Q Y H SLY L L CE RI Till D S 	V 
62 	caataccactcactatatttgctttgtgagcggataacaattataatagattcaattgtg 121 
S G L Q F H T E F I K E E K L T MR G S 
122 agcggacttcaatttcacaCagaattCattaaagaggagaaattaactatgagaggatcg 181 
H H H H H HG S L N DI FE A Q K I E W 
182 catcaccatcaccatcacggatccctgaaCgaCatCttCgaagCtCagaaaatcgaatgg 241 
K K ST CM PP R R Q K L CI Y K L T R 
242 aa aaagtcgacctgcatgcctcctagaagaCaaaaattatgtatatataaattaacaaga 301 
D ND T K DL K ELK MS F 1K 5 A AL 
302 gataatgacacaaaagacctt aaagaatt aaaaatgtcatttatt aaat ctgcagcacta 361 
E T Y LAW ElY KG N N I D A IT EL 
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362 gaaacat at cttgcatgggaaat atataaaggaaataatattgatgccattacggaatta 421 
Q N G Q I PEG F K RIM F Y T F GD F 
422 caaaat ggacaaattccagaaggttttaaaagaataatgttttacacatttggagatttt 481 
RD N CL G I DI S S K A N K ST G V G 
482 cgagat atgt gtttgggtaCtgatatatcatCaaaagCaaataaaagtacaggtgtaggt 541 
K 	ES SINK L F P NV K N S K S 	D 
542 aaagtagaatctagtataaataaacttttcccaaatgtcaaaaattctaaatcacaagac 601 
R 	1W W N S 	EKE V WE G ML C G L 
602 cgtaaaacgtggtggaattCaattgaaaaagaggt atgggaagggatgttatgtgggtta 661 
SHAG G ND A 1K S 	Q D 	Q Y SR G 
662 t cacat gct ggtggcaatgacgCtatCaaaagCaaCCaggactaccaatactcccgagga 721 
Y 	IL SK LW K WY PH Y P N L P ND 
722 tataatattttatccaagttatggaagtggtatccccattatcccaatttgccgaacgac 781 
PR F W D G SR PR INS P L H MT 
782 ccccgattctgggatggttcgcggCCgCgaattaatt cccccttacacatgacgg 836 
836 
B.3.2. 
F Y DIE ED Q K TINY 5K DPI Y P 
2 	tttt acgac agaggagaagatcaaaaaacaactaattattCgaaggatcctacgtatcct 61 
Y N SLY L L C ER 11111 D S 	VS 
62 	tacaactcact atatttgctttgtgagcggataacaatt at aatagattcaattgtgagc 121 
G L Q F HI E F I K E E K L 	MR G S H 
122 ggactt caatttcacacagaattCattaaagaggagaaattaactatgagaggatcgcat 181 
H 	H H HG S L N DI FE A Q K I E W K 
182 caccat caccatcacggatCCCtgaaCgaCatCttCgaagctcagaaaatcgaatggaaa 241 
K SICK IC G R E L 	R L R 	DC SS 
242 aagt cgacct gcaagatctgcggCCgCgaattaattCgCCttagacatgactgttcctca 301 
V 	V G H L RED R SC L 	L 	KR MS 
302 gtt caagttgggcacttacgagaagaccggtCttgCtt gat tCtaatcaagaggatgtca 361 
E C H L PER C 	L H FRY F F IC N L 
362 gaat gccatttgcctgagagatgCaggCttCattttCgataCttttttatttgtacta 421 
Y S 	G F FL SF C F F S YE LAP D Q 
422 tat agt at aggattttttttgtCattttgtttCttCtCgtacgagcttgctcctgatcag 481 
PIS Q L MN IL W S G F G K II R V R 
482 cct a t ct cgcagCtgatgaatatCttgtggtCggggtttgggaaaattt0gagttcga 541 
CF S WY F P L L FR V Q K 1K L DL R 
542 t gtttttcttggtatttCCCaCtCCtCttCagagtaCagaagattaagttagcttcgt 601 
L C C S 	Y Y L L 	L 	NP K L 	D F I 
602 tt gt gcggatccaattattatttacttattttggtCaaCCCCaaattagttgatttcata 661 
L G F I Q KY V V FL DL S 	L SC I Y 
662 cttgggtt cat  tcaaaaatacgtagtCtttttagatCtttCaatattatcatgtatatac 721 
Y N S PT C F IF A N VP PAL SD P 
722 t at aacagcccgacttgtttCattttCgCgaatgttCCCCCagCtttatcggatccc 780 
B.3.3. 
L Y DI LAD Q K TINY S K DPI Y I 
3 	ctttacgacactcttgCagat caaaaaacaactaatt attcgaaggatcctacgtat att 62 
.Y D SLY L L C ER 11111 D S 	VS 
63 	tacgactcactatatttgctttgtgagCggataaCaattataatagattcaattgtgagc 122 
G I Q F HI E F I K E E K L 	MR CS H 
123 ggaactcaatttcacacagaatt catt aaagaggagaaattaact atgagaggatcgcat 182 
H H H H H CS L N DI FE A Q K I E W K 
183 caccatcaccatcacggatccctgaacgacatcttcgaagctcagaaaatcgaatggaaa 242 
K SICM PP R R Q S L CI H DL K V L 
243 aagt cgacctgtatgccacctaggagaCaatCattatgCataCatgatttaaaagtatta 302 
TNT SS E K Q L RE A F INCA AlE 
303 acgaacacttcatcggaaaaacaattaagagaagCttttattaaCtgtgC8gCaataaa 362 
I H F LW I Y Y K N K N S S I V DI Q L 
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363 acacatttttt at ggattt att ataagaataaaaatagtagtattgtagacacacagtta 422 
Q N G NI PD E F K S 	MY Y T F G 	Y 
423 caaaa t ggaaat att ccagacgaa tttaaaagtataatgtattatacgtttggcgattat 482 
RD IC L G T DI S SD S 	1KG IS Q 
483 agagat at at gttt gggaaca gatatttCtagtgattCCaatattaagggaatatcacag 542 
K 	ID IL N S 	Y G K THE Q I lIP 
543 aaggttatt gat atttt aaat agtCaatatggCaaaaCtCatgaacaatatattacacct 602 
NT W WE K 
603 aacacttggtgggaaaaa 620 
B.3.4. 
L 	H L E K 1K K Q P NY S K D PT SD 
3 	tt acgacac tt ggagaagat c aaaaaacaacctaattattCgaaggatCCtacgtcggat 62 
H Y H SLY L L C ER IT III D S 	V 
63 	CACtaccactcactatatttgctttgtgagCggat aacaattataat agattcaattgtg 122 
S G K Q F H T E F I K E E K L 	MR G S 
123 agcggaaaacaattt cacacagaattCattaaagaggagaaattaactatgagaggatcg 182 
H H H H H HG S L N DI FE A Q K I E W 
183 cat caccat caccat ca cggatCCCtgaaCgaCatCttCgaagCtCagaaaatcgaatgg 242 
K 	SICM PP SR Q K L C V I N L K I 
243 aaaaagtcgacctgcatgcctcCaagt agacaaaagttatgtgtaattaatttaaaaaCt 302 
FIG K TI V DL RE A F 1K C A Al E 
303 ttt acagggaaaaca acagtggaCttaCgagaagcttttattaaatgtgctgcaatagaa 362 
T H F LW KY Y K 1K N SEA H D DL K 
363 acacatttttt at ggaaatattataaaactaaaaactcagaagCacatgatgatttgaag 422 
KG TIP E K F KR Q M F Y IF G 	Y X 
423 aaaggaacaa tt cctgagaaatttaaacgtcaaatgttCtataCatttggagattatflgg 482 
DL CL D K NI G N DV SD A K N N 1K 
483 gattt at gttt ggat aaaaatataggtaat gat gtgagtgatgCaaaaaataatataaag 542 
G 	FL Q ML IL PAN 
543 ggtgttttt ctccagatgctaaccctccctgct aacct 580 
B.3.5. 
L Y DID ED Q KIT NY SK DPI Y S 
1 	cttt acgacac tgatgaagatcaaaaaaCaaCtaattattCgaaggatCCtacgtattcg 60 
Y N SLY L L C ER 11111 D S 	VS 
61 	t acaact cact at attt gctttgtgagCggataaCaattataatagattcaattgtga.gc 120 
GE Q F HI E F I K E E K L 	MR G S H 
121 ggagaacaattt cacac agaattCattaaagaggagaaattaaCtatgagaggatcgcat 180 
H FL H H H G S L N D I F E A Q K I E W K 
181 cacca t cacca t cacggatccctgaaCgaCatCttCgaagCtcagaaaatcgaatggaaa 240 
K SICM PP FL R Q K L C V IN L Q H F 
241 aagt cgacctgtatgccaccaaggagacaaaaattatgtgtaattaatttacaacatttt 300 
KEN ISV EL R K A F I Q C A A A El 
301 aaagagaatacat cagttgagttgagaaaagcttttatt caatgcgctgccgcagaaact 360 
FL LW H KY K T D N N G GEE L Q N Q 
361 tttttactatggcataaat acaaaacggataacaatggtggtgaagaaCtacaaaaCCaa 420 
L ES G lIP ED F KR Q M F Y IF G  
421 tt agaaagt ggaat aat ccctgaagattttaagCgCCaaatgttctacacatttggcgat 480 
Y 	DL CL D K NI G RD V S E V E K N 
481 t acagagattt gt gttt ggataaaaatataggtagagatgtgagtgaagtagaaaaaaat 540 
1K R V F S S 	G 	K T P N G Q SR L D 
541 ataaaacgtgt cttctcaagtaatggagacaaaacaCCt aatggccaatcacgtctagac 600 
W W G K N C Q DI W Q GM L C G L S H A 
601 tggtggggaaaaaactgtcaagatatatggcaaggaatgtt atgtggcctatcacacgct 660 
S G N IS N V E TI K N N NI Y S L C Q 
661 agtggaaatataagtaacgtagaaactatcaaaaacaaCaaCaCctaCtCCCtCtgtCaa 720 
I Q W L Q W R PR P L RN S L ND PR S 
721 at ccagtggtta c aatggaggccccgCCCCttgaggaattCtCtaaaCgaCCcCCgttCC 780 
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B.3.6. 
CR1 R PP KS 1CM PP s R Q K L CV 
1 	tgcagaatt cgccctcctaagtcgacctgcatgCCtCCtagtagaCaaaaatt atgtgta 60 
IN L Q H F KENT S V EL R K A F I Q 
61 	attaatttacaacattttaaagagaataCatCagttgagttgagaaaagcttttattcaa 120 
CA A A E T FL LW H KY K T D N N G G 
121 tgcgctgccgcagaaacttttttactatggCataaataCaaaaCggataacaatggtggt 180 
EEL Q N Q L ES Gil P ED F KR Q M 
181 gaagaactacaaaaccaattagaaagtggaataatcCctgaagattttaagcgccaaatg 240 
F Y T F G 	Y 	DL CL D K NI G SD V 
241 ttctacacatttggcgattacagagatttgtgtttggataaaaatataggtagtgatgtg 300 
S E V E K N 1K R V F SS N G 	K T P N 
301 agtgaagtagaaaaaaatataaaacgtgtCttCtCaagtaatggagaCaaaaCacctaat 360 
G 	SR L D W W G K N C Q DI W Q GM L 
361 ggccaatcacgtctagactggtggggaaaaaaCtgtCaagatatatggCaaggaatgtta 420 
C G L S HAS G N IS N V E TI K N N N 
421 tgtggcctatcacacgctagtggaaatataagtaaCgtagaaaCtatCaaaaaCaacaac 480 
T Y S L 	K F S G 	N R G PT LEE F S 
481 acct act ccctcgtcaaattcagtggtgaCaatagaggCCCCaCCCttgaggaattctct 540 
KR P Q FL R W LA A A F W GRIP A H 
541 aaacgaccccaattcct aagatggttagcggccgctttttgggggcgaatt ccagcacac 600 
W 	P L L 	D P S S V 
601 tggcggccgtt actagtggatccgagctcggtacc 635 
B.3.7. 
G R WA L S. C M L ER PP V K WI SIC 
3 	gggcgatgggccctctcctgcatgctcgagCggCCgCCagtgCCCtggatatCtatatgc 62 
RI R PsK ST CM PP SR Q N L C V H 
63 	agaattcgccctagtaagtcgacctgtatgcctCCtagtagaCaaaatttatgtgtacat 122 
Y L 	K L ND D SK E ED L RE A F 1K 
123 tatttaacaaaattgaatgacgact ccaaagaagaagatttaagagaggCatttatt aaa 182 
S A A A El FL L R Q Y Y N SK N V ED 
183 tctgcagcagcagaaacatttcttCtaCggCaatattataatagtaagaatgttgaggac 242 
D K IL H RD MI PP E F FR S 	FYI 
243 gataaaatattacatagagatatgatccctcccgaatttttCagatCCatgttCtataCa 302 
F G 	Y 	DI CL DID IS E K IA OH 
303 tttggagattatagagatatatgtttagatacagatatatCtgaaaaaattgCagat cat 362 
D V I I A K K K I I A V-F Q K I G S K I 
363 gatgtaact acggcaaaaaagaaaataactgctgttttccaaaaaattggctccaaaaCt 422 
IN G K K V L ER E G W W KEY G L S  
423 actaatggaaaaaaggtgctagaacgcgaagggtggtggaaagaatatggtctatctatt 482 
W K GM L CAL S Y NI El K K MD E G 
483 tggaaaggaatgttatgtgctttaagttataatactgaaacaaaaaaaatggatgaagga 542 
V RI Y L M KY 
543 gtgcgcacataccttatgaagtat 566 
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